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Abstract 
Bacteriophages are viruses able to infect and kill their bacterial host upon replication within it. They 
are thought to be the most abundant organism on earth, since their population exceed the one of 
bacteria (about 1030) by a factor of 10. In many cases, the host range where a given bacteriophage 
is active is so narrow that it is usually specific to one species of bacteria. In the early 1920s, phage 
were used to treat bacterial infections in eastern Europe and spread to western companies that 
began to commercialize typhoid and urinary-tract infection therapies. Soon after, because of 
penicillin discovery, researchers abandoned this therapy for antibiotic treatment, mostly due to 
phage susceptibility to the immune system and other unknown behaviours. Due to the overuse and 
misuse of antibiotic drugs, antibiotic resistance fast become a serious problem of global concern, 
currently with no real solution, which represents a threat to humanity leading to a post-antibiotic era 
if no counter-measures and alternative strategies are undertaken. In the last decade, 
bacteriophage application for the treatment of bacterial infections has re-gained huge attention. 
However, phages delivered in buffer solutions are suboptimal, since they are not shielded from 
host defences that inexorably hinder phage activity. Therefore, for effective in vivo applications, 
e.g. crossing the acidic environment of the stomach or infecting intracellular pathogens, phages 
need to be delivered to the site of infection, for example via encapsulation. Encapsulation in 
targeted delivery systems will help phages to reach the target with high specificity, minimizing 
losses, undesired adverse side effects, and limiting the likelihood of emerging “super bacteria”. In 
the last decades, a considerable variety of stimuli-responsive micro/nanocarriers have been 
designed. Such systems show a transition to the supramolecular structure or in their chemical 
structure in response to given stimuli. A wise choice of the stimulus that triggers the variation 
allows releasing of their cargo in a spatial- and temporal- controlled fashion. The stimuli can be 
either external or internal and most commonly are thermal variation, pH, enzyme concentration, 
redox potential, magnetic field, ultrasound intensity and photo sensitivity.  
In this thesis, we study the encapsulation of bacteriophages in lipid carriers able to deliver and 
release the cargo in a controlled manner. Liposomes are biodegradable non-toxic micro/nano 
vesicles composed of a lipid bilayer, which encloses an aqueous core that offer many advantages 
in medicinal applications. It was demonstrated that phage encapsulation in liposomes improves 
stability. Indeed, when inside the aqueous core of a vesicle, the thermodynamics of the system is 
advantageous for phage storage.  
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In this doctoral thesis we have assessed the encapsulation of two model phages, an Escherichia 
coli T3 podovirus (size ~65 nm) and a myovirus Staphylococcus aureus phage K (capsid head ~80 
nm and phage tail length ~200 nm). Encapsulation in liposomes was carried out by producing the 
vesicles by alcohol injection method in a capillary microfluidic device, in the presence of the cargo. 
We generated liposomes having mean sizes between 100–300 nm and the encapsulation yield of 
T3 phages was 109 PFU ml-1 and for phage K was much lower at 105 PFU ml-1. The encapsulation 
efficiency was affected by the aggregation state of the virions. Furthermore, we discovered that 
phage K is able to interact with the lipid bilayer resulting in phages bound to the outer membrane of 
the liposomes instead of being encapsulated inside them. We utilised the encapsulated phages to 
determine whether 1) they are internalized by human macrophages in higher number compared to 
free phages and whether 2) they are able to reach the cytosol were intracellular pathogens reside. 
We discovered that, regardless the formulation of liposomes, encapsulated phages are 
intracellularized more efficiently in comparison to free phages. However, following uptake, 
liposomes and encapsulated phages are trafficked to the lysosome, where they are irreversibly 
digested. Therefore, we envisioned a different approach: a smaller antimicrobial agent than 
phages, namely a phage lysin, was co-encapsulated with a hemolysin able to make pores in the 
endosomal membrane. We observed that the co-encapsulated of the two proteins effectively 
escaped lysosomal degradation and defeated intracellular S. aureus. We expect this approach to 
be easily extended to phages and we suggest further perspectives and concrete future 
experiments. In this doctoral thesis, we made significant advances in the encapsulation and 
intracellular delivery of phages for antimicrobial treatment, and we obtain promising results that 
pave the way to the actual utilization of phages for medical treatment of infections, especially of 
antibiotic resistant ones. 
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phalloidin/CFR680 Cy5 fluorophore conjugate (red, right centre). Image on the right is the merged image. 
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Figure 5.14│Confocal imaging of macrophages exposed to S. aureus and then treated with CHAPK 
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with DAPI (blue, left). Actin filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (red, 
centre). Image on the right is the merged image. Top row = control, bottom row = treated sample. Scale bar 
10 µm.             156 
 
 
 
      
 
List of tables 
Table 1│This table shows the time that passed between antibiotic deployment and when resistance was 
observed for the first time (Pana 2012).        6 
Table 4.0│ Endotoxin removal from phage lysate. Concentration of endotoxins in T3 sample after LLE (initial 
concentration) and after further purification by hydrophobic interaction (octyl resin).   112 
Table 4.1│Phage K stability over 2-week time. Phage K titre stored in PBS or SM buffer after 0, 7 and 14 days. 
Statistical significance was calculated by t-test.        116 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
Table of contents 
Abstract            iii 
Acknowledgments           v 
Publications            vi 
Patent applications           vi 
Presentations at international conferences         vi 
List of figures            vii 
List of tables            xii 
Table of content           xiii 
Chapter 1            1 
 1.1  Summary and objectives        1 
 1.2 Research novelty         2 
 1.3 Literature review         4 
  1.3.1 Bacterial infections        4 
  1.3.2 Antimicrobial resistance       5 
  1.3.3 Mechanisms of resistance       8 
  1.3.4 Bacteriophages and other alternative antimicrobial agents   10 
   1.3.4.1 Brief history of phage discovery     11 
   1.3.4.2 Biology and phage classification     11 
   1.3.4.3 Phage stability       12 
   1.3.4.4 Phage uses        13 
   1.3.4.5 Lysins         15 
  1.3.5 Bacteriophages Encapsulation      16 
   1.3.5.1 Encapsulation in Liposomes      18 
   1.3.5.2 Microfluidics for liposome production    20 
   1.3.5.3 Liposomes in drug delivery      23 
xv 
 
   1.3.5.4 Phospholipids Membranes and Phospholipase A2   25 
 1.4 References          27 
Chapter 2: Materials and Methods         46 
 2.1 Chemical and reagents         46 
 2.2 Bacteria and Virus strains, bacteriological media and buffers    46 
 2.3 Bacteriophage K propagation in S. aureus      47 
 2.4 T3 propagation in E. Coli         47 
 2.5 Size distribution and zeta potential for phages and liposomes    48 
 2.6 T3 phage purification         48 
 2.7 Endotoxins quantification        49 
 2.8 Bacteriophage concentration        49 
 2.9 Microfluidic co-flow device fabrication       50 
 2.10 Ethanol injection: liposomes generation      51 
 2.11 SEM imaging          51 
 2.12 CryoTEM imaging         52 
 2.13 Bacteriophage encapsulation        52 
 2.14 Phage K interaction with empty liposomes      53 
 2.15 Free phage separation         53 
 2.16 Low pH stability          54 
 2.17 Phage viability test upon exposure to alcohol      54 
 2.18 Listeriolysin O expression and purification      54 
 2.19 LLO hemolytic activity         55 
 2.20 LLO and CHAPK encapsulation in liposomes      56 
2.21 Phage K and LLO co-encapsulation in PS and DOPE : CHEMS liposomes for 
intracellular studies          56 
2.22 RAW macrophages         56 
2.23 Passaging RAW macrophages        57 
xvi 
 
2.24 Seeding RAW macrophages        57 
2.25 Preparation of RAW macrophage stocks      57 
2.26 Immunofluorescence with free bacteriophage      57 
2.27 Immunofluorescence with encapsulated bacteriophage    58 
2.28 Immunofluorescence with encapsulated bacteriophage K endolysin   58 
2.29 Confocal microscopy         58 
2.30 Solutions and buffers         57 
2.31 Supplementary information        60 
2.32 References           63 
Chapter 3: Nanoencapsulation of Bacteriophages in Liposomes Prepared Using Microfluidic 
Hydrodynamic Flow Focusing         64 
 3.1 Content of this chapter         64 
 3.2 Abstract           65 
3.3 Studying liposome generation in a microfluidic device                    67 
3.4 Phage encapsulation         75 
3.5 Discussion          80 
3.6 Conclusions          86 
3.7 References          87 
Chapter 4: Risks and challenges associated with the encapsulation of phages into liposomes and 
their isolation            91 
 4.1 Content of this chapter         91 
 4.2 Abstract            92 
 4.3 Phage aggregation (Section 1)        94 
  4.3.1 Aggregation of phage K       94 
  4.3.2 Phage T3 aggregation       101 
4.4 Novel interaction of phage K with phosphatidylcholine vesicles and phosphate ions. 
(Section 2)           113 
xvii 
 
4.5 The effect of low-carbon chain alcohols on phage viability (Section 3)  116 
4.6 Isolation of phage-carrying liposomes (Section 4)     118 
4.7 Discussion          123 
 4.7.1 Aggregation         123 
 4.7.2 Phage K binding        126 
 4.7.3 Alcohol effect         127 
 4.7.4 Deactivation/isolation        128 
4.8 Conclusions          130 
4.9 References          131 
Chapter 5: Macrophage trafficking of liposome-encapsulated phages and co-encapsulation with a 
lysin protein for cargo release into the cytoplasm.       136 
 5.1 Abstract           137 
 5.2 Trafficking inside macrophages of liposome-encapsulated phages   139 
  5.2.1 The cellular uptake of free phages is low and insufficient   139 
5.2.2 Liposomes accumulate in the cell and enter the macrophages via phagocytic 
and endocytic pathway        142 
5.3 Co-encapsulation of lysin proteins LLO and CHAPK in liposomes for the treatment of 
intracellular S. aureus infection        151 
5.4 Discussion          157 
 5.4.1 Uptake of free and encapsulated phages     155 
 5.4.2 Trafficking in macrophages of liposome-encapsulated phage K  156 
 5.4.3 Strategies to escape lysosomal degradation     157 
5.5 Conclusions          162 
5.6 References          163 
Chapter 6: Conclusions and future work        174
 
1 
 
Chapter 1 
 
1.1 Summary and objectives 
 
Antibiotics have been a major breakthrough of modern society and saved hundreds of millions 
of lives. However, as a natural response to the high pressure of selection caused by antibiotics 
on highly-evolvable microorganisms such as bacteria, the steady rise of bacterial resistance to 
antibiotics is not only hindering and effectively nullifying, in some cases, the power of these 
drugs. Most importantly antibiotic resistance is posing a real threat to the population and 
causing increasing deaths. Because of the intrinsic high adaptability of bacteria, the 
development of new traditional antibiotics is not the right answer to the problem. Instead, 
agents able to evade or tackle bacterial evolvability are needed. Among the second category of 
agents, a great interest has been drawn on bacteriophages (phages), the natural enemies of 
bacteria, which are able to evolve at the same pace as bacteria, in a so-called “arm race” 
process. The co-evolution of bacteria and phages effectively overcome the problem of 
resistance, giving raise to phage therapy as a promising strategy for the treatment of bacterial 
infections.  
However, while phages are highly specific and effective at killing bacteria, their bioavailability in 
the human body, and even more specifically inside the human cells, is poor and insufficient for 
a potential therapy, requiring extremely high and frequent administrations, which not only are 
non-practical and non-scalable, but also risky for the development of similar mechanisms of 
resistance.  
The goal of this doctoral work was to develop finely tuneable, highly efficient and well 
characterized systems of delivery for phages to intracellular infections. To be able to achieve 
the highest yield of phage delivery, we encapsulated phages in liposomes, formed via 
microfluidic techniques, using lipid formulations with varying chemistry. In this work, we have 
not only developed the delivery system (Objective 1) and utilized it to treat intracellular 
infections in cells (Objective 3), but we have also deeply characterized and optimized the 
process of phage encapsulation to augment the number and quality of encapsulated phages, 
by identifying and addressing several factors of potential failure (Objective 2). 
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Objective 1: Microfluidic formation of liposomes and phage encapsulation. The first 
objective of this thesis was to devise a delivery system for phages, consisting of liposomes 
produced via microfluidic approaches, using the ethanol injection method. We could form 
nanoliposomes in a low shear stress and high controlled process, produce and concentrate 
phages up to a titre of 106 PFU ml-1 and encapsulate the latter while forming liposomes. 
 
Objective 2: Characterization and optimization of phage encapsulation. Before being able 
to effectively employ encapsulated phages to treat bacterial infection into cells, a second aim 
was to finely tune and characterize the phage behaviour during encapsulation, as well as 
overcome challenges intrinsically associated with the process, such as loss of viability, low 
encapsulation efficiency, undesired interactions and sample purification. 
 
Objective 3: Intracellular delivery of encapsulated phages and lysin proteins. Finally, we 
characterized the trafficking of free phages and liposomes into bacteria-infected macrophages 
and found that cellular recycling and degradation processes hinder the effective delivery of 
phages in the vicinity of the intracellular bacteria. Therefore, we envisioned and tested 
strategies to overcome cellular recycling, paving the way to the effective fighting of intracellular 
pathogens using novel nano-antimicrobial agents. 
 
1.2 Research novelty 
Due to the current most serious rise of antibiotic resistant infections and the lack of new 
therapeutic strategies, the use of bacteriophages for antibiotic phage therapy is gathering 
momentum. Phages are viral vectors and natural enemy of bacteria, with a strong capacity to 
co-evolve with them in a constant arms race. However, being simples entities mostly made of a 
protein capsid, phages are unable to access deep infections such as those of intracellular 
pathogens, and up to now have been mostly tested for intestinal infections and superficial ones 
(e.g. wounds). In order to use bacteriophages to fight all kind of infections, and in a targeted 
and controlled way, phage encapsulation is a necessary strategy. However, while there is vast 
knowledge on drug encapsulation, only little work has been attempted on bacteriophage 
encapsulation, due to the intrinsic challenging size and chemistry of phage, and some of these 
works fail to properly characterize the encapsulation phenomena when phages are used.  
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The novelty of this doctoral thesis is the achievement of phage encapsulation in liposomes, by 
the in-depth optimization of both phage and liposome production and purification, as well as the 
actual characterization of the full process through a wide array of cutting-edge approaches. 
Moreover, having accomplished the encapsulation of phages in liposomes, we took a few steps 
forward and studied the intracellular trafficking and delivery in human cells, which prior to this 
work was only attempted once, without a convincing outcome. We used microfluidics to 
generate liposomes and encapsulate bacteriophages of different morphology (i.e. phage K and 
T3). With the microfluidic approach of choice, we were able to finely control the size of the 
vesicles and generate nanostructure that are more likely to be applicable in real-life medical 
treatment. In this process, we described for the first time and overcame some challenging 
phenomena that are intrinsically associated with encapsulation of phages and nanoliposomes, 
due to the fact that their sizes are of the same order of magnitude. We were particularly 
interested in estimating without bias the efficiency of encapsulation and improving it. We made 
some new interesting discoveries on phage behaviour around liposomes and on factors that 
may affect their viability, and proposed ways to address it. We employed encapsulated phages 
with infected macrophages and studied their trafficking, gaining unprecedented insight of the 
cellular uptake and processing of phages encapsulated in liposomes. We finally encapsulated 
and delivered a smaller antimicrobial agent, which is not only a known, currently investigated 
alternative strategy for the treatment of infections, but which also served as a model for our 
encapsulation system to be effectively delivered to the site of infection and to kill intracellular S. 
aureus. 
In conclusion, in this doctoral thesis we made significant advances in the encapsulation and 
utilization of phages for antimicrobial treatment, characterizing and addressing for the first time 
several challenges that are intrinsic of the process and that would otherwise hinder the 
effectiveness of phage therapy. With the work of this thesis, we establish strong foundations 
and pave way to the actual utilization of phages to overcome one of our society most urgent 
and dreadful problem, antibiotic drug resistance. 
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1.3 Literature review 
 
1.3.1 Bacterial infections   
 
Bacteria represent one of the three domains in the tree of life (Wheelis, Woese, and Kandler 1990). 
As a result of at least ~ 3.5 million years of evolution (Schopf et al. 2018), bacteria vary widely in 
size, shape and function. These microorganisms have evolved to thrive in any condition (Bunney et 
al. 2017), and human beings have evolved around them (Zaneveld et al. 2009), in a symbiotic yet 
fragile relationship (Bliven et al 2016). Indeed, we live surrounded by bacteria, most of them 
beneficial and absolutely essential to our own life, while others are harmful. In normal conditions, 
all bacteria residing inside and outside us are in a perfect but delicate balance. When this 
equilibrium is perturbed, however, pathogenic bacteria can infect and multiply within the host and 
release toxins, which can kill or interfere with the function of human cells (Alberts et al. 2002), 
causing an infection. If the innate immune system of the host is not able to clear and fight the 
pathogens, the bacterial infection will eventually lead to death. Bacteria able to cause infections 
have been traditionally classified as either primary pathogens, which are always harmful to us, or 
opportunistic bacteria, which naturally colonize our body but can be harmful under specific 
circumstances. However, such classification is becoming less and less sharp as new discoveries 
on bacteria functions and behaviours accumulate (Méthot et al. 2014).  
As bacteria evolved to survive and flourish in any environments, other organisms (including 
bacteria) evolved mechanisms or acquired strategies to survive bacterial attacks. In nature, a great 
number of chemical agents able to kill or stop microbes from growing, namely antibiotics, are 
produced, e.g. by other microorganisms as a defence system or in the fight for food, and we 
humans have always taken advantage of such chemicals. In older times, moulds naturally 
containing antibiotics were used for topical application on wounds and burns  to prevent infections 
(Wainwright et al. 2019), although neither the mechanism of action nor the concept of antibiotics 
itself were known. Since the discovery of penicillin in 1928 accomplished by Sir Alexander Fleming 
and after its introduction in 1943, along with a greater awareness of hygiene, vaccination and 
prevention, the number of deaths have considerably decreased increasing life expectancy. After 
the discovery of antibiotics, we learnt not only how to take advantage of those produced by other 
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microorganisms, but we also started synthetically producing many others with promising results (da 
Cunha et al. 2019).  
However, bacterial infections still represent one of the major threats to humanity. Among the most 
dangerous bacteria, are Bacillus anthracis (Sweeney et al. 2011), species of Chlamydia (Dielissen 
et al.), Clostridium (Ragusa et al. 2018), Enterococcus (Agudelo Higuita et al. 2014), Escherichia 
(Abernethy et al. 2017), Helicobacter (Sjomina et al. 2018), Legionella (Llewellyn et al. 2017), 
Listeria (Farber and Peterkin 1991), Mycobacterium (Ashford et al. 2001), Pseudomonas (Shi et al. 
2019), Salmonella (Eng et al. 2015) and Staphylococcus (Tong et al. 2015). This huge variety of 
species is able to infect any tissue and organ in the human body, and in some cases to “hide” 
inside macrophages, causing a so-called intracellular infection. Intracellular infections, caused for 
example by the deadly bacteria of M. tuberculosis, S. Enterica, L. Monocytogenes, are particularly 
challenging to eradicate due to the lower accessibility to the site of infection, and crucially require 
efficient therapeutic strategies.   
 
1.3.2 Antimicrobial resistance 
While availability of antibiotics that work for the different bacterial strains and for the different tissue 
is of pivotal importance, the major challenge in fighting bacterial infections is represented by the 
intrinsic proficiency of bacteria to evolve and escape toxicity of antibiotics. Such mechanism of 
induced evolution of bacteria exposed to cytotoxic compounds such as antibiotics is widely referred 
to as antimicrobial resistance. This bacterial adaptive response is based on cellular and molecular 
machineries that evolved in millions of years to ensure bacteria survival in response of the 
changing environment.  
However, since the discovery and then the commercialization of penicillin in 1943, the evolutionary 
pressure on bacteria has been particularly high due to the widely spread use and misuse of 
antibiotics and the exposure to high doses for long or frequent treatments. Antibiotics have not 
been used incautiously in medicine only, but also for many other non-medical applications, such as 
animal husbandry, fish farming, aquaculture, food preservation, etc (Meek et al. 2015). The 
uncontrolled and fast evolution of pathogenic bacteria is posing a serious threat to society, which if 
not addressed could take us back to a pre-antibiotic-like era, commonly referred to as a post-
antibiotic era. 
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Antibiotic Year deployed Resistance observed Cell target 
Penicillin 1943 1946 Inhibition of cell 
wall synthesis 
Streptomycin 1943 1959 Inhibition of 
protein 
synthesis 
Chloramphenicol 1947 1959 Inhibition of 
protein 
synthesis 
Tetracycline 1948 1953 Inhibition of 
translation 
Erythromycin 1052 1988 Inhibition of 
protein 
synthesis 
Vancomycin 1956 1988 Inhibition of cell 
wall synthesis  
Methicillin 1960 1961 Inhibition of cell 
wall synthesis  
Ampicillin 1961 1973 Inhibition of cell 
wall synthesis  
Cephalosporin 1960s late 1960s Inhibition of cell 
wall synthesis  
 
Table 1│This table shows the time that passed between antibiotic deployment and when resistance was 
observed for the first time (Pana 2012). 
 
The success of antibiotics so far lays on their high specificity, which is easily achieved given that 
bacteria and host cells (prokaryotic and eukaryotic cells, respectively) differ substantially, not only 
in the components of the cell itself, but also in the function that even the same organelles have 
acquired during evolution. The current wide array of antibiotics (some examples in Table 1) affects 
some of the major functions in the bacterial cells, with typical targets being DNA replication 
(Rajendram et al. 2014), RNA transcription (Yang et al. 2016), bacterial ribosome (Nikolay et al. 
2016), enzymes (Robertson 2005) and bacterial cell wall (Koch 2003; Sarkar et al. 2017; Tejada et 
al. 2012). Antibiotic compounds can be classified in cytostatic and cytotoxic, according to whether 
the disruption of cellular functions induced by those compound causes the arrest of bacterial 
growth or leads to cell death. While some drugs might be ineffective to fight some species of 
bacteria if they inherently lack the antibiotic target (e.g. obligate anaerobic bacteria lack the 
electron transport system and are therefore immune to gentamicin, streptomycin and other similar 
antibiotics), the inefficacy of antibiotics due to drug resistance (Jerman and Kras 2003) is arising 
from more complex, acquired mechanisms. Such mechanisms (discussed in the relevant 
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subparagraph 1.3.3) are mostly initiated by different kinds of genomic mutations, which are 
presented below. 
Spontaneous mutation. Errors during replication or DNA damages that are not correctly repaired by 
the repair mechanisms are a source of spontaneous mutation (Drake 1991) that may lead to 
antibiotic resistance. For example, in a study conducted in 2001 (Wang et al. 2001), the mutation 
rate of Helicobacter pilori against clarithromycin, metronidazole, amoxicillin, ciprofloxacin and 
rifampin was found to be  between 10-8 to 10-9 per cell per division. In another study (Nyinoh et al. 
2001), in vitro spontaneous mutations in Mycobacterium smegmatis for isoniazid, rifampicin, 
kanamycin and streptomycin were found to be in the range 10-7 to 10-10 mutations per cell division.  
Hypermutation. The association between antibiotic resistance and hypermutation has been rather 
recently suggested. Hypermutation is a cellular condition in which DNA polymerases with varying 
degrees of proneness to produce errors during transcription are overexpressed. This condition is 
usually observed in the presence of selective pressure or as a consequence of cellular stress 
(Bridges 2001). Some bacteria like Pseudomonas aeruginosa show a higher frequency of mutable 
strains in their population (Blanquer et al. 2005). The presence of such strains in patients affected 
by chronic diseases represents a challenge in clinical practice. It has been shown that, in 
Pseudomonas aeruginosa populations exposed to antibiotic selective pressure, mutated strains will 
become dominant within 36 h (Oliver et al. 2004). This indicates an enhanced or almost certain risk 
of developing antibiotic resistance.  
Horizontal gene transfer.  Horizontal gene transfer (Graf et al. 2018; Lerminiaux et al 2019; 
Leungtongkam et al. 2018; Simjee 1997) consists of a group of processes including transformation, 
conjugation and transduction, by which bacteria share genetic materials. In the case of 
transduction, bacteria take advantage of temperate bacteriophages to spread genetic material that 
may carry antibiotic resistance genes. Phage instead of lysing cells, inject DNA that is then 
incorporated in the recipient genome (Hasegawa, et al. 2018; Schneider.; Transfer, et al. 2018). 
Gene transformation indicates the process of incorporating in their genome exogenous DNA from 
other bacterial surrounding (Hasegawa, v 2018). If the exogenous genetic material contains a 
resistance gene, this will be acquired in the host genome. Finally, in the conjugation process, 
genetic material like plasmid DNA is passed from donor to recipient bacteria by direct cell-to-cell 
contact (Id et al. 2018; Ripoll-rozada et al. 2015; D. Sun 2018). The potency of this mechanism 
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arises from the fact that multiple genetic rearrangements happen inside the cell, allowing the 
further spreading of the resistant genetic material. For instance, transposons are genetic elements 
able to “jump” anywhere within a genome causing genetic variability (Babakhani 2018; Blot 1994; 
Klompe et al.; Navarro 2017; Rubio-cosials et al. 2018). Alternatively, integrons are genetic 
structures able to gather gene cassettes that usually carry antibiotic resistance (Ghaly et al. 2017; 
Gillings 2014; Jones-dias et al. 2016; Mazel 2006; Rowe-magnus and Mazel.; Shariati et al. 2018). 
In the context of antibiotic treatment and resistance, a major concern is that integrons may carry 
more than one resistance gene cassette, generating a “superbug” that is multi-resistant to 
antibiotics.  
 
1.3.3 Mechanisms of resistance 
Following genomic mutation, bacteria can acquire diverse characteristics that can cause resistance 
to antibiotics. Some of the most common mechanisms of acquired resistance are presented herein. 
Antibiotic inactivation (Egorov,  et al. 2018; Munita and Arias 2016) is a very common strategy that 
bacteria use to turn drugs into harmless molecules by disruption of the reactive site or irreversible 
rearrangement conducted in physiological conditions (Pascale and Wright 2010). A famous 
example is the breakage of the four-atom ring amide of β-lactam (common structural moiety of 
some antibiotics) by the β-lactamase enzymes, which are usually produced in the presence of 
antibiotics and released in the environment (Bush and Macielag 2010; Kotra and Mobashery 
1998). In the 80s, an extended-spectrum of β-lactamase was detected, which could confer 
resistance to cefotaxime, ceftriaxone, and ceftazidime, β-lactam compounds with an oxyimino 
group (Pana and Zaoutis 2018; Paterson and Bonomo 2005; Sullivan et al. 2015), thus turning the 
bacteria that carry this gene into multi-resistant species.  
Another mechanism of drug inactivation other than molecule cleavage occurs via the chemical 
modification, in particular by insertion of chemical groups, including O-phosphorylation, O-
ribosylation, O-glycosylation, O-nucleotidylylation and O- and N-acetylation (Ramirez and 
Tolmasky 2010).  
A less common mechanism of resistance involves the loss of bacterial enzymes that are needed 
for the activation of the drug itself. As an example, antibiotics of the nitrofuran family need 
bioreduction; if these compounds are not reduced in the cytosol, following the loss of the relevant 
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enzyme, resistance occurs (Kumar and Jayaraman 1991; Whiteway et al. 1998; Zenno et al. 
1996).  
Efflux pumps are active protein machineries that span the bacteria membrane, having important 
roles in regulating molecules concentration between the inner and the outer membrane, and have 
been associated with antibiotic resistance (Li and Plésiat 2015; Poole 2009; J. Sun, Deng, and Yan 
2014). Efflux pumps not only can extrude antibiotics outside the cell, but also play key roles in the 
physiological regulation of bacteria cell, facilitating the adaptation of bacteria to new environments. 
For instance, it was found that the efflux pump AcrAB-Tol in E. coli is able to expel the bile salts 
that accumulate in the cells as a result of intestine colonization by the bacteria (Thanassi,  et al. 
1997). Efflux pumps can also affect invasiveness of P. aeruginosa (Hirakata et al. 2002). While the 
genes that codify for less specialized efflux pumps are located in the bacterial genome, genes of 
more specific pumps are usually mobile genetic material that can be exchanged among cells. 
Furthermore, there is growing evidence that efflux pumps can foster and support the formation of 
stable biofilms (Soto 2013). It was also shown that efflux pump mutation causes the transcriptional 
repression of the biosynthesis of Curli protein (Barnhart and Chapman 2006), associated with 
biofilm formation. Finally, with an elegant study conducted on E. coli, it was shown how efflux 
pumps affect neighbouring bacteria: when cells with no efflux pumps were co-cultured in the 
proximity of cells with efflux pumps, the former grew much slower (Wen, et al. 2018) leading to a 
quick shift in the bacterial population in favour of more resistant bacteria. In conclusion, efflux 
pumps support bacterial resistance to drugs via several mechanisms, such as expelling the drug 
out of the cells, as well as supporting cell growth and adaptation. 
Variation in the surrounding of the active site of the antibiotic target is another mechanism that 
bacteria exploit to develop resistance (Tomlinson et al. 2016). Penicillin-binding proteins 2a 
(PBP2a) encoded by the mecA gene are a class of mutated proteins to which penicillin and similar 
antibiotics bind with lower affinity compared to non-mutant species. This gene has been found in 
methicillin resistant S. aureus (MRSA) and confers elevate resistance to antibiotics (Lambert 
2005). Mutated PBP proteins are pivotal to another strategy that bacteria have developed to avoid 
antibiotics activity: some strains of MRSA produce simultaneously PBP with low affinity to penicillin 
and PBP with high affinity to penicillin, ensuring in any case the survival of bacteria exposed to 
penicillin (Michel and Gutmann 1997).  
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Finally, bacterial cells can change their morphology and develop physical barriers to the uptake of 
antibiotics. Vancomycin is a glycopeptide antibiotic that blocks the assembly of the bacterial cell 
wall by interaction with its precursors (Clin 1989). In 1997, vancomycin resistant S. aureus was 
discovered in Japan and from its comparison with non-mutant S. aureus it was found that the 
bacterial cell wall is two times thicker, preventing the antibiotic to reach the cytoplasmic membrane 
where it can exploit its function (Clin 1989). Otherwise, a variation in the amino acid sequence (i.e. 
d-Ala-d-Lac instead of d-Ala-d-Ala) as proved to disfavour interaction with vancomycin (Biophys et 
al. 1991; Cooper et al. 2000).  
 
In conclusion, the abuse of antibiotics can give rise to drug resistance via several mechanisms, as 
a response to selective pressure. Noteworthy, the fact that antibiotic resistance is induced by the 
presence itself of the drug does not mean that this problem is localized in certain areas of the 
globe where antibiotics are still misused. It has been shown people travelling around the world 
heavily promote and exacerbate the spread of AMR bacteria, particularly Enterobacteriaceae 
coming from developing countries of the world (Schwartz and Morris 2018). Spreading occurs by 
contact with infected people or animals, by ingestion of contaminated food and water or simply in 
the environment (Barlam and Gupta 2008; Zumla et al. 2018). Once individuals have been 
infected, AMR bacteria can cross borders and reach countries far away from each other. Even 
countries were regulations are more strict and AMR is virtually under control may be plagued by 
AMR bacteria at any time, supporting the need for a global rather than local effort in reducing 
antibiotic resistance development and increasing awareness of the problem.   
 
1.3.4 Bacteriophages and other alternative antimicrobial agents 
The always-growing concern about antibiotic resistance has led researchers to envision new ways 
to fight “superbugs” (G. Cheng et al. 2014; Nwokoro et al. 2016; Seal et al. 2013). Some of these 
alternatives include: antimicrobial peptides and proteins (Behrens et al. 2017; Mahlapuu et al. 
2016; Mccaughey et al. 2016; Pfalzgraff, et al. 2018), antibacterial vaccines (Clift and Salisbury 
2017; Ginsburg and Klugman 2017; Lipsitch and Siber 2016), therapeutic antibodies 
(Digiandomenico and Sellman; et al. 2018), faecal transplantation and probiotics (Gargiullo et al. 
2019; Khoruts 2018; Wilson et al. 2019; Wong and Santiago 2017; Zeng et al. 2019; Zilberman-
schapira et al. 2018), bacteriophages and lysins (Domingo-calap 2018; M. Entenza et al. 2018; V. 
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A. Fischetti 2018; Flaherty, et al. 2009; Hill, et al. 2018; Mikonranta et al. 2019; Paul and Opal 
2017; Principi, et al. 2019; Rios et al. 2016; Schuch et al. 2013; Tagliaferri et al. 2019; Torres-
barceló 2018; Vázquez et al. 2018; Vidal et al. 2014). In this work and following paragraphs, we will 
delve into bacteriophages, with a particular insight onto phage lysins.  
Bacteriophages are a class of virus able to infect and kill bacteria cells upon replication within it. 
They are thought to be the most abundant organism on earth, since their population exceed the 
bacterial one (about 1030) by a factor of 10 to 1 (Whitman, et al. 1998). There is a growing interest 
in phage application to treat bacterial infections due to an increasing concern about antibiotic 
resistant strains (Report 1983). Phages are so valuable because they evolve constantly along with 
bacteria in an unavoidable evolutionary race to arms, constituting an always-working weapon in the 
fight against bacteria. 
 
1.3.4.1 Brief history of phage discovery  
In 1896, Ernest Hanbury Hankin reported in his “L’action bactéricide des eaux de la Jumma et du 
Gange” the presence of something very small with antibacterial activity against cholera in the river 
Ganges and Yumana (Hankin 1896). In the early 1920s, those small entities were identified as 
being phages, although the fatherhood of phage discovery is controversial (Duckworth 1976), and 
could be attributed to either the British bacteriologist Frederick William Twort only (1915) or also to 
the French-Canadian microbiologist Félix d'Hérelle (1917), who claimed to have discovered 
phages independently from Twort two years later. Since then, phage use to treat bacterial 
infections became widespread in east Europe and spread to the western companies that began to 
commercialize typhoid and urinary-tract infections therapies (Parfitt 2005). However, thanks to the 
discovery of penicillin, dependence on phages for antibiotic treatment became less stringent, and 
phages therapy was forgotten for a while, due to phage susceptibility to the immune system and 
uncertain behaviour. 
 
1.3.4.2 Biology and phage classification 
Bacteriophages or phages are viral entities constituted of an assembly of protein units. With 
morphology that varies greatly, most of the phages share a common structure consisting of a head 
and a tail of variable length, with a tip made of receptor proteins. The head encloses single/double 
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strand (ss/ds) RNA or DNA that during infection is ejected through the tail (that is supposed to be 
contractible). Phages are nanometre scale objects in the range of 40 to 400 nm, and cannot be 
seen without the help of electron microscopy. No universally accepted method for phage 
classification exists nowadays; however, the International Committee of Taxonomy of Viruses 
(ICTV) has established  that there are 14 families plus 5 awaiting for acceptance, 37 genera and 6 
basic morphological types of which T4, λ, T7, φX174, MS2, and fd are examples (Ackermann 
2009). The greater majority of virions (96%) have a tail and contain dsDNA; the remaining 4% 
include cubic or filamentous virions. In their reproductive cycle, bacteriophages can be lytic or 
lysogenic, and few phages can have both. In the lytic cycle, phages inject their genome, reproduce 
inside their host and quickly break open the cell to look for other hosts, making lytic phages 
suitable for phage therapy. Phages with lysogenic cycle (called temperate phages) enter a dormant 
state after having injected their DNA that becomes integrated with the host genome. The dormant 
temperate phage will activate again and lyse the host cell only under certain conditions, e.g. 
nutrient depletion (Ackermann 2009).  
 
1.3.4.3 Phage stability 
Phages are the most abundant organisms on earth. They have been found in the soil, water, food 
and even in most adverse environmental conditions such as hot springs, desert and polar inland 
water (Jo et al. 2011). Humans and animals carry phages on them too. Interestingly, they are able 
to penetrate the central nervous system and can be found in the intestine, urine, faeces, saliva etc. 
Since phages have colonized nearly any place on the Earth, they exhibit a considerable variety of 
morphologies and of other features. These forms and features are the result of an evolutionary 
shaping that lasted millions of years, during which phages have developed varying sensibility to 
external factors like temperature, pH and salinity concentration. Apart from phages found living and 
proliferating under extreme conditions, thermal treatments usually inactivate phages through 
protein denaturation, although phages are generally even more resistant than bacteria (Mocé-
Llivina et al. 2003). Being generally important for phage stability, temperature also plays an 
important role in their storage. It has been shown that an addition of 5-10% of glycerol increases 
phage viability of up to 30 days (Olson, et al. 2004).  
Temperature is not only important for stability but also for activity as phages have an optimal 
temperature to infect bacteria, and a narrow pH window where activity is unchanged. For example, 
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T7 phage shows its highest stability at pH between 6 and 8; phages specific for lactic acid bacteria 
are more stable at pH 3.5 (Davis et al. 1985); B. cereus CP-51 phage have a maximum at pH 5.6. 
At temperatures lower than the optimal one, the efficiency of DNA penetration is reduced; 
meanwhile at higher temperatures, phages usually enter in a latent state that can last for longer 
than the time of exposure to the temperature.  
To preserve the active, stable, monomeric state of phages, not only temperature is important, but 
also pH. Langlet et al. found that phages are also susceptible to aggregation when the surrounding 
H+ concentration and the phage isoelectric point (pI) are in the same order of magnitude (Langlet, 
et al. 2007). Salinity and ions can also preserve or inactivate phages. For instance, a sudden 
change in et al.pressure can lead to DNA extrusion from the tail. Whereas, divalent ions may 
induce changing in phage behaviour.  
While phages have shown a great adaptability to almost any environmental condition, it is clear 
that each kind of phage is actually only resistant to a strict set of chemical/physical parameters, 
due to their structural simplicity. Therefore, encapsulation of phages within micro/nano capsules 
may be the best way to prevent phage inactivation caused by adverse conditions present in the 
human body, such as low pH, enzymatic degradation, shear stress caused by the administration 
method (e.g. via aerosol), activation of the immune system and consequent clearance. 
 
1.3.4.4 Phage uses 
Because of an increasing concern regarding antibiotic resistant strains (Report 1983) and the 
characteristic specificity of phages toward their host, during the last years phage therapy is re-
gaining more and more attention. Over the past decade, bacteriophages were used to control 
pathogen growth in food, e.g. to reduce E. coli O157:H7 population in ruminant GI tracts (Higgins 
et al. 2005), to lower salmonella levels in chicken by spraying the animals with an aqueous solution 
of phages (Borie et al. 2008; Higgins et al. 2005), and to treat pathogen contamination in fresh 
vegetables and fruits (Abuladze et al. 2008).  
The use of bacteriophages to treat oral infections has been recently suggested and tested although 
not yet for clinical applications. (Steier and Oliveira 2019) The main area where phages have 
already been employed is the treatment of localized infections. Phage therapy was used by the 
URSS in the 40s to treat infected wounds. Several attempts were made, some more successful 
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than others (Morozova, et al. 2018), where phages were used in combination (i.e. phage cocktail) 
or as single specific bacteriophage.  
Another already tested and successful application of phages is in burns, which represent a thriving 
environment for bacterial infections (Lachiewicz et al. 2017) where phages have been used 
especially in the presence of antibiotic resistant strains. For instance, burns in patient infected with 
multi drug resistant (MDR) P. aeruginosa were treated with bacteriophages and 18 cases out of 30 
were successful. However, the authors of the work described the process as time consuming and 
suggest its application only for treatment of antibiotic resistant species (Morozova, et al. 2018). 
Furthermore, phage therapy was not always as effective as reported in a study from 2009 
(Merabishvili et al. 2009), where many factors could have negatively affected phage therapy in 
wounds and burns application, such as titre, mode of administration, time of application, 
accessibility of the host by the phage, presence of biofilms.  
Also, ulcers provide an environment where a variety of bacteria are found, spanning from aerobic 
to anaerobic species and the exact composition is never easy to guess. Chronic trophic ulcers are 
the result of chronic disorders such as diabetes (Morozova, et al. 2018). Recent and less deep 
wounds are infected with S. aureus, while persistent infections with a deeper profile contains 
anaerobes, e.g. Anaerococcus, Peptonihilus, Bacteroides and Clostridium genera (Gardner et al. 
2012; Spichler et al. 2015). By using 16S rDNA pyrosequencing S. aureus and P. aeruginosa have 
been found to be the most common species in persistent infections (Wolcott et al. 2016). 
Unfortunately, chronic ulcers are always problematic to treat due to the presence of biofilms, where 
the microbes show high resistance to antibiotic therapy (Gino et al. 2017; Malik, et al. 2013; Rahim 
et al. 2016). On the other hand, bacteriophages have been applied successfully and safely in many 
studies for the treatment of chronic ulcers in humans (Markoishvili et al. 2002; Morozova et al. 
2018; Rhoads et al.).  
Finally, phages have been explored for and employed in a wide array of other situations. Phages 
have been tested for chronic lung infections in a mouse model infected with P. aeruginosa and for 
a P. aeruginosa biofilms typical of a cystic fibrosis environment (Waters EM, et al. 2017). Recently, 
a young patient affected with cystic fibrosis, colonized by a multi-drug resistant strain of 
Mycobacterium abscessus was treated with a phage cocktail of engineered phages that was able 
to kill the pathogen, improving some vital functions of the patient (Dedrick et al. 2019). Finally, a 
42-year-old patient with a trauma to his leg was infected with extensively drug resistant (XDR) A. 
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baumannii and multi-drug resistant  (MDR) K. pneumoniae. Using a combination of lytic 
bacteriophages (ɸAbKT21phi3 and ɸKpKT21phi1, targeting respectively A. baumannii and K. 
pneumoniae) and antibiotics (IV meropenem and colistin), the patient was able to recuperate 
quickly and first signs of recovery were observed after 2 days. In the 8-month post-treatment 
period no phage-resistant bacterial strains were detected.  
All these examples highlight the high therapeutic potential and the great promise of phages. 
However, our understanding and knowledge of the correlation between phage titre, dose and 
activity is scarce and explain the great variability of phage administration in the reported cases. 
 
1.3.4.5 Lysins 
Lysins are enzymes found in the bacteriophage tail able to disrupt locally the peptidoglycan 
structure of the bacteria wall and facilitate the injection of phage DNA inside the cell. Although 
lysins are more effective with Gram-positive bacteria due the peptidoglycan being more exposed, 
lysins for Gram-negative bacteria have also been found, but not applied successfully yet. Some 
advantages of lysins include specificity against the target and virtual absence of resistance as it 
has not yet reported (Loeffler, et al. 2003; Nelson, et al. 2001; Schuch, et al. 2002). Furthermore, 
lysins can be isolated from any phage, both from lytic and temperate ones. Given the small size of 
proteins compared to phages, lysins are expected to be effective in biofilms too. Finally, there is no 
risk of horizontal gene transfer; on the contrary, lysins are more susceptible to degradation than 
phages, being simply proteins. 
A first evidence of a phenomena described as “nascent lysis” was observed in the 30s (Evans 
1934) for the lysis of streptococci and later in the 60s for the lysis of S. aureus (Doughty and 
Hayashi 1961). However, first attempts to purify lysins were only partially successful (Mcgowan et 
al. 2012), due to the stability of the lysin under study (B. Y. V. A. Fischetti, et al. 1971).  
Most recently, lysins have been used to show their prophylactic activity in in vivo models against 
streptococci (Nelson, et al. 2001), for the treatment of S. pneumoniae infections in a mouse model 
(Loeffler 2013; Loeffler, et al. 2003) and for the endocarditis and bacterial meningitis in rats (J. M. 
Entenza et al. 2005; Grandgirard et al. 2008). A lysin isolated from γ phage that infect B. antracis 
was employed to treat mice that were heavily infected and all of them recovered fully (Schuch, et 
al. 2002). Similar successful reports of lysin usage are numerous in the literature (Q. Cheng et al. 
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2005; Gaeng, et al. 2000; Loessner and Wendlinger 1995; Rashel et al. 2007; Yoong et al. 2004, 
2006).  
Recently, a truncated lysin derived from staphylococcal phage K has been successfully isolated 
and purified (M Fenton et al. 2011; Kashani et al. 2017; Vázquez et al. 2018). This enzyme called 
CHAPK (Cysteine, histidine dependant amidohydrolase/peptidase CHAP K) is more active than the 
entire lysin and the phage K itself. Its functions consists in the cleavage of the cross bridge in the 
peptidoglycan wall in S. aureus between the D-alanine and the first glycine and shows rapid 
activity even with S. epidermidis. It has been used to prevent S. aureus from growing and biofilms 
have been disrupted successfully, and its co-encapsulation with staphylococcal bacteriocin 
lysostaphin in Poly(Nisopropylacrylamide) (PNIPAM) nanoparticles has been demonstrated to be 
useful for the treatment of skin infections (Mark Fenton et al. 2012; Hathaway et al. 2016). Despite 
limitations mainly due to proteins purification and isolation, these data are promising, suggesting 
that the myriad of different phages present in nature could be a source of lysin proteins or their 
derivatives, employable in the treatment of antibiotic resistant species that are threatening 
humanity.  
 
1.3.5 Bacteriophage Encapsulation  
The use of bacteriophages for the treatment of bacterial infections is a highly and urgently needed 
alternative to traditional antibiotics, due to the reasons and rationale discussed in the previous 
paragraphs. However, to ensure the effectiveness of phages activity on infection, as well as 
minimize their employment and, therefore, minimize the risk of resistance that has plagues the 
previous approaches, the selective delivery of phages via advanced encapsulation is a promising 
strategy. The aim of encapsulation is to make the phages live longer in a micro-environment 
tailored to protect them while enhancing storage time. The application of encapsulated phages is of 
wide interest not only for medicinal phage therapy but also in food preservation technologies, 
reduction of pathogens in livestock, bio sanitation of hospital surfaces and as natural antimicrobial 
agents.  
In 2008, bacteriophage Felix O1 has been encapsulated in chitosan-alginate microsphere (Ma et 
al. 2008) and tested in simulated gastric fluids. The acidic environment of the stomach was shown 
to be highly damaging and affect phages viability. Free Felix O1 has not been detected after 5 min 
of exposure to pH below 3.7. On the other hand, microencapsulated phages were almost not 
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affected by the surrounding low pH, recording a decrease in phage titre as small as 0.67 log units 
under the same conditions. Moreover, it has been detected after 6 weeks of storage at 4 °C and 
wholly released upon exposure at intestinal pH (6.8). To accelerate the release of phages from 
alginate-microparticles, Tang and coworkers (Tang et al. 2013) used a formulation of alginate-
whey proteins. Using this mixture, the stability of phages was not varied, and the release profile 
could be modulated according to the ratio alginate/whey protein.  
Vonasek and coworkers (Vonasek, et al. 2014) have used a T4 bacteriophage as model to show 
that phages can be immobilised in whey proteins (WPI) to lengthen the storage. The results exhibit 
an enhanced efficiency on stability over a period of 1 month for ambient (22 °C and light) and 
refrigerated (4 °C and dark) conditions.  
Korehei and Kadla have studied the release profile of immobilised phages in electrospun fibres 
(Korehei and Kadla 2014). If fibres were prepared with only of poly(ethylene oxide) (PEO), a burst 
release was detected. Using a blend of PEO and cellulose diacetate (CDA) the release rate was 
markedly decreased, while CDA fibres showed almost no release. This study suggests that 
polymer dissolution/swelling is a key point to control the release rate.  
Balcão et al. in an attempt to house bacteriophages and protect them from the degradation and 
viability decline have used a water-in-oil-in-water (w/o/w) emulsion (Balcão et al. 2014). Phages 
have been dissolved in an aqueous solution and then in melted lipids, followed by high-
performance homogenization. The outer aqueous phase has been added and re-homogenised. 
Long-term storage experiments have been carried out and the results confirm the effectiveness of 
this method. Quantitative results on the antibacterial activity of encapsulated phage were not 
provided although lytic activity of encapsulated phage was observed following phage release. 
Other approaches of phage encapsulation are available, albeit with some limitations. Strategies 
exploiting the dehydration of phage solution under extreme conditions (e.g. low or high 
temperature, high vacuum) include the freeze drying method, which consists of a freezing step, 
during which the sample is cooled down to its triple point, followed by a drying step, which involves 
a reduction of the pressure so that the solid aqueous phase can sublime. While freeze drying is a 
well-established approach, widely and successfully employed by the pharmaceutical industry, in 
the case of phages, freeze drying implies a substantial loss of viability due to osmotic shock of the 
cooling step, although strategies have been investigated to ameliorate the survival rate, such as 
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the use of disaccharides (Malik et al. 2017, Malenovská et al., Golshahi et al., Puapermpoonsiri et 
al., Dai et al.). Additionally, few works have been published on phage encapsulated in polymeric 
matrix using the freeze drying process (Dai et al., Alfadhel et al.), although not all of them have 
reported positive outcomes (Puapermpoonsiri et al.). 
Another method exploiting the dehydration of phage solution is the spray drying method. In the 
spray drying method, a solution and its solute are separated by passing through a nozzle that 
atomizes the solution generating droplets of a controlled size (20 – 200 µm). Due to the high 
surface area to volume ratio and the presence of a hot air stream, the liquid is quickly vaporized 
and the solid particles generated are collected. The resulting product contains the solute, the 
excipients and residual moisture. Despite being widely reported, the high shear stress and the 
elevate temperature reached during the spray drying process negatively affect phage viability 
(Leung et al., Davies et al., Jończyk et al., Vandenheuvel et al.). In an attempt to reduce this 
detrimental effect, to prevent excessive dehydration and thermal stress, researcher have included 
excipients in the formulation (e.g. lactose (131), glucose, sucrose, mannitol, (Leung et al. 2016) 
and trehalose, the most used probably due to its high glass transition temperature (Leung et al. 
2016, Leung et al. 2017, Matinkhoo et al., Vandenheuvel et al.)). Although harsh and disruptive to 
phages, spray drying is easily scalable and, once achieved, phage are stable over a long period of 
time, even without refrigeration. 
Given the success and relatively easy and routine use of liposome encapsulation for intracellular 
delivery of small molecule drugs (Owais and Gupta 2005), few research groups have investigated 
the encapsulation of bacteriophage in liposomes as a potential approach to tackle antibiotic 
resistant bacterial infections. Published studies that explored the encapsulation of bacteriophage in 
liposomes are revised in the following section. 
 
1.3.5.1 Encapsulation in Liposomes  
The success of liposome-based drug delivery encouraged the employment of such systems for the 
delivery of phages too. Neith et al. recently achieved the successful encapsulation of 
mycobacteriophage TM4 in giant unilamellar vesicles (Nieth et al. 2015). On the other hand, by 
encapsulation of a lambda phage expressing yellow fluorescent protein and by fluorescent labelling 
of macrophage endosomal proteins, they could show the intracellular delivery and co-localisation 
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of the lambda phage and the endosomes. Nieth also experienced some challenges when 
encapsulating bacteriophages in liposomes. Encapsulation efficiency, control over the size ans  
phage titre were identified as key features for the successful encapsulation of phage. 
In 2015, Colom et al. studied the consequence of oral phage therapy against salmonella in poultry 
(Colom et al. 2015). A cocktail of phage was encapsulated in liposomes and effect on salmonella 
tested. Alongside the superior resistance to simulated gastric fluids between encapsulated and 
non-encapsulated phages, the residence time in the intestine was also prolonged. Phages were 
encapsulated in cationic liposomes (liposome size range ~ 200 – 1000 nm). The choice of cationic 
liposomes to load bacteriophages is meant to 1) protect the bacteriophage from gastric acids and 
2) act as a promoter for mucoadhesiveness owing to their positively charged surfaces, therefore 
prolonging intestinal residence time of phages. In vitro studies showed that encapsulated phages 
were released upon exposure to simulated intestinal fluid (SIF) within 60 min. S. enterica phage 
encapsulated in cationic liposomes were mildly protected from viability loss due to exposure to  
simulated gastric fluid (SGF) when compared with free phage. The intestinal residence time of 
liposome encapsulated phage in the cecum of newly hatched chickens was considerably longer 
than for free phage, probably due to the small size and mucoadhesive properties of the cationic 
liposomes. Animals have been treated with encapsulated and free phages. In the first case, 
phages have been detected in the 38.1% of the sample while only the 9.5% of the control has 
shown active viruses. Moreover, when treatment has been stopped, only the former has shown 
activity against salmonella for over 1 week. 
Finally, Singla et al. encapsulated K. pneumonia phage in liposomes, ranging 500 nm – 1000 nm 
and prepared via film-hydration method, using different phospholipid : cholesterol ratios, and 
adding charge-inducing agents to prevent liposome aggregation (Singla et al. 2016). Phage 
encapsulation efficiency was shown to be higher for the electrostatically stabilised positively 
charged liposomes with higher lipid content. Phage encapsulated liposomes were stable for 9 
weeks when stored at 4 °C. Storage at ambient temperature or 37 °C resulted in changes in size 
(increase) as well as loss of phage titre. In vivo toxicity and bio-distribution were assessed for 
encapsulated phages in mice. Blood titres of phage reached ~10 PFU ml-1 shortly after injection 
(within the 1st hour) for both free and liposome encapsulated phages. However, liposome 
encapsulated phage remained in blood and other organs for longer periods compared with free 
phage. Indeed, free phage were cleared from the blood and organs 48 h-post treatment whereas 
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liposome-encapsulated phage were detectable in blood and all organs up until day 3 (albeit at low 
concentrations ~ 1 PFU ml-1) post treatment and remained detectable in the spleen for up to 14 
days  
 
 
 
 
 
 
 
 
 
Figure 1.0│3D representation of a phospholipid vesicle.  Open vesicle (left), shows the lipid bilayer formed 
by two phospholipids with the hydrophobic tail facing inwards and the head facing outwards. Closed vesicle 
(right).  
 
 
1.3.5.2 Microfluidics for liposome production 
Liposomes are spherical structures (figure 1.0) delimited by a double layer of phospholipids and an 
aqueous core. It has been shown that liposome size affects lag-phase in a proportional fashion 
(Gheriani Gruszka et al. 1988): as liposome size increases, lag-phase increases, therefore, 
liposome degradation and cargo release are delayed with diameter. Hence, to control cargo 
release, it is of pivotal important to decide and determine liposome size. In particular, it has been 
reported that by reducing the size of particles below 1 µm (i.e. nm scale) liposome nanoparticle 
access is enhanced, potentially allowing delivery to difficult niches, e.g. sites deep in the intestinal 
mucosa (Takeuchi et al. 2005; Thirawong et al. 2008). Furthermore, the residence time of 
nanoparticles is longer compared to larger microparticles, which are more prone to peristaltic 
action and rapid transit through the colon. Nanoparticles have been shown interact with epithelial 
cells (Bo Xiao, et al.,), as a potential basis for longer retention. Microparticles have been shown to 
adhere to the inflamed mucosal wall whereas nanoparticles are absorbed across the epithelial 
barrier (Schmidt et al. 2013). 
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Figure 1.1│3D representation of a capillary microfluidic device.  In orange, the organic phase delivered 
through the inner capillary and in light blue, the aqueous phase delivered through the outer capillary. 
 
In nearly all previously reported cases of phage encapsulation in liposomes, the thin-film hydration 
method has been used for liposome preparation, resulting in relatively large (~ 1 µm) and 
heterogeneous multilamellar liposomes (Colom et al. 2015; Nieth et al. 2015). Alternatively, 
extrusion of the liposome mixture through porous membranes has been used to form smaller 
liposomes (100 – 200 nm). Nieth et al., employed a method, previously reported (Meier and 
Schmatko 2013), to prepare phage encapsulated in giant unilamellar vesicles (GUV) using gel-
assisted formation of GUV by rehydrating lipid layers on polyvinyl alcohol gels. Confocal 
microscopy showed that this method allowed good encapsulation of a fluorescently labelled E. coli 
phage. When the E. coli phage was provided externally with the swelling buffer, no encapsulation 
was observed suggesting that the lipid stacks themselves were impermeable to the phage present 
in the external solution. The GUV prepared using this technique were large vesicles (5 µm – 50 
µm). Extrusion of GUV through a 5 µm pore size membrane resulted in reduction in vesicle size to 
less than 5 µm, however, also in significant if not total loss of E. coli phage, which could not be 
detected by fluorescent microscopy. Nieth et al. also employed inverse emulsion liposome 
preparation method, using a previously reported protocol (Pautot, Frisken, and Weitz 2003), to 
encapsulate fluorescent E. coli phage, resulting in GUV with an average diameter between 10  µm 
and 15 µm..  
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It is a matter of general knowledge to prepare liposome 5 -10 °C or more above Tm (main lamellar 
chain-melting phase transition temperature). Its value depends on the chemical/physical nature of 
membrane composition and it defines the boundary between crystalline-analogue state (“gel”) and 
the liquid-analogue state (“liquid-crystalline”). Above this temperature, lipids are mechanically 
treatable. The long polar chains of the fatty acids explore more conformations than in the solid 
state. As the bilayer is fluid, lateral and rotational diffusion increase resembling a liquid system. 
Usually membranes are a mixture of more components. Along phospholipids, cholesterol plays a 
key role in liposomes formation. Its concentration can lower or increase Tm. The way it interacts 
with lipids is quite complex. Its rigidity influences the surrounding lipids immobilising some of them 
around it, thereby providing an extra support. The general procedures to form liposomes are lipid 
film hydration, phase evaporation and detergent depletion. In these techniques the liposomes 
production relays on the mechanical dispersion of dried lipids at high shear stress under non-
uniform conditions. Uniform liposomes with a mean diameter ranging from 50 to 300 nm have been 
made using microfluidic flow focusing in 2D microchannels obtained from a silica wafer by means 
of photolithography and Deep Reactive Ion Etching (Colom et al. 2015; Jahn et al. 2010; 
Thirawong et al. 2008). However, this approach requires expensive devices and is time 
consuming. Most importantly, because of the 2D geometry of the channels, mixing conditions are 
not uniform. A cheaper and more uniform technique, as previously described (Vladisavljevic et al. 
2014), uses the same principles of ethanol injection but with a glass capillaries system (figure 1.1). 
Mean size, distribution and lamellarity depend of three parameters: flow-rate ratio, lipid 
composition and temperature, however, only few authors have studied the effect of temperature in 
liposomes formation (Sulkowski et al. 2005; Zook and Vreeland 2010). 
The theory that explains liposomes formation in alcohol injection method is derived from an 
experimental verified model for the detergent dilution liposomes preparation technique (Leng, et al. 
2003). Once the two solutions come in contact, phospholipids experience a more polar solvent. In 
order to reduce the unfavourable interactions between the polar part of their fatty chains and the 
aqueous solution, they begin to self-assemble into planar lipid bilayers. These planar discs grow by 
association with each other and/or with the free phospholipids in the alcohol – water mixture. In 
doing so, they tend to bend to reduce the surface of the apolar area around the perimeter that is in 
contact with the solvent. Eventually, they close into spherical vesicles encasing an aqueous core.  
The energy required to close the liposome (i.e., “the energy of curvature”) is equal to the difference 
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between the energy required to bend the planar lipid bilayers (i.e., “elastic energy”) and the energy 
of the hydrophobic tails around the edges of the perimeter exposed to the polar solvent (i.e., “line 
energy”). The characteristic closure time Τc decreases exponentially as the energy of curvature 
increases. 
 
1.3.5.3 Liposomes in drug delivery 
Liposomes are a promising drug delivery system and a pharmaceutical carrier of choice (Torchilin 
2005). Liposomes are highly biocompatible and they have been widely used to encapsulate 
hydrophilic or hydrophobic therapeutic agents in their aqueous core or within the bilayer thereby 
enhancing drug bioavailability and stability over time. In the context of phage therapy, the potential 
ability of liposome-encapsulated phage to enter live cells containing intracellular pathogens is of 
crucial importance e.g. for M. tuberculosis or other intracellular bacteria such as S. aureus and E. 
coli. Indeed, liposome-encapsulated bacteriophage would be protected from physical and chemical 
stresses and are expected to trigger a much lower or no immune response in the human body. The 
efficiency in therapeutic use of drug-loaded liposomes is often influenced by macro and micro 
characteristics such as formulation, charge, size, fluidity, bending rigidity and surface 
functionalization. All these properties define one or more specific features of liposomes and their 
understanding can allow minimization of undesired side effects and maximization of the liposome-
based treatment. Size and lamellarity vary as a result of the manufacturing process. Fluidity and 
superficial charge depend on the chemical nature of the lipids and on their relative ratio. The 
surface of liposomes may be functionalized to achieve various goals, such as attachment of 
specific ligands for targeted delivery or controlled cargo release, just as few examples. 
Cargo release triggered by low pH is a milestone in liposomes delivery (Gerasimov et al. 1999). 
The phase transition of dioleoylphosphatidylethanolamine (DOPE) liposomes blended with pH-
sensitive surfactants is the first reported example of acid triggered release (Chul, et al. 1994). 
Leakage is very low when pH is near neutrality and increase dramatically with pH down to pH 4. 
When the environment changes toward a more acidic one, the ionic state of the PE head varies 
too. Two possible scenarios can occur: 1) the head becomes smaller and a micellar aggregation is 
favoured, Lα – HII transition occurs; 2) vesicles leakage follow destabilization upon aggregation 
phenomena.  
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Slepushkin and coworkers have studied the effects of lipid-anchored polyethylene glycol(PEG-PE) 
in liposomes (4:6:0.3 CHEMS:DOPE:PEG2000-DPSE) that destabilize at mildly acidic pH (Simões 
et al. 2001). They have found that even if the pH-dependent response was significantly decreased, 
the vesicles were still able to delivery and release their cargo intracellularly. Alternative 
formulations employed 3β – (N – (N’, N’ – dimethylaminoethane)carbamoyl) cholesterol (DC-
Chol):DOPE have been used as gene carrier for transgene expression therapies (W. Camplen, 
Kinrade E, 1995). Fusogenic liposomes bearing imidazole and 4-aminopyridyl protonatable groups 
have been used ad transfecting agents in vitro (Budker et al. 1996). Later on, pH-sensitive 
polymers blended with 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) and 1,2-Dipalmitoyl-sn-glycero-3-phosphorylglycerol sodium 
salt (DPPG) have shown micellation when pH is reduced below 6.55. Kono et al. have prepared a 
succinylated poly(glycidol) (SPG) derivate (Kono, et al. 1997). SPG seems to adsorb on the 
liposome surface and its conformation changes with the pH. A noteworthy approach consists in the 
use of a thiol cleavable poly(ethylene glycol)-grafted distearoylphosphatidylethanolamine (DSPE) 
at low molecular concentration (3-6 mol%) to stabilize the lamellar phase of DOPE liposomes 
(Holland et al. 1996). Using a thiolytic agent such as dithiothreitol (DTT) to break the disulphide 
bond, surface destabilization occurs, entailing aggregation and so leakage. It has been also 
investigated the effects of an acid-sensible polymer (vinyl ether) for DOPE liposomes (Holland et 
al. 1996). Degradation of the vinyl ether segment triggers de-PEGylation with subsequent revert to 
the preferred hexagonal phase that implicates releasing of the loaded drug. Although the 
impressive outcomes crown PE-liposomes as promising formulations in making pH-responsive 
formulations, a technical difficulty arises from the fact that the pH rarely declines below 6.5 in the 
human body. In addition, the main mechanism that characterizes liposomes leaking comes from 
aggregation. In contrast, aggregation is dramatically reduced in PEGylated systems that aim to 
enhance circulation time and reduce clearance by the immune system. Remarkably, Leroux et al. 
have proposed a modification of a thermal-responsive polymer (N-isopropylacrylamide NIPAM) 
with randomly introduced titratable comonomer (Leroux et al. 2001). The strategy is to increase the 
Lower Critical Solution Temperature (LCST) from 32 C° to above 37 C°, making the polymer 
soluble below this temperature and responsive to variations on pH. When the transition region is 
reached, the polymer becomes more hydrophobic and tends to contract, creating holes, defects 
and spaces in the surface. In 2011, Mamasheva and coworkers designed a heterogeneous 
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membrane formulation, which releases its content as pH variation activates a gel-gel domains 
separation (Mamasheva et al. 2011). The lipid bilayers have been built with two classes of 
phospholipids, a titratable one with anionic head groups (class A i.e. phosphatidic acid or 
phosphatidyl serine) and a nonionizable type (class B i.e. phosphatidylcholine) with different acyl 
chain length. When the pH is high enough to protonate the A class, the electrostatic repulsion 
keeps the membrane homogenously distributed. If the pH is lowered until the head groups of the A 
class lipids is protonated and neutral, the attractive interactions prevail favouring phase separation. 
 
1.3.5.4 Phospholipid Membranes and Phospholipase A2 
Phospholipase A2 (sPLA2) is 125-amino acid enzyme that is secreted by the pancreas and that 
catalyses the releasing of fatty acid and lysolipids (LisoPC) from stereospecific phospholipids 
during digestion. sPLA2 is involved in many biological functions like inflammatory signalling, 
smooth muscle contraction, cells proliferation and may play some roles during cancer development 
(N’Goma et al. 2012). sPLA2 is unable to interact with free phospholipids; indeed, its activity is 
triggered upon interaction with water/lipid surface in the presence of Ca2+ as cofactor. It is possible 
to modulate the enzyme activity playing with composition and chemical/physical properties of the 
bilayers. Following the intrinsic tryptophan fluorescence, two regions are clearly identified: 1) a lag-
phase (τ), where the number of enzymes attached to the lipid membrane and hydrolysis products 
inside of it increases, and 2) a burst-phase, where the membrane instability is quickly propagated 
throughout the bilayer, eventually releasing the load. In the early 2000s, the reasons behind this 
peculiar behaviour have been revealed, which are based on the observation that any double layer 
made of lipids is a dynamic system. The degree of dynamism depends on the composition and the 
chemical/physical properties of the bilayer. The smaller is the interaction between phospholipids, 
the greater is the amount of protrusion on the membrane. Long acyl chains and high cholesterol 
content reduce the dynamism and so the defects. Short acyl chains, low cholesterol content and 
double bounds favourite deformities. Moreover, hydrolysis bio-products, LysoPC and fatty acids, 
promote respectively normal micelles and inverted hexagonal mesophases that facilitate lipids to 
make vertical extrusion (Halperin and Mouritsen 2005) due to heterogeneity, defects or pore 
formation (Arouri and Mouritsen 2013). Since the sPLA2 active site is placed ≈ 1.5 nm above the 
surface, any factor that encourages protrusion development helps phospholipids to reach the 
active site, boosting the enzyme activity. The variation of τ (T) is thought to be due to a contribution 
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of three factors (Callisen et al. 2004). The first factor (lipid protrusions) accounts for the Arrhenius 
contribution, so the process is thermally activated. The second term (membrane softness) shows a 
minimum at Tm, that it is expected to be related to the degree of heterogeneity on the surface. 
Finally, the third point (enzyme activity) decreases as the temperature increases, and the 
equilibrium folded/unfolded is pushed unbalanced towards the unfolded state. In 1998, Vermehren 
et al. have shown a relationship between lipopolymeric content in liposomes and sPLA2 activity 
(Vermehren et al. 1998). Embellishing the phospholipid composition with DPPE-PEG2000 is a 
common strategy to lend stealth properties to nanocarriers have otherwise have to face the 
immune system (e.g. delivery into the blood stream). Furthermore, functionalization with DPPE-
PEG2000 has an impact on the microscopic lateral organization of the lipids, inducing a 
macroscopic destabilization of the overall liposome. Through computer simulation, it has been 
shown that the interface between gel and fluid lipid domain near Tm leads to micro heterogeneity 
formation (Hønger et al. 1996). Its development influences macroscopic properties such as specific 
heat, bending rigidity, passive permeability, etc. LiPlasome formulation, designed for high liability to 
sPLA2-IIA hydrolysis, has been tested on patients with solid tumour in clinical trials, which were, 
however, later interrupted due to side effects (De Jonge et al. 2010). It is possible that the role 
played by DPPE-PEG2000 on enhancing lipids vertical fluctuations was not specific to cancer 
tissue. Indeed, the higher solubility of grafted lipids does not find any variation among human 
tissues. Since the complexity of biological systems, it would be wiser to use double, triple or even 
quadruple stimuli trigger approach to avoid unspecific release. Lipid membranes made out of 
saturated and unsaturated phospholipids typically show a two-phase coexistence region 
(Simonsen 2008). If phospholipase sPLA2 is used to degrade membrane bilayers, the two domains 
are digested at a different rate, leading to a gradual decrease of one of them that eventually 
disappears. No lag-phase has been measured, probably because sPLA2 activity is enhanced by 
the presence of domain boundaries that provide enough defects. 
In conclusion, phospholipase sPLA2 represents a valid way to release the cargo of phospholipidic 
vesicles by liposome degradation, which however requires a deep understanding of sPLA2 mode 
of action to achieve targeted and controlled release. 
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Chapter 2: Materials and Methods 
         
2.1 Chemicals and reagents          
18:0 PC (1,2-distearoyl-sn-glycero-3-phosphocholine), 16:0 PC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine), 14:0 PC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), 18:0 PEG2000 PE (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000], ammonium 
salt), 16:0 PEG2000 PE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000], ammonium salt), 18:1 (Δ9-Cis) PE (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine), 18:1 PS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine, sodium salt), 18:0-
18:1 PS (1-stearoyl-2-oleoyl-sn-glycero-3-phospho-L-serine, sodium salt), 18:1 TAP (1,2-dioleoyl-
3-trimethylammonium-propane, chloride salt), DSPE-PEG(2000)-DBCO (1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[dibenzocyclooctyl(polyethylene glycol)-2000], ammonium salt), 18:0 
Cy7 PE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-Cyanine 7), 18:1-12:0 NBD PC (1-
Oleoyl-2-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-sn-Glycero-3-Phosphocholine), 
Cholesterol, CHEMS (cholesteryl hemisuccinate) were purchased either as a powder or in 
chloroform from Sigma-Aldrich (United Kingdom) and used without any further purification. DNase 
I, cOmplete™ Mini EDTA-free protease inhibitor cocktail and calcein were purchased from Sigma-
Aldrich. Glycerol (Molecular Biology), D(+)-trehalose dihydrate 99%, chloroform, 99+% extra pure 
stabilised with amylene, ethanol 99.5% (extra dry), isopropanol anhydrous 99.5%, n-hexane 97% 
Acros Organics™, n-pentane +99% AcroSeal™ ACROS Organics™, 98+% Alfa Aesar™, 
polyethylene glycol 8000 (PEG), PBS 1X powder, pH 7.4, Triton X-100, Thermo Scientific™ 
Pierce™ BCA™ protein assay, Expedeon InstantBlue™ stain protein, Alfa Aesar™ Laemmli SDS 
sample buffer reducing 4X, Thermo Scientific™ pierce™ lysozyme,  Thermo Scientific™ bond-
breaker™ neutral pH TCEP solution, and Nile Red 99% ACROS Organics™ were purchased from 
Fisher Scientific (UK).  
 
2.2 Bacteria and Virus strains, bacteriological media and buffers     
Staphylococcus aureus (ATCC® 19685), Escherichia coli (ATCC® 11303), bacteriophages K 
(ATCC® 1985-B1) and bacteriophage T3 (ATCC® 11303-B3) were sourced from LGC standards, 
United Kingdom (UK). Staphylococcus aureus was grown at 37 °C in Brain Heart Infusion (BHI, 
Sigma-Aldrich, United Kingdom) and used to propagate Phage K. Escherichia coli was grown at 37 
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°C in Luria-Bertani medium (LB, Sigma-Aldrich, united Kingdom) and used to propagate T3. SM 
buffer (50mM Tris-HCl, 100mM NaCl, 8mM MgSO4 pH 7.5) was used to store phages and 
resuspend bacteria. PBS (137mM NaCl, 2.7mM KCl, Na2HPO4 10Mm, KH2PO4 1.8mM pH 7.5) 
was used during zeta potential measurements. Acetate (CH3COONa 67Mm, CH3COOH 33Mm pH 
5) and Glycine-HCl (100mM C2H5NO2, HCl to final pH 3) were used for phage viability test at low 
pH. 
 
2.3 Bacteriophage K propagation in S. aureus      
A single colony picked from a streaked plate was inoculated in BHI and left to shake at 37° C 
overnight. Fresh BHI was added to OD600 0.05 and left to grow to OD600 between 0.2 and 0.3. 
Phage K of a known titre was added to the culture at a multiplicity of infection (MOI) of 0.01. 
MgSO4 was added to a final concentration of 2.5% w/v 5 min after infection (Hotchin 1955). Culture 
was left to clear (4-6 hours) and then centrifuged at 17000 g for 20 min. Finally, supernatant was 
filtered through 0.22µm syringe filter and stored at 4° C. Correlation between OD600 and CFU was 
assessed through growth curve replicates under identical conditions. CFU/ml between OD600 0.2 
and 0.3 is in the order of 108. Phage titre was determined as previously described (Adams Mark H. 
1959). Briefly, serial dilutions of phage suspension were spotted (4 replicates) on a double agar 
plate. Dried plate was incubated overnight at 37 °C and plaques counted on the following day. 
Phage titre is expressed as plaque forming units (PFU ml-1). 
 
2.4 T3 propagation in E. coli        
A single colony picked from a streaked plate was inoculated in LB and left to shake at 37° C 
overnight. Fresh LB was added to OD600 0.05 and left to grow to OD600 between 0.2 and 0.3. T3 of 
a known titre was added to the culture at a MOI of 0.001. (NH4)2SO4 was added to a final 
concentration of 2.5 % w/v 5 min after infection. Culture was left to clear (2-4 hours) and then 
centrifuged at 17000 g for 20 min. Then, supernatant was filtered through 0.22µm syringe filter and 
stored at 4° C. Correlation between OD600 and CFU was assessed through growth curve replicates 
under identical conditions. CFU/ml between OD600 0.2 and 0.3 is in the order of 108. 
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2.5 Size distribution and zeta potential for phages and liposomes     
Size, size distribution and zeta potential for phage suspension and liposomes were determined 
using nano tracking analysis (NTA, nanosight LM10, Malvern Panalytical Ltd, United Kingdom) and 
Tunable Resistive Pulse Sensing (TRPS, QNanoGold, IZON SCIENCE, United Kingdom). NTA 
was used for highly dispersed samples (50 – 1000nm) while TRPS was preferred for tighter 
distributions. For NTA analysis, fresh lysate, purified phage sample or liposomes suspension was 
diluted to a final concentration of 107 – 1010 particles/ml in filtered SM buffer. One ml syringe was 
used to inject the sample into the visualization chamber and five measurements of 60 second per 
sample were recorded and analysed. The temperature was registered with a thermometer (RTD 
Pt100, OMEGA, UK) and temperature correction was carried out. The software used for capturing 
and data analysis was NTA 3.0 (Malvern Instruments Ltd., UK). Zeta potential was measured using 
Tunable Resistive Pulse Sensing (TRPS, QNanoGold, IZON SCIENCE, United Kingdom). Briefly, 
the fluid cell and the nanopore were pre-wetted with an electrolyte containing 0.02 % w/v of 
Tween-20. The QNano was let to run for 15 min before particle measurements to establish a stable 
baseline current. 25 µl aliquot of particle suspensions was loaded and 500 blockade events were 
recorded for zeta potential measurements. Zeta values were calculated using the zeta template 
provided by IZON SCIENCE. 
 
2.6 Phage purification           
T3 phage was purified from endotoxins using a combination of methods: liquid-liquid extraction 
(LLE), buffer exchange, hydrophobic interaction chromatography (HIC). For the LLE, T3 filtered 
lysate was mixed 1 to 1 with 1-octanol and gently stirred in a covered beaker over night with a 
stand stirrer at room temperature. The aqueous phase was separated from the oil by centrifugation 
(20 min 3900g) in a 50 ml falcon tube and recovered by piercing the bottom of the tube. Then, the 
phage suspension was dialysed three times against SM buffer pH 7.5, filtered through 0.22µm 
syringe filter and stored at 4° C until further processing. For buffer exchange, 50 ml of phage 
suspension after LLE was placed in a stirred cell (Millipore U.K. Limited) equipped with 1000 KDa 
polyethersulfone membrane (supplied by Merck Millipore UK and Alfalaval) and washed with fresh 
endotoxin-free buffer. In order to avoid endotoxins concentration, the initial volume was reduced by 
no more than 50 % before fresh buffer was added. For HIC, Capto core and capto octyl (GE 
Healthcare Life Sciences) resin were used to assess their efficacy in endotoxin removal. In a 30 ml 
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endotoxin-free container (Thermo Scientific™ Sterilin Certified Universal Containers) 1 ml of resin 
was washed three times with endotoxin-free PBS. 1 ml of T3 phage suspension (endotoxin content 
≈ 4x103 EU ml-1) was added to the resin and let to interact for two hours in a rotary mixer at 4°C. 
Then, the supernatant was separated from the resin by centrifugation (3900g for 2 min Labofuge® 
400R) and added to 1ml of fresh resin. This step was repeated three times. Supernatant was 
collect after each step and endotoxin concentration was measured with LAL assay. EndoTrap® red 
endotoxin removal 1 ml column was used to remove the endotoxins from a T3 phage suspension. 
After regeneration and equilibration 1 ml of T3 (endotoxin content ≈ 4x103 EU ml-1) was loaded into 
the column. After eluate collection, 1 ml of equilibration buffer was added to wash the column and 
then collected. 3 ml of regeneration buffer were added and collected. Endotoxin concentration 
measurements and phage titre was performed for all the fractions collected. 
Phage K lysate was purified by buffer exchange using either an Amicon™ Ultra-15 centrifugal filter 
unit with 100 or 300 kDa cut off or tangential flow ultrafiltration cassettes, with 100 or 300 kDa 
(Merck Millipore, UK). 
 
2.7 Endotoxins quantification          
T3 samples contamination with lipopolysaccharides (LPS) was quantified using Pierce™ LAL 
Chromogenic Endotoxin Quantitation Kit (Thermo Fisher, UK) or the Limulus Amebocyte Lysate 
Chromogenic Endpoint Assay (Hycult Biotech, UK). An endotoxin standard derived from E. coli 
strain O111:B4 is provided in each kit and used to create a standard curve. The concentration of 
endotoxins of an unknown sample is determined by extrapolating its absorbance against the 
standard curve.  
 
2.8 Bacteriophage concentration         
Bacteriophages were concentrated using different approaches: Amicon™ Ultra-15 centrifugal filter 
unit with 100 kDa cut off; tangential flow ultrafiltration cassettes 100 kDa (Merck Millipore, UK) for 
bigger batches. When higher titre was needed, phages were purified by cesium chloride gradient 
as follow: phage lysate was poured in centrifuge bottles and spun at 4,000 g at 4°C for 15 min. the 
supernatant was transferred in sterile bottles, NaCl added to 0.2 M and incubated on ice for 1 hour. 
The NaCl solution was transferred into centrifuge bottles and spun at 5,000 g at 4°C for 45 min. 
The supernatant was poured into sterile bottles and PEG8000 was added to a final concentration 
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of 10% w/v. The solution was agitated until complete dissolution of the PEG8000 and stored at 4°C 
overnight. The PEG8000 solution was transferred into sterile centrifuge bottles and spun 25,000 g 
at 4 °C for 60 minutes to precipitate phage particles. The pellets was resuspended in SM buffer at 
a total volume of 10 ml and store at 4 °C. A CsCl gradient was prepared in a polymer centrifuge 
tube by layering three CsCl solutions at 1.7g/ml, 1.5g/ml and 1.4g/ml respectively. The phage 
solution was brought to 1.3g/ml by adding 0.31g of CsCl to 690µl of phage solution, layered on top 
of the preformed gradient and centrifuged at 150,000 g at 4° C for 20 hours using a SW28 rotor in 
a Beckman L-90K centrifuge. A grey band forming in the middle third was recovered by piercing 
the centrifuge tube with a needle and withdrawn using a plastic syringe. The recovered phage 
band was placed in a dialysis tube (12-14,000 kDa cut off) and dialysed against SM buffer 
overnight at 4° C. The dialysis bag was transferred into fresh SM buffer and dialysed for 2 hours at 
room temperature, this step was repeated two times. Following dialysis the phage solution was 
filtered through 0.22µm syringe filter, divided into aliquots and stored at -20° C. 
 
2.9 Microfluidic co-flow device fabrication        
The co-flow microfluidic (MF) device used for liposome formation was fabricated in-house (figure 
1.1) following the procedure reported earlier (Vladisavljevic et al., 2014). The main body of the MF 
device consisted of two coaxial borosilicate glass capillaries glued onto a microscope glass slide. 
To assemble the device, a round tapered-end borosilicate glass capillary (Intracel,Royston, UK) 
with a 1mm outer diameter, 0.58mm inner diameter, and 100–200μm orifice diameter was inserted 
halfway into an outer square glass capillary (1mm inner dimension, AIT Glass, Rockaway, US) and 
aligned. A P-97 Flaming/Brown micropipette puller (Sutter Instrument Co., USA) was used to 
produce a sharp capillary tip of about 20μm in diameter. The orifice size of inner capillary was then 
increased by sanding the tip against sand paper until the orifice with a required size and smooth 
rim was obtained. The orifice size was controlled using a Narishige’s MF-830 microforge 
microscope (Intracel Ltd., Stephenson, UK). Two syringe needles (BD Precisionglide R , Sigma–
Aldrich, O.D. 0.9mm) and PTFE tubing (I.D. 0.8mm) were used to deliver the organic phase and 
the aqueous phage solution. 
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2.10 Ethanol injection: liposomes generation       
Liposomes were produced using the MF device described above and the method of direct co-flow 
alcohol injection (Vladisavljevic et al. 2014).Lipid solutions (with different lipids ratios) were 
prepared by dissolution of lipids in chloroform in a round bottom flask. The lipids were dried using a 
rotary evaporator for 2 hours to obtain a thin film, and subsequently further dried overnight under 
vacuum. Isopropanol (IPA) was used to solubilize the film of lipids to a final concentration of 
between 3 and 20 mg ml−1. The organic lipid solution and the aqueous buffer solution were 
delivered, respectively, through the inner tapered round capillary and the outer square capillary by 
means of Vici Model M6 microfluidic pumps (Valco Instruments Co. Inc.). The flow rates of the 
organic phase, Qo and the aqueous phase, Qa were adjusted to control the degree of 
hydrodynamic focusing and the width of the central stream, thus controlling the IPA/buffer 
micromixing process. The flow rate ratio (FRR = Qa:Qo) between the outer aqueous phase and the 
inner organic phase of 2:1 was used. The MF device was immersed in a water bath and allowed to 
reach thermal steady state under experimental conditions to ensure the experiments were 
performed under constant temperature. The IPA solution was filtered through 0.1μm PVDF syringe 
filters (Fisher Scientific, UK) prior to pumping through the MF device. Liposomes were collected in 
sterile glass vials (Fisher Scientific, UK). 
 
2.11 SEM imaging           
For FEG-SEM analysis, samples were prefixed with a 4% v/v formaldehyde (36.5-38% Solution, 
Sigma-Aldrich Company Ltd., UK) and 2% glutaraldehyde v/v/ (Sigma-Aldrich Company Ltd., UK) 
solution for 1h. The sample were loaded in a  centrifugal filter units (Filter device Amicon Ultra 
centrifugal styrene 15 ml 50K NMWL), rinsed with water and spun at 4500 rpm for 10 min three 
times or until a total volume of 1 ml was reached. Then post-fixed with 1% v/v OsO4 (Sigma-
Aldrich Company Ltd., UK) for 1h in a 5 ml glass vial. The samples were filtered with a Isopore TM 
Membrane 0.2µm GTTP (Merck Millipore, UK) in a Swinnex filtration apparatus (Merck Millipore, 
UK) and washed three times with 5 ml aliquots of distilled water. A second filter was placed on the 
top of the first to make a cage able to retain the liposomes during the subsequent steps. Samples 
were then dehydrated with a gradient of ethanol/water solution that was passed through the 
Swinnex apparatus as follow: 10, 20, 30% for 10 min, 50, 70, 80% for 30 min, 90, 95, 100% for 1h. 
Finally, the samples were dried further with dry HMDS (Sigma-Aldrich Company Ltd., UK) for 1h. 
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At the end of the treatment the Swinnex apparatus was open and both the filters were let dry at 
room temperature under a fume hood overnight. Before the analysis the filter were cut in a square 
of 0.5 centimetres per side and placed onto a new carbon disk stub. Electric contact was improved 
with two drops of silver paste at two opposite corners of the filter square. The stubs were then 
sputter coated with a nanometric layer of gold-palladium 20/80%.  All the procedures were 
conducted under a fume hood. Syringes and the needles were washed and then dried at 115° C 
overnight before use. Sample were imaged using a FEGSEM Jeol 7100 at 2.00 kV. 
 
2.12 CryoTEM imaging          
An 8 μl aliquot of sample was pipetted onto a carbon coated copper grid (HC300Cu, Holey Carbon 
film on Copper 300 mesh, EM Resolutions, UK). Excess liquid was blotted away with filter paper 
(Whatman number 1) and the grid was plunge-frozen in a liquid mixture of ethane/propane cooled 
by liquid nitrogen. The sample was then kept at liquid nitrogen temperatures throughout the 
analysis. TEM images were taken on a JEOL 2200FS TEM at 200 keV using a Gatan K2 Summit 
and Gatan 914 cryo-holder. 
 
2.13 Bacteriophage encapsulation         
Bacteriophages were encapsulated in liposomes as per the procedure outlined above. Purified 
concentrated bacteriophages in SM buffer were prepared at titres >1011 PFU ml-1. This 
concentrated phage stock was diluted to the appropriate working concentration by mixing with SM 
buffer prior to use in the MF device if lower concentrations of phage were used for encapsulation 
(working concentrations were varied as needed in the range 109-1010 PFU ml-1). The aqueous 
phage solution was delivered through the outer capillary, while the organic lipid solution was 
injected through the inner capillary. To evaluate the inactivation of liposome bound phages, empty 
liposomes were left in contact with K phages for 15min at 37°C to allow the phages to adsorb to 
the liposomes (as described below). The solution was then dialyzed against glycine-HCl buffer (pH 
2.75) for 60min. The solution was subsequently neutralized with NaOH (0.1 M) followed by 
measurement of the phage titre by double overlay plaque assay technique. Inactivation of phage K 
adsorbed to the liposome bilayer membrane was undertaken to evaluate the encapsulated phage 
K titre. Liposomes containing K phages were exposed to pH 2.75 to inactivate the liposome 
adsorbed phages. Phage K were prepared in a pH 5.5 acetate buffer and were encapsulated using 
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the microfluidic device as per the procedure described above. The lower pH of the buffer was used 
to reduce the proton concentration gradient and therefore the proton flux across the membrane to 
minimize pH change within the liposome compartment (Deamer 1987). Free phage K (titre ∼1010 
PFU ml-1) was dialyzed against glycine-HCl buffer (pH 2.75) for 60min. The solution was 
subsequently neutralized with NaOH (0.1 M) followed by measurement of the phage titre by double 
overlay plaque assay technique. The liposome samples containing encapsulated phages was 
dialyzed against glycine-HCl buffer (pH 2.75) for 60min, subsequently neutralized with NaOH (0.1 
M) followed by measurement of the phage titre by double overlay plaque assay technique to 
ensure that all remaining free phages were rendered unviable. The pH in the dialysis bag was 
measured and attained at pH 2.75 within 30min. Encapsulated phages were then released by 
disrupting the liposomes with Triton X-100 according to a previously described protocol (Patra, 
Alonso, and Gon 1998). The final concentration of both Triton X-100 and (NH4)2SO4 in the 
liposomal dispersion was 5 mM. The sample was left in a water bath at 40°C for 1 hour and the 
phage titre after disruption of the liposomes was assessed by plaque assay. At 40°C, there was no 
change in phage titre for both phage K and T3 phages. 
 
2.14 Phage K interaction with empty liposomes      
To evaluate the binding of free K phages to liposomes, empty liposomes (formulation described 
previously) at a concentration of 1010 liposomes ml-1 were gently mixed with phage K solution (final 
concentration in liposome solution ∼1010 PFU ml-1). The total volume was 1ml. The empty 
liposomes were left in contact with K phages for 15 minutes at either 4, 25, or 37°C to allow the 
phages to adsorb to the liposomes. Liposomes were separated from unbound free phages by 
centrifugation at 13,000 g for 3 minutes and phage titre in the supernatant measured by double 
overlayer plaque assay. 
 
2.15 Free phage separation        
The S. aureus phage K product stream collected from the MF device containing a mixture of free 
and encapsulated phages was dialyzed (Visking Dialysis Membranes, Molecular Weight Cut-off 
3,500 Da) overnight against SM buffer (pH 7.5) to remove residual isopropanol. Free K phages 
were separated from liposomes using a 0.22 μm MidGee hoop ultrafiltration hollow fibre tangential 
flow cartridge with a 1 ml hold-up volume (GE Healthcare, UK). The membrane flux was 2 l m-2 h-1 
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and run for 8 hours until no further change in retentate phage titre was recorded. The liposomes 
were retained in the retentate and free phage removed in the permeate. 
 
2.16 Low pH stability         
Phage viability at low pH was evaluated exposing a known titre to buffers at different pH (e.g. 
acetate pH 5, glycine-HCl pH 3) as follow: 10µl of phage lysate was diluted in 9.990 ml of buffer, 
left under shaking at 37°C for 1 to 3h, neutralised with NaOH and titre measured by double overlay 
plaque assay technique.   
 
2.17 Phage viability test upon exposure to alcohol      
Bacteriophage T3 and K were exposed at increasing concentration of low carbon chain alcohols 
(isopropanol and ethanol respectively) to assess viability loss. Along that, trehalose and glycerol 
were used as chemical chaperones to validate their protective activity. Phage K at a concentration 
of 1010 PFU ml-1 was exposed for 10 and 30 min at 10%, 20%, 30%, 40% and 50% ethanol. 
Trehalose and glycerol at a final concentration of 5% w/v was used in two independent 
experiments. T3 at a concentration of 108 PFU ml-1 was exposed for 10 min at 10%, 20%, 30%, 
40% and 50% isopropanol. Experiments were conducted in 24-well plates at 37°C under shaking.  
           
2.18 Listeriolysin O expression and purification       
An agar stock of E. coli-BL21 harvesting the LLO plasmid, kindly provided by prof. Anat Herskovits 
(School of Molecular Cell Biology and Biotechnology, Tel Aviv University), was streaked on an agar 
plate for overnight expansion. A single colony picked from the streaked plate was inoculated in LB-
Kanamycin 100µg/ml and left to shake at 37°C overnight. The pre-culture was inoculated in 200ml 
of fresh LB-Kanamycin 100 µg ml-1 to final OD600 0.05 and left to grow in a baffled 1 L flask until 
OD600 reached 0.3. Then, Isopropyl β-D-1-thiogalactopyranoside (IPTG, Sigma-Aldrich, United 
Kingdom) was added to a final concentration of 0.5 mM and left for 6 hours at 30°C under shaking. 
Bacteria culture was transferred in 250 ml centrifuge bottles and spun down at 17000 g for 20 
minutes (Beckmann Coulter centrifuge model, rotor JA-14). Supernatant was discarded and cell 
pellet resuspended in 20 ml of lysis buffer and stored at - 80°C overnight. Cells were thawed, 
sonicated on ice for 3 minute at 30% amplitude (sonifier 250, Branson Ultrasonic Corporation), with 
20% pulse cycles and then centrifuged at 40000 g for 30 minutes (Beckman coulter model, rotor 
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JA-20). Supernatant was filtered with 0.22 µm syringe filter and loaded on a pre-equilibrated 
column (10 ml), filled with 1 ml of Ni-NTA agarose resin (Fisher Scientific, UK) per litre of culture. 
The column was left at 4°C for 1 hour in a rotary mixer to allow interaction between the Ni-NTA 
resin and the histidine tag. Thereafter, the flow through containing the unbound protein was let to 
flow by opening the column stopper and collected as FT; the resin was washed with 10 column 
volumes (CV) of low salt buffer (LS1), 10 CV of high salt buffer (HS) and 10 CV of LS2. 4 ml of 
Elution Buffer (EB) were used to resuspend the resin and incubated in a rotary mixer at 4°C for 60 
minutes. The eluate containing the LLO protein was collected (E) and the resin washed and stored 
in EtOH 20%. All the fractions eluted were collected and the protein content estimated by Bradford 
reagent kit (Fisher). Collected fractions (FT, LS1, HS, LS2 and EB) were analysed by SDS-PAGE. 
 
2.19 LLO hemolytic activity          
LLO activity was assessed by release of calcein encapsulated in cholesterol-liposome. Briefly, 10 
mg ml-1 of DMPC : cholesterol molar ration 2 : 1 was weighed in a 5 ml round-bottom flask and 
dissolved in chloroform. The solvent was evaporated using a rota evaporator (Buchi, Switzerland) 
for 2 h allowing a thin film to form around the wall of the round flask and further dried overnight 
using an oil pump (GVPSV8, Girovac Ltd). A solution of 70 mM calcein in SM buffer (pH 7.5) was 
added to the flask and let to rehydrate the thin lipid film at room temperature for 2h. Liposomes 
were formed by extrusion of the lipid suspension using an Avanti extruder (Avanti Polar Lipids, 
Inc.) at 25°C. After 11 extrusion cycles, liposomes were collected and extrusion repeated through a 
membrane with smaller pore size. In order, liposomes were extruded through 1 µm, then 400 nm, 
200 nm and 100 nm and finally collected in a glass vial and stored at 4 °C in the darkness. Non-
encapsulated calcein was removed by centrifugation as follow: 1ml of liposomes suspension was 
transferred in a 1.5 ml Eppendorf and spun down at 16100 g (Eppendorf centrifuge 5430R). 
Supernatant was removed and pellet resuspended in fresh SM buffer (pH 7.5). This process was 
repeated three times. Two aliquots of 10µl of liposome suspension were diluted in 980 µl of acetate 
buffer (pH 5) and in 980 µl of SM buffer (pH 7.5) to make 990 µl liposomes suspension at two 
different pHs. Calcein was excited at 495 nm and emission followed over time at 515 nm. To the 
990 µl buffered liposome suspension, 10 µl of LLO were added to a final concentration of 100 ng 
ml-1 and calcein emission recorded.     
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2.20 LLO  and CHAPK encapsulation in liposomes    
CHAPK was kindly provided by prof. Aidan Coffey (Department of Biological Sciences, Cork 
Institute of Technology) and co-encapsulated with LLO in liposomes by the extrusion method. 
Three different formulations were tested: DOPE-DOTAP (1 : 1 w/w), DOPE-CHEMS (2 : 1 molar 
ratio) and DMPC-cholesterol-DOPS (75 : 20 : 5). 20mg of lipids were weighed in a 5 ml round-
bottom flask. 1 ml of chloroform was added to solubilise the lipid powder and the solvent dried off 
in a rotavapor (Buchi, Switzerland) for 2 hours. The round flask was then attached to an oil pump 
and left overnight to dry further. The thin film was hydrated for 2 hours with 1ml of SM buffer pH 8 
containing CHAPK (125µg ml-1) and LLO (200 µg ml-1), sonicated and extruded eleven times 
(Avanti Polar Lipids, Inc.) through Polycarbonate Membranes 1 µm, 400 nm, 200 nm and finally 
100 nm. Liposomes bearing LLO and CHAPK were separated from free proteins by centrifugation. 
The supernatant was removed and liposome pellet resuspended and dialysed overnight against 
SM buffer. The encapsulation process was carefully conducted below 20° C. Liposomes were 
disrupted using Triton X-100 (as described in “Bacteriophage K encapsulation”) and protein 
content was analysed by SDS-page.  
 
2.21 Phage K and LLO co-encapsulation in PS and DOPE : CHEMS liposomes for 
intracellular studies 
CsCl purified phage K was co-encapsulated with LLO in PS (DMPC : cholesterol : DOPS, 75 : 20 : 
5) and in pH-responsive (DOPE : CHEMS, 2: 1) liposomes by extrusion. 20mg of lipids were 
weighed in a 5ml round-bottom flask. 1 ml of chloroform was added to solubilise the lipid powder 
and the solvent dried off in a rotavapor (Buchi, Switzerland) for 2 hours. The round flask was the 
attached to an oil pump and left overnight to dry further. The thin film was hydrated for 2 hours with 
1 ml of SM buffer pH 8 containing LLO (200 µg ml-1) and phage K (1013 PFU ml-1), sonicated and 
extruded eleven times (Avanti Polar Lipids, Inc.) through polycarbonate membranes of 1 µm and 
then 400 nm. Liposomes were collected in a glass vial and stored 4°C in the darkness until use.  
 
2.22 RAW macrophages 
RAW macrophages were grown in DMEM growth media from a cell stock or from a recently split 
cell culture supplemented with 10% FBS, 1% penicillin/streptomycin and 1% L-glutamine in T75 
culturing flasks at 37°C and 5% CO2. Cells were split and passaged every 48 hours.  
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2.23 Passaging RAW macrophages 
Macrophages were split by aspirating off the growth media and washing with 5 ml of PBS. The 
PBS was aspirated and 2.5 ml trypsin was added and incubated at 37°C for 10 minutes to mobilize 
the cells. The cells were then resuspended in 7.5 ml DMEM to a total volume of 10 ml and 
centrifuged at 1100 rpm for 4 minutes at ambient temperature. Afterwards, the supernatant was 
aspirated and the cells were resuspended in 10 ml DMEM.  Macrophages were passaged into a 
new flask containing 10 ml DMEM at 37°C for 48 hours before passaging again.   
 
2.24 Seeding RAW macrophages 
RAW macrophages were mobilised and resuspended as described previously. Macrophages were 
quantified by dropping 20 µl of cell resuspension onto an AC1000 Improved Neubauer cell 
counting chamber (Hawksley) and were enumerated. Macrophages were seeded onto coverslips in 
6 well plates at a concentration of 4 x105 cells per well. DMEM was added to the wells up to a total 
volume of 2 ml, and were incubated at 37°C and 5% CO2 for 24 hours. 
 
2.25 Preparation of RAW macrophage stocks 
RAW macrophages were mobilised and resuspended as previously described. A 1:10 dilution of 
macrophages was made in DMEM, and DMSO was added to achieve a concentration of 5% v/v to 
create the cryoprotective media. Cells were split into 1 ml aliquots in cryogenic vials, and were 
cryogenically frozen at a rate of -1°C/minute in the Mr. Frosty Freezing Container (Fisher Scientific) 
containing 100% isopropyl alcohol and were stored at -80°C until use. Macrophages cultured from 
cryogenic stocks were initially split after 24 hours instead of 48 hours to remove DMSO from the 
growth media. 
 
2.26 Immunofluorescence with free bacteriophage 
RAW macrophages were seeded into 6 well plates as described previously, and infected with 
8.4x109 CFU ml-1 S. aureus, 9.8x109 PFU ml-1 bacteriophage K and both bacteria and 
bacteriophage at 37°C for 1 hour. An uninfected well was used as a control. After incubation, cells 
were fixed with 4% v/v PFA on ice for 15 minutes and washed three times with PBS for 5 minutes 
per wash. Cells were permeabilized with ice-cold PEM/0.05% saponin for 15 minutes on ice and 
washed with PBS, then incubated with 50mM NH4Cl at room temperature for 15 minutes. Cells 
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were washed with PBS/0.05% saponin for 5 minutes and incubated with 40µl phalloidin/CFR680 
Cy5 fluorophore conjugate (Biotium) in a 1:40 dilution in PBS/0.05% saponin for 45 minutes in dark 
conditions. Cells were then washed with PBS and mounted using Fluoroshield™ mounting medium 
with DAPI (Sigma-Aldrich) and stored in dark conditions at 4°C until imaging. 
 
2.27 Immunofluorescence with encapsulated bacteriophage 
RAW macrophages were seeded into 6 well plates as described previously. Macrophages were 
infected with 8.4x109 CFU ml-1 S. aureus for 1 hour. Then, 100µl of SYBR-Gold tagged 
bacteriophage K encapsulated in PS liposomes or DOPE-CHEMS liposomes was added to the 
wells, and the cells were further incubated for 1 hour at 37°C. The cells were then fixed, 
permeabilized and mounted as described before. 
To determine the trafficking mechanism of the encapsulated bacteriophage, macrophages were 
stained with primary antibodies for EEA1, Rab7 and Cathepsin-L for 1 hour after fixing and 
permeabilization which correspond to markers for the endocytic, phagosomal and lysosomal 
pathways, respectively. After washing with PBS/0.05% saponin for 15 minutes, the cells were 
stained with the relevant secondary antibody conjugated to the Cy5 fluorophore. The cells were 
then mounted as previously described. 
 
2.28 Immunofluorescence with encapsulated bacteriophage K endolysin 
RAW macrophages were seeded and infected with S. aureus as described previously. Then, 100µl 
of DOPE-DOTAP, DOPE-CHEMS or PS liposome-encapsulated CHAPK/LLO were added to the 
macrophages at 37°C for 1 hour. Empty liposomes were used as a control. Cells were prepared for 
confocal microscopy as described previously.  
 
2.29 Confocal microscopy 
Samples were prepared for microscopy by mounting coverslips onto microscope slides after fixing, 
permeabilization and relevant antibody staining steps (two coverslips per slide). Samples were 
analysed using the Zeiss LSM710 or LSM880 confocal microscopes at 100x magnification. Image 
acquisition was performed using the ZEN software and image analysis was performed with Fiji. 
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2.30 Solutions and buffers 
 
- Luria Broth: 10g of tryptone, 5g of yeast extract, 5g NaCl were solubilised per litre of H2O and 
the pH adjusted to pH 7.4.  The solution was then sterilised by autoclaving.  
- LB for plates: to prepare 200ml, 2g of tryptone, 1g of yeast extract, 1g NaCl, 0,2ml 1N NaOH 
and 3g of agar were solubilised in H2O. The solution was then sterilised by autoclaving. Ampicillin 
or kanamycin (Sigma Aldrich, UK) was added in order to reach the final concentration of 
100μg/ml and 30μg/ml respectively.  
- Ampicillin: the powder (Sigma Aldrich, UK) was solubilised in H2O in order to reach the final 
concentration of 100mg/ml. The solution was filtered with a filter syringe (Millipore).  
- Kanamycin: the powder (Sigma Aldrich, UK) was solubilised in H2O in order to reach the final 
concentration of 30mg/ml. The solution was filtered with a filter syringe (Millipore). 
- Tris 1M pH 8: the proper amount of powder was solubilised in H2O. The pH was lowered with 
HCl 1M.  
- NaCl 5M: the proper amount of powder was solubilised in H2O.  
- IPTG 0.5M: the powder was solubilised in H2O in order to reach the final concentration.  
- EDTA 0,5M pH 8: the proper amount of powder was solubilised in H2O and solid NaOH were 
added to reach the pH 8. The solution was sterilised using an autoclave.  
- PBS: 8g NaCl, 0.2g KCl,1.44g Na2HPO4, 0.24g KH2PO4 were dissolved in 800ml of H2O. The pH 
was adjusted to 7.4 with HCl and then H2O was added to reach the final volume of 1l.  
- Lysis Buffer: 20mM Tris pH 8, 150mM NaCl, 10mM Imidazole, 2mM TCEP, 0.2% v/v Igepal, 
Lysozyme, DNAse I (Roche), complete Proteinase inhibitor (Roche), H2O up to the final volume. 
Stock solutions were prepared; TCEP, lysozyme, DNAse and Protein inhibitor were added fresh 
each time. 
- Low-salt column buffer: 20mM Tris pH 8, 150mM NaCl, 10mM Imidazole, 0.2% v/v Igepal, 2mM 
TCEP. Stock solutions were prepared; TCEP was added fresh each time. 
- High-salt column buffer: 20mM Tris pH 8, 1M NaCl, 10mM Imidazole, 2mM TCEP. Stock 
solutions were prepared; TCEP was added fresh each time. 
- Equilibrium Buffer, Wash Buffer 1 and Wash Buffer 3: low-salt column buffer. 
- Wash Buffer 2: high-salt column buffer. 
- Elution Buffer: 300mM Imidazole, 150 mM NaCl, 20mM Tris pH 8, 2mM TCEP. Stock solutions 
were prepared; TCEP was added fresh each time. 
- Dialysis Buffer: 20mM Tris pH 8, 150mM NaCl, 5mM β-mercaptoethanol, which was added fresh 
at last. 
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2.31 Supplementary information 
 
 
 
 
 
S1│SDS page of LLO purification. This image shows a SDS page gel of the purification steps for LLO. The 
arrows points at LLO purified after size exclusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
S2│LLO purification by size exclusion. This image shows LLO purified by size exclusion after Ni affinity 
purification on a Sephadex-100 (GE Healthcare). 
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S3│LLO activity at pH 7.5. This image shows the effect of LLO on calcein encapsulated PC : cholesterol 
liposomes at pH 7.5. Calcein is excited at 495 nm and emission (515 nm) registered overtime. Arrows 
indicate when LLO is added to the liposome suspension. The image shows so sign of calcein release upon 
addition of LLO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S4│LLO activity at pH 5. This image shows the effect of LLO on calcein encapsulated PC : cholesterol 
liposomes at pH 5. Calcein is excited at 495 nm and emission (515 nm) registered overtime. Arrows indicate 
when LLO is added to the liposome suspension. The image shows calcein release upon addition of LLO. 
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S5│Triton X-100 activity at pH 5. This image shows the effect of Triton X-100 on calcein encapsulated PC : 
cholesterol liposomes at pH 5. Calcein is excited at 495 nm and emission (515 nm) registered overtime. 
Arrows indicate when Triton X-100  is added to the liposome suspension. The image shows calcein release 
upon addition of Triton X-100. In comparison with LLO the release seems moderate. The final Triton X-100 
concentrations is 20mM. 
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Chapter 3: Nanoencapsulation of Bacteriophages in Liposomes Prepared Using Microfluidic 
Hydrodynamic Flow Focusing 
 
3.1 Content of this chapter 
In this chapter, we describe the formation of liposomal vesicles in a glass capillary microfluidic 
device and how it has been employed to encapsulate bacteriophages for the long-term 
development of targeted delivery systems in the context of phage therapy. 
In section 1, we focus on those parameters important to the liposome assembling in a microfluidic 
device and we describe some challenges associated with microfluidic-based techniques for 
liposome formation. 
In section 2, we report on the encapsulation of phage K and T3 (phage models), using a 
hydrodynamic flow focusing glass capillary device for the production of nanovesicles.  
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3.2 Abstract 
The discovery of antibiotics in the 1920s has radically changed our approach to treat bacterial 
infections and saved millions of lives. However, in the last 50 years, the increased use and misuse 
of antibiotics resulted in a strong evolutionary pressure on bacteria and the quick and exponential 
development of antibiotics resistance. A recent report from the IACG (Interagency Coordination 
Group on Antimicrobial Resistance) warns that 10 million people are expected to die each year by 
2050 because of antibiotic resistant bacteria (IACG 2019). Under the urgency and severity of such 
problem that is of worldwide interest, the scientific community has invested great efforts to address 
the issue of antibiotic efficacy and the innate potential for bacterial resistance. The use of 
bacteriophages that are the natural enemy of bacteria hold the potential to tackle the problem of 
drug resistance. Bacteriophages are able to infect pathogens with a high specificity, eventually 
killing the host. The last decade has witnessed a rising interest in using and studying phages to 
treat bacterial infections, as phages target their host with high specificity and with the potential to 
co-evolve with the corresponding bacterial host. However, the use of phages for phage therapy is 
plagued by some shortcomings, both administrative (e.g. characterization of the sample/drug) and 
experimental. For example, phage do not diffuse through the eukaryotic cell membrane nor to 
reach the niches were some bacteria (e.g. Staphylococcus aureus, Mycobacterium tuberculosis, 
Listeria, Salmonella) may reside. The use of systems for drug delivery has the potential to tackle 
both of the aforementioned shortcomings. In particular, lipid vesicles known as liposomes are 
commonly used to encapsulate hydrophilic components in their aqueous core and to deliver the 
cargo in several locations inside the human body with high specificity. A ‘Trojan Horse’ approach 
employing liposome-encapsulated phages may, therefore, allow the access of phages to 
phagocytic cells, where infectious bacteria reside and hide. 
Moreover, liposome-encapsulated phages may be tailored either to show mucoadhesive properties 
to enhance the retention time in the intestinal tract or to diffuse deep inside the mucus layers when 
PEGylated. However, the literature on phage encapsulation in liposomes is scarce and poorly 
characterized. In our work, to encapsulate phages in liposomes, we employed microfluidic 
techniques that allow high precision encapsulation in highly monodisperse nano vesicles. We also 
characterized and extensively optimized the encapsulation of phages (Chapter 4) and found out 
that encapsulation efficiency is easily and misleadingly overestimated by accounting for phages 
that are still in suspension. Such consideration urged us with the need to characterize and deeply 
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understand the encapsulation process via microfluidic strategies. In this chapter, we discuss the 
use of a microfluidic-based technique for the generation of large unilamellar vesicles (LUV), i.e. 
liposomes, and for the encapsulation of bacteriophages in the inner aqueous core of liposomes. 
Specifically, encapsulation has been evaluated for two model phages, namely the E. coli T3 
podovirus (size ~65 nm) and a myovirus staphylococcus phage K (capsid head ~80 nm and phage 
tail length ~200 nm). In chapter 4, we report all the factors and parameters of microfluidic 
techniques applied to phages that can dramatically lower phage encapsulation efficiency in 
liposomes.  
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3.3 Section 1  
Studying liposome generation in a microfluidic device 
Monodisperse populations of liposomes ranging from 50 to 200 nm in diameter have been 
traditionally generated using a microfluidic device obtained by means of photolithography and 
made of deep ion etching of silica wafers (Jahn et al. 2004, 2008, 2010). These chips present a 2D 
flow focusing arrangement in which three delivery channels meet and fuse in one channel called 
collection channel. However, the construction of such device is time-consuming and expensive. 
Most importantly, the 2D geometry of such devices does not ensure uniform mixing throughout the 
channels. A cheaper approach that also provides better mixing conditions has been previously 
described (Vladisavljevic et al. 2014) and is characterized by an axisymmetric geometry. Such a 
device by Vladisavljevic et al was effective in the generation of uniform liposomes using the alcohol 
injection method (Batzri and Korn 1973; Pons, et al. 1993). The theoretical model to rationalize 
liposome formation via the alcohol injection method is derived from an experimental model verified 
for the detergent dilution liposomes preparation technique (Leng, et al. 2003). Briefly, once the 
alcohol stream mixes with the polar aqueous phase, the phospholipids contained in the alcohol will 
experience an increase in polarity. In order to reduce the unfavourable interactions between the 
apolar part of the fatty chain of the phospholipids and the aqueous solution, phospholipids self-
assemble into planar lipid bilayers. These planar discs grow by association with each other and 
with the free phospholipids in the alcohol-water mixture until they reach a critical point, after which 
they bend to form a spherical structure, known as a vesicle. The characteristic time required to 
close a lipid disc into a liposome (closure time Tc) increases exponentially with the energy of 
curvature, i.e. the energy required to close the disc into a liposome. Two parameters affect the 
energy of curvature: (1) the line energy, i.e. the energy of the hydrophobic tails around the edges 
of the perimeter exposed to the polar solvent; (2) the elastic energy, i.e. the energy required to 
bend the planar lipid bilayers. During the bending of the lipid disc, the volume that is around the 
disc surface will be enclosed inside its core. As a result of this, a bigger lipid disc is required to 
encapsulate bigger volumes or bigger objects. When mass transfer is governed by diffusion, i.e. 
low Reynolds number flow conditions (Re ~ 1) and low Peclet number (Peclet number ≤ 1), 
(Phapal and Sunthar 2013), the parameters that mainly affect size and size distribution are flow-
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rate ratio, i.e. the ratio between the outer and the inner phase, lipid composition and temperature 
(Zook and Vreeland 2010).  
Initial studies were performed in a co-flow capillary microfluidic device (Figure 3.0) and liposomes 
visualised by mean of a high-speed camera. Our results show that, when liposomes are generated 
at temperature below 25°C and with lipid concentration ≥ 20 mg ml-1, lipid films begin to 
aggregates on the surface of the glass capillary, eventually clogging the collection capillary. We 
found that coating the capillary with a hydrophobic silane does not help in reducing the aggregation 
phenomena, while the use of PEGylated lipids slow it considerably. The result of such aggregation 
is the formation of lipid stacks that can be flushed by increasing the total flow rate (TFR). Indeed, 
when analysed by CryoTEM we observed the presence of liposomes with tightly packed 
multilamellae (Figure 3.1).  
 
 
 
 
Figure 3.0│Magnified image of a glass capillary device taken with 10x lens that shows lipid aggregation on 
the wall of the device. Image taken after 15 min (left) shows first signs of aggregation; after 25 min (centre) 
aggregates growth: after 60 min (right) the lipid aggregates have blocked the capillary. Scale bar 300 µm.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1│CryoTEM image of multilamellar liposomes. Lipid stacks formed inside the capillary during 
liposome formation were collected and images using CryoTEM. The image shows the multilamellar nature of 
the liposomes generated in these conditions. Scale bar 300 nm. 
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Figure 3.2│Nanosight measurement of mean size for liposome populations generated varying the flow rate 
ratio (FRR), temperature and lipid concentration. Top graph shows how size varies with temperature (4°C 
and 25°C) and FRR, keeping the lipid concentration and the formulation constant. Bottom graph shows size 
variation caused by FRR and lipid concentration (3 mg ml-1 and 20 mg ml-1), keeping the temperature and the 
formulation constant. Error bars indicate SD calculated on three independent measurements. Statistical 
significance was calculated by performing t-test.  
 
Therefore, to generate large unilamellar vesicles, we had to be careful and avoid aggregation on the 
capillary wall. We attempted this by using a low concentration lipid solution, by controlling the 
temperature with the use of a water bath in which we immersed the device and by reducing the time 
of the run e.g. < 30 min. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3│CryoTEM image of unilamellar liposomes. Liposomes generated under the conditions reported 
in figure 3.2 were imaged using CryoTEM and show a unilamellar structure and an average size between 100 
and 300nm. Scale bar 300 nm. 
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However, in our case the temperature range in which we could operate was limited. In particular, 
low temperature favours the formation of big liposomes but also induces lipid aggregation; on the 
other hand, high temperatures are not compatible with the planned encapsulation of phages 
sensitive to temperature > 40° C. Therefore, we evaluated how a combination of finely-tuned 
temperature (4°C or 25°C), lipid concentration and flow rate ratio (FRR) could affect the size of the 
liposomes (figure 3.2). When we kept the lipid concentration fixed (3 mg ml-1), increasing the flow 
rate ratio did not affect  the mean size of the liposome population, neither at 4°C nor 25°C, with the 
only exception of FRR = 4, for which we found a statistically significant difference between the 
means of the two populations (P< 0.05). Differently, when we kept the FRR fixed at some discrete 
values (1, 2 and 4) and varied the lipid concentration, we registered no statistical difference in 
mean size of the liposome populations at any of the FRRs examined here, except for FRR = 2 for 
which we got a value of P < 0.05. Overall, for the tested values of temperature, flow rate and lipid 
concentration, we were able to generate liposome populations with an average size of around 200 
nm, which is acceptable as it could fit most of the bacteriophage species (figure 3.2). Interestingly, 
all population distributions showed tails towards higher values, suggesting the presence of bigger 
vesicles capable of encapsulating phage as big as 300 nm (e.g staphylococcus phage K). The 
CryoTEM image (figure 3.3) shows that the liposomes generated are mainly unilamellar and the 
range size confirms what previously found with the NTA. The liposome structure was also analysed 
by SEM, after fixation and spatter coating with Au/Pd (figure 3.4). However, the fixation and coating 
steps may have affected the actual size of the starting sample, adding layers on its surface.  
 
 
 
 
 
 
 
 
 
Figure 3.4│SEM image of DSPC liposomes. Liposomes generated under the conditions reported in figure 3.2 
were imaged using SEM. Scale bar 1 µm. 
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During the formation of liposomes via our microfluidic system, we found out that by increasing the 
amount of cholesterol while keeping constant the other parameters (temperature and FRR), the 
mean size increased from 120 nm +/- 12 (pure DSPC) to 220 nm +/- 22 (DSPC : cholesterol, 5 : 1) 
to 310 nm +/- 33 (DSPC : cholesterol, 1 : 1) (figure 3.5b). Our observation supports the theory 
previously proposed by Zook and Vreeland that  liposomes size can be increased by enhancing 
the stiffness of the bilayer. (Zook and Vreeland 2010) The mean of the three populations with 
different levels of cholesterol was significantly different, increasing on both average size and width 
of the distribution.  
 
 
Figure 3.5│a, Size distribution profile of liposomes formed using different formulations: DSPC (dot), 5 : 1 
DSPC : cholesterol (dash) and 1 : 1 DSPC : cholesterol (straight) liposomes obtained at r.t. using aqueous to 
organic phase flow rate ratio of 2 : 1. b, Average size of the liposome populations, error bars indicate SD. 
Statistical significance was calculated by performing one-way ANOVA with Tukey post-hoc test (** p<0.01, 
*** p<0.001, **** p<0.0001). 
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Figure 3.6│Size distribution profile of liposomes generated at different peclet number values: 5 : 1 DSPC : 
cholesterol liposomes were generated in  glass capillary MF device under peclet number < 1 (solid line) and 
peclet number > 1.   
 
We found that the liposome population distribution with our microfluidic device can be contained by 
working under low peclet number. Indeed, we were able to record a correlation between the size 
distribution profile and the peclet number (figure 3.6). In particular, when the peclet number is > 1, 
the distribution profile looks wide with a long right tail. Reversely, when the peclet number is < 1, 
the distribution has a mean of 134.2 +/- nm with a SD of 13.0 nm, suggesting that the liposome 
population is almost monodisperse. Such narrow distribution may be the result of mass transfer 
governed by diffusion that offers a more controlled mixing, as previously demonstrated. (Phapal 
and Sunthar 2013)  To rationalize why the population generated at high peclet number shows a 
main peak exactly superimposable with the main peak of the population obtained at peclet number 
< 1, we hypothesised the following: when the total flow rate reaches a certain value, the mass 
transfer is “partially” governed by mixing, due to the asymmetry of our outer capillary which is 
squared, in contrast with the inner round capillary. Such mode of mass transfer is likely to generate 
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areas with greater concentration of lipids, and lipid discs will have a higher chance to meet and 
grow. As a result, while both experiments at high and low peclet number generate a liposome 
population with a main peak at ≈ 130 nm, the population generated at peclet number > 1 also 
shows bigger liposomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7│Size distribution profile of liposomes formed using different aqueous buffer: 5 : 1 DSPC : 
cholesterol liposomes were generated in  glass capillary MF device using two different buffers, PBS (red line) 
and SM buffer (blue line). Error bars indicate one standard deviation, n = 3.    
 
Finally, to evaluate the effect of the aqueous buffer on liposome size, we generated  liposomes 
employing two widely used buffers, namely phosphate buffer saline (PBS) and SM buffer. In 
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contrast with what previously reported,(Joshi et al. 2016) we did not observe any significant 
difference in liposome population size, as PBS and SM buffer a yielded a population with average 
size of 182.6 nm +/- 22.9  and 208.9 nm +/- 38.8, respectively. Only restrained regions of the 
population distribution displayed different values, but distribution profiles were mostly 
superimposable, suggesting that under our conditions and using our device, the choice of the 
buffer had no effect on liposome size and distribution.  
By CryoTEM imagining, we measured  a thickness of the bilayer membrane of about 4-5 nm, in 
agreement with what estimated from small angle neutron and X-ray scattering for the DSPC bilayer 
(~4.2 nm) (Kučerka, Nieh, and Katsaras 2011). 
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3.4 Section 2  
Phage encapsulation 
Bacteriophage K and T3 were used as phage models to study the feasibility of encapsulation in 
nano liposomes. Based on our previous studies, we decided to use a lipid formulation that contains 
cholesterol since the liposomes generated with it resulted to be on average big enough to 
accommodate at least one phage.   
 
Figure 3.8│T3 encapsulation in DSPC : cholesterol liposomes at different initial titres. Phages were 
encapsulated at FRR of 2 : 1 at r.t. and free phages separated by centrifugation for 10 min at 13.000g and 
resuspended in SM buffer, the process was repeated three times. Liposomes were disrupted with Triton X-
100 and phage titre assessed by plaque assay. Statistical significance was calculated by performing two-way 
ANOVA with Sidak’s multiple comparisons test (ns = not significant, **** p<0.0001). Error bars indicate one 
SD. 
 
First, we investigated the encapsulation of phage T3 at three different titres. T3 is a podovirus of 
roughly 66 nm in diameter. Phages were encapsulated in DPSC : cholesterol (molar ration 5:1) 
liposomes generated using a FRR of 2:1. Under these conditions, we were able to produce 
liposomes with an average size of 200 nm and a narrow distribution (figure 3.5), therefore, 
sufficiently big to accommodate T3 in its aqueous core. Interestingly, we found that the 
encapsulation efficiency did not increase with increasing the phage titre (figure 3.8). In particular, 
we investigated encapsulation efficiency for initial titre of 109 PFU ml-1, 1010 PFU ml-1 and 1011 PFU 
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ml-1 that resulted to be respectively 3.5%, 10%, 1%. In more details, by comparing the samples at 
1011 PFU ml-1 and 1010 PFU ml-1, we found that, although the initial titres are statistically different, 
the titres of encapsulated phages was not (figure 3.8). Therefore, our results suggest that when 
high titres of phages are employed, increasing the initial titre can be counterproductive to the 
encapsulation. We hypothesized that at high initial titre, phage aggregation might occur reducing 
the amount of actually free phage available for encapsulation. On the other hand, if the initial titre is 
too low, the chances that a closing vesicles can catch flowing virions diminishes. We found that the 
optimal initial titre for the encapsulation of T3 in liposomes using our set-up was 1010 PFU ml-1. In 
contrast with our finding, Leung et al. found that encapsulation efficiency increased with the initial 
titre, and did not identify any threshold value, after which encapsulation efficiency instead would 
decrease. We hypothesize that the different geometry of the microfluidic system, as well as the 
different phage and chemical formulation used might play a role in the different phage behaviour 
and resulting encapsulation. To investigate the reason behind the observed encapsulation 
decreases at high phage titre and test our hypothesis on phage aggregation, we analysed the size 
of the phage aggregates (Chapter 4 of this thesis). Our results indicate that T3 is very prone to 
form aggregates that have an average size bigger then the liposomes themselves. When the 
average size of the aggregates equals or is similar to average size of the liposomes, the likelihood 
for a phage aggregate to be encapsulated is low or close to zero. The average size of the particles 
is the result of a dynamic equilibrium in which phages tend to aggregate because of attractive 
forces (e.g. electrostatic interactions, hydrogen bond, Van Der Walls) at the surface of the phages 
itself, and disaggregate because of thermal motion. Moreover, increasing the phage concentration 
results in an increase in the rate of collisions, leading to further aggregation.  
 
 
 
 
 
 
Figure 3.9│T3 encapsulated in DSPC : cholesterol unilamellar liposome. T3 phage encapsulated in liposomes. 
Red arrow points at the encapsulated phage in unilamellar liposome. Scale bar 200 nm. 
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We finally assessed the encapsulation of phage T3 by CryoTEM imaging (figure 3.9), finding that 
only the big liposomes contains phage particles and no more than two phages per liposome. 
CryoTEM imaging shows also that liposome lamellarity is not affected when a phage suspension is 
used. Successively, we encapsulated phage K and assessed the encapsulation efficiency, similarly 
to what done for phage T3. Interestingly, we found that the titre of encapsulated phage K was 
always high regardless the initial titre. To understand and rationalize such discrepancy, we 
performed CryoTEM imaging experiments on diverse encapsulated phage K samples. Generally, 
phage K was found encapsulated in unilamellar liposomes as a single virion or, more rarely, as two 
virions (figure 3.10). Tomography was used to verify that phage particles were trapped inside the 
vesicles core rather than being outside. By tilting the sample from – 60° to + 60°, we were able to 
observe the three-dimensional structure of the phage, proving that phage K was surrounded by a 
lipid membrane. The majority of the phages were not inside liposomes, and instead found in 
aggregates of about tens of virions (figure 4.3 b, c and d). Furthermore, phage K seemed to be 
able to interact with the bilayer, as was found adsorbed on the outer surface of the vesicles (figure 
3.11). Interestingly, most of the adsorbed phages showed contracted tails, while some of the 
unbound phages were found with separated heads and tails. We found out that phage K binds 
indistinctively to lipid bilayers (figure 3.11b) and to intact liposomes (figure 3.11c), as in some way 
previously reported for a pseudomonas phage (Leung et al. 2018).  
 
 
 
 
 
 
 
 
 
Figure 3.10│Phage K encapsulated in DPSC : cholesterol liposomes. Phage K encapsulated in liposomes. Red 
arrows point at the encapsulated phages in unilamellar liposome. Scale bar 100 nm.  
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Finally, differently from phage T3, we found phage K encapsulated only in very large liposomes 
(~500nm or bigger). Most likely, this is due to the relatively large size of phage K (almost 300 nm in 
length).  
To assess the real efficiency of phage encapsulation and exclude those phages that are found 
bound to liposomes from the outside, we developed a method based on low pH to deactivate 
external phages and, therefore, count only the encapsulated phages (chapter 4). From our 
measurement after removal of non-encapsulated phages (chapter 4), we found an encapsulation  
 
Figure 3.11│Interaction of S. aureus phage K with unilamellar liposome wall and with lipid bilayers. 
CryoTEM images show a, encapsulation, and b, c, interaction between phage K tails and liposomes (DSPC : 
cholesterol, 5 : 1), some tails look contracted (red arrows point at phage interaction with the lipid bilayer). 
Schematics that show encapsulation (a.1) and phage-liposomes interaction (b.1, c.1). d, e, chemical structure 
of respectively DSPC and teichoic acid (phosphate groups highlighted in red). 
 
efficiency for phage K between two to three order of magnitude lower that what we measured for 
T3 phage. Moreover, our data are in contrast to what previously described (Chadha, et al. 2017; 
Colom et al. 2015; Leung et al. 2018) where high titres of phages (1010-1011 PFU ml-1) were used to 
boost encapsulation efficiency.  
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Once removed or deactivated the external phages, we wanted to determine the stability of the 
encapsulated phages. Encapsulated phages were concentrated to ~ 108 PFU ml-1 and their 
stability over the course of 30 days was compared with that of phage K lysate. Phage K titre drops 
by more than one log over 30 days, while encapsulated phage K stays stable within 0.2 log units 
(figure 3.12).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12│Stability of encapsulated phage K. Viability of encapsulated phage K was measured over 1 
month period. Liposomes were disrupted using Triton X-100 and phage counted by double layer plaque assay. 
Error bars indicate one SD (n = 4). 
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3.5 Discussion 
Micromixing generated in a glass capillary device between an aqueous buffer and a lipid-
containing alcohol phase resulted in the formation of lipid bilayers that self-assembled to generate 
vesicles. Phospholipids are insoluble in water (Marsh 2013) and self-assemble to minimise the 
surface area that is exposed to the aqueous environment, resulting in lipid bilayers driven by the 
hydrophobic effect (Carugo et al. 2016). In our system, the lipid-in-alcohol stream was surrounded 
by a coaxial aqueous stream resulting in hydrodynamic flow focusing on the core fluid 
(Vladisavljevic et al., 2014). Microfluidic flow focusing allows to mix the two phases under low 
Reynolds number flow conditions (Re ~ 1) and diffusion-dominated mass transfer (Peclet number < 
1) thereby generating nanoliposomes in a tightly controlled way (Jahn et al. 2008). The lipid-
containing alcohol phase delivered from the central stream diffuses radially with high symmetry 
and mixes with the aqueous phase. This generates low polydispersity and high production rates 
(Hood 2014). The cross-sectional area that the inner solution occupies can be adjusted by 
changing the orifice diameter of the injection capillary and the flow rate ratio of the outer (aqueous) 
and inner (organic) phases (Jahn et al., 2010). Under the conditions adopted in this work (low 
Reynolds and Peclet numbers < 1), the two phases were mixing under laminar flow and bilayer 
self-assembling was dominated by diffusion rather than advection. With our microfluidic device, we 
were able to mix in a robust and reproducible way aqueous and alcohol phase containing lipids, 
resulting in liposome population characterized by a narrow size distribution. Our approach clearly 
proves that within a limited size range, liposome size can be tuned by adjusting FRR and lipid 
composition. We show that the addition of cholesterol to the biphasic solution strengthen the lipid 
bilayer and, therefore, allows the formation of bigger vesicles. Indeed, cholesterol interacts with the 
lipids molecules in its surrounding and reduces the lipid bilayer mobility, which becomes stiffer; 
therefore, more energy is required to bend the lipid disc (Sawant and Torchilin 2012). Raising the 
proportion of organic phase in respect to aqueous phase resulted in a shallower lipid concentration 
gradient and probably in larger liposomes, as it has previously been shown (Jahn et al., 2010; 
Leung et al., 2018). We employed a FRR of 2:1 and a low total flow rate of ~ 1ml hr-1, which 
resulted in liposome sizes comparable to those obtained under similar hydrodynamic conditions 
(Carugo et al., 2016; Leung et al., 2018; Wi et al., 2012). Cryo-ultramicrotomy and cryo-SEM (Jahn 
et al. 2013) were used recently to demonstrate the existence of lipid disc-like structures in a region 
where the alcohol phase mixes with the aqueous stream. Once the environment becomes too polar 
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due to the aqueous phase, lipid molecules (Wiggins 2004) aggregate, however, the concentration 
gradient of alcohol still plays a significant role in liposome growth. Indeed, alcohol molecules in 
solution are able to stabilize the lipid disc edges allowing them to grow in size, and this has a 
significant effect on the liposome formation process that with gentle gradients (low FRR) favours 
large vesicles formation (Jahn et al., 2013). On the other hand, we found no effect on the size that 
was statistically significant for buffer and lipid concentration. In contrast, it has been reported 
elsewhere that the choice of the buffer can have an impact on liposomes formation (Joshi et al. 
2016; Wi et al. 2012). While we acknowledge that such discrepancy could be due to  different set–
up conditions, lipid formulation and the particle characterization used between the present work 
and works conducted elsewhere, we remain sceptical on whether the buffer used during liposomes 
formation has an impact on the liposome size at all. In view of the findings from the present study 
and our thorough efforts to enhance the size of liposomes during liposome formation, we believe 
that strategies to better characterize liposome size and exclude false positive such as liposome 
aggregates are needed in the field microfluidics for nanoparticle formation. 
In our work we have not been able to generate monodisperse population at size bigger than 
200nm. Parabolic velocity profile in pressure-driven laminar flows suggests that the velocity 
decreases towards the capillary wall, affecting axial and radial concentration. The rate of mass 
transfer of the lipids is affected by the velocity distribution along and across the channel resulting in 
variations in mixing times across and along the microcapillary affecting the size distribution of the 
liposomes formed. The rate of diffusion depends on the size and mass; therefore, lipid aggregates 
of different sizes will travel at different velocity. All these aspects may account for the moderate 
polydispersity we observed, however, our data show a clear tendency: increasing the average size 
of the liposome population always comes with an increase in polydispersity. Shifts to bigger size 
always come with an increase in the width of the population with a typical tail to the right. This 
somehow resembles the exponential decrease of Tc. Since the closing lipid bilayer may trap any 
bacteriophage in the vicinity, we wanted to find a good compromise between liposome average 
size and polydispersity. However, our intention in this work was not to study these effects which 
have been considered in detail elsewhere (Carugo et al., 2016; Fernandez-Puente et al., 1994; 
Zook and Vreeland, 2010). 
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While generating liposomes using the glass capillary device, we experienced capillary clogging due 
to  lipids aggregation on the wall of the collection capillary, especially at  low temperature and with 
some lipid formulations. It is well known that deposition of lipids on a surface and then rehydration 
under strong hydrodynamic flow yield multilamellar liposomes (Patil and Jadhav 2014).  In previous 
works, higher FRRs have been employed compared to this work. Therefore, we hypothesized that 
lipid aggregates either were not formed because of their short local contact to the capillary wall or 
were washed away. However, at such high flow rates, liposomes formation is controlled by mixing 
and not diffusion. In this work we have shown that, under mixing conditions, liposome populations 
have a higher dispersity, and, thereby, encapsulation may be affected. Moreover, although 
multilamellar liposomes have many applications in drug delivery our results (figure 3.1) show that 
there is no room to encapsulate phage particles in the aqueous core, reducing encapsulation 
efficiency and affecting phage delivery.  
 
 
Figure 3.13│Schematic showing the microcapillary device and working principles. a, 3D model of the glass 
capillary device. Solutions are pumped with the help of two syringe pumps. b, The round capillary that 
delivers the lipids solution in IPA is inserted into the square capillary that delivers the aqueous phase 
containing phages in a co-flow arrangement. c, Once the organic phase mixes with the aqueous phase, 
phospholipids experience a highly polar environment that leads to self-assembling of lipid bilayer discs. The 
latter grow by collision with other discs or by phospholipids addition. When the bending rigidity is overcome, 
the planar bilayer closes itself in a spherical structure entrapping the surrounding solution. 
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Previous studies on phage encapsulation in liposomes reported how, after the generation of 
liposomes in the presence of phages, regardless the method employed, the majority of the 
liposomes were empty with some phages attached on the outside of the vesicles (Colom et al. 
2015; Leung et al. 2018; Nieth, Verseux, Barnert, et al. 2015; Nieth, Verseux, and Römer 2015). In 
this work, we have quantified for the first time the proportion of encapsulated phages vs. that of 
non-encapsulated phages and liposome-bound phages. To increase the number of encapsulated 
virions, generally high titres of phages are employed (1010-1013 PFU ml-1), with reported 
encapsulation efficiency of 40-80 % (Chadha et al., 2017; Colom et al., 2015; Leung et al., 2018). 
In this work, we show (chapter 4) that, at high phage titre, there is a significant degree of phage 
aggregation that is crucial to take into account, as the size of the phage clusters may exceed that 
of the forming liposomes. From our data on the encapsulation of T3, we found a threshold titre, 
both below and above which encapsulation efficiency is lower. On one hand because at low titre 
the chance that a closing bilayer encapsulate a phage is small. On the other hand because at high 
titre phages are prone to aggregation and phage clusters may exceed or equal the size of 200 to 
400 nm liposome. In addition, big clusters travel slower than single phages and vesicles form only 
in specific regions between the two streams of alcohol and buffer. As a result of all these aspects, 
we found that phage encapsulation is a trading off between having the phage in a monodisperse 
form and its titre in solution. This principle is of general application for all the methods that involve 
statistical encapsulation. Nevertheless, some extra considerations might need to be done in 
specific cases, including special morphologic phage features. For example, some studies have 
reported the formation of phage aggregates with a characteristic structure known as rosette 
(Bourdin et al. 2014; Serwer et al. 2007). In these clusters, phages are organized in a circle having 
the tails pointing towards its centre and the heads pointing outwards, with a size twice as long as 
that of a single phage. In this example, dispersion methods can alleviate the phage superstructure 
(Szermer-olearnik and Boraty 2015).  
Our results on the encapsulation of phage K show that a substantial overestimation of the actual 
encapsulated phages may result when phages bind externally to liposomes. An encapsulation 
efficiency between 40 and 80 % was calculated from the results of a plaque assay on a control and 
on Triton disrupted liposomes (Chadha et al., 2017; Colom et al., 2015; Leung et al., 2018). 
However, the discrepancy between the two measurements may be the result of liposome-bound 
phages that during disruption become available to infect bacteria cells. Likewise, in our 
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experiments we have always found at least one log difference between control and encapsulated 
phages in favour of the latter, suggesting an encapsulation efficiency of more than 90 %. 
Unfortunately, this result never found confirmation from CryoTEM analysis. Bacteriophages have 
evolved to interact with bacteria membranes that present similar characteristic to lipid vesicles. As 
a consequence, phages may bind to the lipid bilayers due to electrostatic interactions between 
negatively charged phosphate groups on the phospholipid head and positively charged residues on 
the tail fibres of the phages (chapter 4). This interaction resembles a reversible interaction between 
phages and their hosts via wall teichoic acids, e.g. glycopolymers present in Gram-positive 
bacterial cell membranes. This adsorption process is a reversible interaction that leads to an 
equilibrium between bound and unbound phages (Baptista, et al. 2008; Xia et al. 2011). In support 
of our hypothesis, in a recent study (Colom et al., 2015), Salmonella phages encapsulated in 
liposomes were exposed for 60 min to low pH (2.8) to model the pH of  gastric fluids. Exposure to 
such low pH resulted in phage activity loss of about 4 log . Phage sensitivity to low pH is also 
strongly observed in the context of the present work. In an attempt to decouple the free and bound 
phages from the encapsulated ones, we exposed our sample to low pH (2.75). However, 
liposomes are permeable to protons (Biloti, et al. 2003) when the ΔpH between the internal 
compartment and the external environment is > 3 units. Therefore, in order to reduce the proton 
current across the bilayer, we reduced the internal pH to the lowest possible that does not affect 
phage K viability (pH to 5.5). This sample was exposed to pH 2.7 for 60 min, after which we 
measured an encapsulation titre of 105 PFU ml-1, with only a modest but statistically significant 
increase of the titre upon liposome disruption with Triton X-100. In addition, if we take into 
consideration that free and bound phage exposed to the same condition show no signs of activity, 
we can assume that those counted phages are encapsulated in the inner core. CryoTEM analysis 
support our previous findings that suggested the presence of no more than one or two phages per 
liposomes, and hence a considerable increase in phage counting upon liposomes disruption was 
unrealistic. Moreover, it shows that for bigger phages liposomes larger than 300 nm are needed.  
Noteworthy, we observed a big amount of phages bound externally but no phage internally bound. 
We formulated two hypotheses to rationalize such observation. First, the rate of formation of 
liposomes is much higher than the rate of phage diffusion to the vicinity of where liposomes form. 
External phages bind only successively to vesicle formation due to thermal motion, while internal 
phages move in conjunct with the vesicle with not enough energy to bind to the lipid bilayer. 
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Second, phages interact instantaneously with lipid discs in their proximity. Due to this interaction, 
the curvature of the lipid discs changes and preferably closes outwards. Therefore, phage might be 
confined in the external regions due to their action on the closing lipid disc.  
The findings from this work advance the understanding of phage encapsulation in nanoliposomes, 
and more in general for nano particle encapsulation, and urge the need for developing strategies to 
overcome such inherent challenges of microfluidic approaches. In this thesis, we suggest, test and 
provide strategies to address some of these challenges and pave the way to the use of microfluidic 
techniques for the encapsulation of large particles, such as bacteriophages, in nanostructured 
materials. 
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3.6 Conclusions 
In this chapter, we show that liposomes in a range between 100 and 300 nm can be produced in a 
glass micro capillary device. We were able to control both liposome size and size distribution, 
mostly by fine tuning and adjusting lipid formulation, FRR and temperature, but not buffer, which in 
our hands had no impact on the final mean size of the generated liposomes. On the other hand, 
low Reynolds number flow conditions (Re ~ 1) and low Peclet number (Peclet number ≤ 1) ensure 
that mixing is governed by mass diffusion rather than convection, leading to liposome populations 
with a very narrow size distribution. We observed that under the conditions used in this work 
liposomes are unilamellar and very few broken membranes were observed. We found out that in 
certain conditions, lipid can aggregate on the glass capillary wall and then form liposomes after a 
strong flow is applied. These liposomes present a high degree of multilamellarity that affects 
encapsulation of hydrophilic entities inside the inner aqueous core. Such liposomes, can only be 
employed for the encapsulation of hydrophobic drugs, however, multilamellarity reduces the 
amount of available lipids that may form vesicles, resulting in poor yields. Importantly, we found 
that phage T3 is very prone to form clusters that are bigger then the size of the average liposome 
in a concentration dependent manner, and that such issue can be circumvented by employing an 
optimal phage titre that ensures the highest encapsulation efficiency of 1010 PFU ml-1and the 
lowest aggregation rate. This shows that phage encapsulation is a trading between monodisperse 
particles and phage titre in solution. Finally, we identify an important factor that can lead to 
overestimate the efficiency of encapsulation while in reality hindering a successful encapsulation 
itself, namely the capability of phage K to bind to the outer membrane of the lipid bilayer.  While 
phages externally bound to liposomes would be still carried together with the liposomes, such 
phages would be rapidly inactivated by the stomach acidity and lose the advantages of 
encapsulation itself, with a consequence poor outcome of a putative phage therapy.   
87 
 
3.7 References 
Baptista, Catarina, A. Santos, and Carlos Sa. 2008. “Phage SPP1 Reversible Adsorption to 
Bacillus Subtilis Cell Wall Teichoic Acids Accelerates Virus Recognition of Membrane 
Receptor YueB ᰔ †.” JOURNAL OF BACTERIOLOGY 190(14):4989–96. 
Batzri, Shmuel and Edward D. Korn. 1973. “BBA Report.” 298:1015–19. 
Biloti, Débora Nakai, Maria Helena Andrade Santana, and Francisco Benedito Teixeira Pessine. 
2003. “Lipid Membrane with Low Proton Permeability.” Biochimica et Biophysica Acta - 
Biomembranes 1611(1–2):1–4. 
Bourdin, Gilles et al. 2014. “Amplification and Purification of T4-Like Escherichia Coli Phages for 
Phage Therapy: From Laboratory to Pilot Scale.” Applied and Environmental Microbiology 
80(4):1469–76. 
Carugo, Dario, Elisabetta Bottaro, Joshua Owen, Eleanor Stride, and Claudio Nastruzzi. 2016. 
“Liposome Production by Microfluidics: Potential and Limiting Factors.” Scientific Reports 
6(1):25876. Retrieved (http://www.nature.com/articles/srep25876). 
Chadha, Parul, Om Prakash Katare, and Sanjay Chhibber. 2017. “Liposome Loaded Phage 
Cocktail: Enhanced Therapeutic Potential in Resolving Klebsiella Pneumoniae Mediated Burn 
Wound Infections.” Burns 43(7):1532–43. Retrieved 
(http://dx.doi.org/10.1016/j.burns.2017.03.029). 
Colom, Joan et al. 2015. “Liposome-Encapsulated Bacteriophages for Enhanced Oral Phage 
Therapy against Salmonella Spp.” Applied and Environmental Microbiology 81(14):4841–49. 
Hood, et al. 2014. “A Facile Route to the Synthesis of Monodisperse Nanoscale Liposomes Using 
3D Microfluidic Hydrodynamic Focusing in a Concentric Capillary Array.” Lab on a Chip 
14(14). 
IACG. 2019. “No Time To Wait : Securing The Future From Drug-Resistant Infections.” (April 
2019). 
Jahn, a. et al. 2008. “Controlled Encapsulation of a Hydrophilic Drug Simulant in Nano-Liposomes 
Using Continuous Flow Microfluidics.” Proc. Nanotechnology 2008: Materials, Fabrication, 
Particles, and Characterization 1:684–87. Retrieved 
88 
 
(http://www.nsti.org/procs/Nanotech2008v1/5/W41.203). 
Jahn, Andreas et al. 2010. “Microfluidic Mixing and the Formation of Nanoscale Lipid Vesicles.” 
ACS Nano 4(4):2077–87. 
Jahn, Andreas, Falk Lucas, Roger A. Wepf, and Petra S. Dittrich. 2013. “Freezing Continuous-Flow 
Self-Assembly in a Micro Fl Uidic Device: Toward Imaging of Liposome Formation.” 
Jahn, Andreas, Wyatt N. Vreeland, Michael Gaitan, and Laurie E. Locascio. 2004. “Controlled 
Vesicle Self-Assembly in Microfluidic Channels with Hydrodynamic Focusing.” Journal of the 
American Chemical Society 126(9):2674–75. 
Joshi, Sameer et al. 2016. “Micro Fl Uidics Based Manufacture of Liposomes Simultaneously 
Entrapping Hydrophilic and Lipophilic Drugs.” International Journal of Pharmaceutics 
514(1):160–68. Retrieved (http://dx.doi.org/10.1016/j.ijpharm.2016.09.027). 
Kučerka, Norbert, Mu-ping Nieh, and John Katsaras. 2011. “Fluid Phase Lipid Areas and Bilayer 
Thicknesses of Commonly Used Phosphatidylcholines as a Function of Temperature.” 
Biochimica et Biophysica Acta (BBA) - Biomembranes 1808:2761–71. 
Leng, J., S. U. Egelhaaf, and M. E. Cates. 2003. “Kinetics of the Micelle-to-Vesicle Transition: 
Aqueous Lecithin-Bile Salt Mixtures.” Biophysical Journal 85(3):1624–46. Retrieved 
(http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1303337&tool=pmcentrez&rendert
ype=abstract). 
Leung, Sharon S. Y., Sandra Morales, Warwick Britton, Elizabeth Kutter, and Hak Kim Chan. 2018. 
“Microfluidic-Assisted Bacteriophage Encapsulation into Liposomes.” International Journal of 
Pharmaceutics 545(1–2):176–82. Retrieved (https://doi.org/10.1016/j.ijpharm.2018.04.063). 
Marsh, Derek. 2013. Handbook of Lipid Bilayers. 
Nieth, Anita, Cyprien Verseux, Sabine Barnert, Regine Süss, and Winfried Römer. 2015. “A First 
Step toward Liposome-Mediated Intracellular Bacteriophage Therapy.” Expert Opinion on 
Drug Delivery 1–14. Retrieved 
(http://informahealthcare.com/doi/abs/10.1517/17425247.2015.1043125). 
Nieth, Anita, Cyprien Verseux, and Winfried Römer. 2015. “A Question of Attire: Dressing Up 
Bacteriophage Therapy for the Battle Against Antibiotic-Resistant Intracellular Bacteria.” 
89 
 
Springer Science Reviews 3(1):1–11. Retrieved (http://link.springer.com/10.1007/s40362-014-
0027-x). 
Patil, Yogita P. and Sameer Jadhav. 2014. “Novel Methods for Liposome Preparation.” Chemistry 
and Physics of Lipids 177:8–18. Retrieved 
(http://dx.doi.org/10.1016/j.chemphyslip.2013.10.011). 
Phapal, Sopan M. and P. Sunthar. 2013. “Influence of Micro-Mixing on the Size of Liposomes Self-
Assembled from Miscible Liquid Phases.” Chemistry and Physics of Lipids 172–173:20–30. 
Retrieved (http://dx.doi.org/10.1016/j.chemphyslip.2013.04.006). 
Pons, Miquel, Mercè Foradada, and Joan Estelrich. 1993. “Liposomes Obtained by the Ethanol 
Injection Method.” International Journal of Pharmaceutics 95(1–3):51–56. 
Sawant, Rupa R. and Vladimir P. Torchilin. 2012. “Challenges in Development of Targeted 
Liposomal Therapeutics.” 14(2). 
Serwer, Philip, Shirley J. Hayes, Karen Lieman, and Gary A. Griess. 2007. “In Situ Fluorescence 
Microscopy of Bacteriophage Aggregates.” Journal of Microscopy 228(3):309–21. 
Szermer-olearnik, Bo and Janusz Boraty. 2015. “Removal of Endotoxins from Bacteriophage 
Preparations by Extraction with Organic Solvents.” 1–10. 
Vladisavljevic, Goran T. et al. 2014. “Production of Liposomes Using Microengineered Membrane 
and Co-Flow Microfluidic Device.” Colloids and Surfaces A: Physicochemical and Engineering 
Aspects 458(1):168–77. 
Wi, Rinbok, Yeonsu Oh, Chanhee Chae, and Do Hyun Kim. 2012. “Formation of Liposome by 
Microfluidic Flow Focusing and Its Application in Gene Delivery.” 24(2):129–35. 
Wiggins, Julio M. Ottino and Stephen. 2004. “Introduction : Mixing in Microfluidics.” Phil. Trans. R. 
Soc. Lond. A 923–35. 
Xia, Guoqing et al. 2011. “Wall Teichoic Acid-Dependent Adsorption of Staphylococcal Siphovirus 
and Myovirus .” JOURNAL OF BACTERIOLOGY 193(15):4006–9. 
Zook, Justin M. and Wyatt N. Vreeland. 2010. “Effects of Temperature, Acyl Chain Length, and 
Flow-Rate Ratio on Liposome Formation and Size in a Microfluidic Hydrodynamic Focusing 
90 
 
Device.” Soft Matter 6(6):1352–60. Retrieved 
(http://pubs.rsc.org/en/content/articlehtml/2010/sm/b923299k). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
Chapter 4: Risks and challenges associated with the encapsulation of phages into 
liposomes and their isolation 
4.1 Content of this chapter 
This chapter describes issues associated with phage encapsulation in liposomes and removal of 
the resulting vacant vesicles. Due to their different morphology and host specificity, phage T3 and 
K were used as phage models, representative of the diverse nature of different phages. In section 
1, we tackled the issue of the phage aggregation. We show that endotoxins naturally present in 
phage samples play a crucial role in the aggregation of T3 phage. Herein we present an effective 
strategy for the removal of those endotoxins from phage samples, making advances of broader 
interest in the production of phages. 
In section 2, it is reported the peculiar and unprecendently observed behaviour of phage K that 
contracts its tail upon interaction with phosphatidylcholine vesicles and phosphate ions.  
In section 3, the impact of low-carbon chain alcohols on phage viability is tested and a possible 
solution to alleviate this damaging effect is suggested. 
In section 4, a separation methods is tested and its capacity of isolating phage-carrying liposomes 
and removal of empty liposomes. In addition, a deactivation method is proposed to estimate the 
amount of truly encapsulated phages.  
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4.2 Abstract 
The use of bacteriophages as natural antibiotics has regained interest in the western world for their 
potential to treat bacterial infections. However, despite their high specificity and potency against its 
bacterial host, bacteriophages show limitations when used in-vitro and in in-vivo models e.g. 
unable to fight intracellular infection. Additionally, in only few published studies bacteriophages 
have been used efficiently to treat human patients and often high doses were required (Lavergne 
et al.). Phage encapsulation represents a strongly promising strategy to address some of the 
shortcomings associated with the use of phages. Lower administered doses, prolonged shelf-life, 
increased potency and bioavailability at the site of infection could all be achieve through phage 
encapsulation. However, due to the complexity of the phage structure and their comparable size to 
nano-vesicles, encapsulation of phages can present some challenges. For example, both phage K 
and T3 form aggregates with diameter of the order of hundreds nanometers. While phage K 
tendency to aggregate is concentration-dependent, T3 shows a higher proneness to form clusters 
even at low concentrations. Up to a titre between 108 - 109 PFU/ml, phage K is mainly in a 
monodispersed state. Above this concentration, clusters are formed and their size increases to 
almost a micron, forming rosette structures. On the other hand, T3 forms aggregates even at low 
titre. We found that the concentration of endotoxins plays a crucial role in T3 aggregation state and 
their removal yields monodisperse population of T3. Furthermore, CryoTEM images showed phage 
K interacting with the surface of phosphatidylcholine (PC) liposomes by its tail and many virions 
with contracted tails. Surprisingly, we found out that the presence of phosphate in the surrounding 
environment of the buffer was enough to trigger the observed tail contraction. Our observation 
suggests that the choice of the buffer may play a crucial role in enhancing shelf life of phages. We 
found that another critical contribution to phage viability consisted in the use of alcohol during 
encapsulation, as both phages showed sensitivity to ethanol and isopropanol (IPA) when used 
above 20%. To address such problem, we tested the potentially protective effect of some sugars. 
Trehalose is effective in protecting from the damaging effect of the alcohol. Notably, the 
combination ethanol above 20% (v/v) and glycerol 5% (w/v) was instead lethal to phage T3. 
Finally, hollow fibres and phage deactivation by mean of low pH were used to estimate the amount 
of encapsulated phages. In this comparison study, the use of low pH was the most efficient way to 
determine the titre of encapsulated phages. On the other hand, hollow fibres gave little recovery 
and scarce separation. The purpose of this chapter is to report on the aforementioned issues 
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linked to phage entrapment in nano vesicles, as well as solutions to overcome them. Findings here 
presented will be of a great interest in the area of nano encapsulation and phage therapy, paving 
the way to a more efficient and better designed phage encapsulation and delivery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
4.3 Phage aggregation (Section 1) 
Morphology, size and size distribution of phage K (Myoviridae family, capsid head ∼80 nm and 
phage tail length ∼200 nm) and phage T3 (Podoviridae family; phage dimensions ∼65 nm) were 
studied using Cryo transmission electron microscopy (CryoTEM), nano particles tracking analysis 
(NTA) and Tunable Resistive Pulse Sensing (TRPS, QNano). NTA represents a quick way to 
measure particle size and size distribution profile in aqueous solution. It correlates the particle 
velocity (i.e. Brownian motion) to its hydrodynamic radius using the Stokes–Einstein equation. 
TRPS uses a stretchable nanopore to measure particles volume; the particle size is then computed 
by the software with comparison to a standard. TRPS is based on a particle-by-particle analysis 
system that allows also zeta potential measurements. Transmission electron microscopy can be 
performed in cryo-mode, preserving the native structure of the sample by keeping it in a cryogenic 
state throughout the analysis. All these approaches taken individually show points of strength and 
weakness; in this study, we combine them for a more comprehensive analysis and understanding 
of phage aggregation. 
 
4.3.1 Aggregation of phage K 
Purified phage K in SM buffer was serially diluted to final concentrations of 1010 PFU ml-1, 109 PFU 
ml-1, 108 PFU ml-1, 107 PFU ml-1, 106 PFU ml-1 and analysed by NTA. NTA results show no sign of 
aggregation between 106 PFU ml-1 and 109 PFU ml-1(figure 4.1). Results recorded at 106 PFU ml-1 
could be falsified by the presence of contaminants in solution, 106 PFU ml-1 being the lower 
detection limit of the instrument. However, despite being the measurement associated with lower 
reliability and higher noise, it is unlikely that phages aggregate at the lowest concentration tested. 
Indeed, phages start to aggregate at the highest concentration tested of 1010 PFU ml-1. At 1010 
PFU ml-1, the graph of the size distribution has a right shoulder (> 250nm; figure 4.1 solid line) that 
represents the bigger size of phage clusters and accounts for 10% of the area below the curve. 
Noteworthy, the hydrodynamic radius calculated by the NTA for a monodisperse phage K is ~ 180 
nm, which is bigger than the head itself (80nm) but smaller than actual size of the phage (280nm), 
implying that NTA provides an average size value for tailed phages. 
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Figure 4.1│Phage K size distribution profile measured by NTA: effect of phage titre. Phage concentration 
1010 PFU ml-1 (solid line), phage concentration 109 PFU ml-1 (short dots), phage concentration 108 PFU ml-1 
(dash dot), phage concentration 107 PFU ml-1 (dots), phage concentration 106 PFU ml-1 (dashes). 
 
 
Phage K purified using a CsCl gradient was analysed at a concentration of 1010 PFU ml-1 using the 
QNano. As figure 4.2 shows, the size distribution profile confirms results from NTA (figure 4.1). The 
most intense peak at 92 nm represents the phage in its monodisperse form, while the tail indicates 
some degree of aggregation with particle size up to 240nm. Although phage K has a total size of 
~280 nm, the measurement by QNano indicates a particle size of ~90 nm for the monodisperse 
phage. Such instrumental bias might be due to phage K special morphology and to the fact that 
QNano measures particle volume. Indeed, the head of phage K constitutes most of the phage 
volume, while the tail albeit long (200x15nm) occupies a smaller volume and results challenging to 
detect. Because QNano measures particle volume and the monodisperse phage is measured as a 
particle of ~90 nm, the observed phage aggregates of up to 240 nm indicates more than 10 virions 
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clustered together. This estimation and hypothesis is confirmed by CryoTEM images (discussed in 
the next paragraph). Particles below 80 nm measured by QNano (figure 4.2) are most likely phage 
fragments or DNA. While the actual QNano size values differ from the NTA ones, they are in 
agreement with TEM measurement of phage K. This is most likely due to the measurement 
principle for the NTA that derives particle hydrodynamic radius from its velocity. Using TRPS is 
possible to assign a zeta potential value to each analysed particle, which is a measurement of the 
electrical charge on the surface of the particle. Figure 4.2 shows that phage K in PBS (1011 PFU ml-
1) has a negative zeta potential with an average of ~ 44 mV and in this case the major contribution 
to the zeta potential value comes from the phage head that is negatively charged (Perez, Jenkins, 
and Arnot 2016). The zeta value does not change between the monodisperse virion and the 
clusters, meaning that it is not possible to identify phage aggregation by measurement of the zeta 
potential.  
 
 
Figure 4.2│Size and zeta potential of phage K measured by TRPS. CsCl purified phage K was diluted to a 
concentration of 1011 PFU ml-1 in PBS and size and zeta measurements taken with the QNano.  
 
Phage K purified using a CsCl gradient was imaged using Transmission Electron Microscopy in 
cryogenic mode (CryoTEM). The structure of phage K is shown in figure 4.3a. Phage K head is 
about 80 nm in diameter and its tail is 210 nm in length. This measurement is in agreement with 
the TRPS analysis. At a magnification of 25000x, it is possible to visualize and discriminate the 
single proteins that constitute the head, the tail and the proteins at its tip that are responsible for 
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host recognition. At a concentration between 1012 and 1013 PFU ml-1, phage K is mainly in its 
aggregated form, with clusters of phages reaching the order of 1 micron in width (figure 4.3b and 
4.3c). We hypothesized that both electrostatic interactions between charged surface and high 
concentration of phages could contribute to the observed elevated degree of aggregation. Indeed, 
dilution of concentrated phage suspension (1013 PFU ml-1) resulted in disaggregation. Finally, by 
CryoTEM imaging, we also observed rosette structures, that were very common at the 
concentration of 1013 PFU ml-1. In this rosette arrangement, two to up to ten virions interact by the 
tip tail proteins, resulting in big clusters (up to 600 nm) despite the contribution of only few virions 
(Figure 4.4a and 4.4b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3│Cryo electron microscopy of phage K. Phage K at 1013 PFU ml-1 in SM buffer was imaged using 
CryoTEM; (a) phage K structure in details, error bar 100 nm (b,c,d) phage K aggregates, scale bar 1000nm.  
 
a b 
d c 
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Figure 4.4│Cryo electron microscopy of phage K. Phage K at 1013 PFU ml-1 in SM buffer showing rosettes 
structures. 
 
To achieve the phage monodispersion desired for encapsulation, we evaluated how to minimise 
aggregation of phage K. Our strategy to hinder phage clustering was threefold: (1) enhance 
dispersion with the aid of a surfactant; (2) disrupt phage interactions by either changing ionic 
strength (3) or increasing electrostatic repulsion by varying pH. These three factors were tested at 
high concentrations of phage K, as our data show signs of aggregation when phage concentration 
is ≥ 1010 PFU ml-1. 
To stabilize phages in their monodisperse state, we employed surfactants, which are a common 
strategy to achieve monodispersion in nanoparticle technologies. In particular, the action of Tween-
80 and Poloxamer 188 in phage K aggregation was tested. Figure 4.5 shows phage K purified 
lysate at a concentration of 1010 PFU ml-1 not treated (solid line), with the addition of Poloxamer 
188 to a final concentration of 50 mg ml-1 (dashed line) and after addition of Tween 80 1% w/v 
(dotted line). Compared to the untreated sample (control), the addition of surfactant significantly 
broadened the size distribution profile of phage samples, as well as increased the average size 
from 161 +/- 28 nm of the control to 276 +/- 82.5 nm and 546 +/- 37.5 nm respectively for Tween-
80 and Poloxamer-treated samples. These observations suggest that both surfactants caused 
even more formation of phage aggregates, which resulted stable and persistent even after filtering 
samples through a 200 nm polycarbonate etched filter.  
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Figure 4.5│Phage K size distribution profile measured by NTA: surfactant effect. Phage K lysate (solid line), 
phage K lysate with addition of poloxamer (final concentration 50 mg ml-1, dashed line), phage K lysate with 
addition of Tween-80 (final concentration 1% w/v, dotted line). 
 
To evaluate whether salt has an effect in the aggregation of phage K, we tested different 
concentrations of sodium chloride, as it was shown how ion strength of the surrounding solution 
was crucial for the transition between aggregation and disaggregation for phage T4 (Olearnik et al. 
2017). Concentrated phage K was diluted to a final concentration of 5 x 1010 PFU ml-1 in Tris 20 
mM and varying concentrations of NaCl: 30 mM (dash line), 60 mM (dot line), 90 mM (dash dot 
line), 120 mM (dash dot dot), 150 mM (short dash line). Additionally, a sample with 0 mM NaCl 
(solid line) was prepared and tested as well, however the size analysis from this sample were not 
reliable. By measuring the size distribution, no significant difference in aggregation was observed 
for the different samples (figure 4.6), suggesting that NaCl concentration does not affect 
measurably phage clustering of phage K. 
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Figure 4.6│ Phage K size distribution profile measured by NTA: salt effect. Phage K in Tris buffer NaCl 0 
mM (solid line), phage K Tris buffer NaCl 30 mM (dash line), phage K Tris buffer NaCl 60 mM (dot line), 
phage K Tris buffer NaCl 90 mM (dash dot line), phage K Tris buffer NaCl 120 mM (dash dot dot line), phage 
K Tris buffer NaCl 150 mM (short dash line). 
 
To test whether we could discourage clustering of phages by increasing their electrostatic 
repulsion, we modulated the pH of the solution within the range of viability of phage K. Purified 
phage K at a concentration of 5 x 1010 PFU ml-1 in SM buffer was used to assess the effect of pH 
on phage clustering. The pH in solution was adjusted with either HCl or NaOH yielding a range of 
pH that does not affect phage viability and at the same time is within the physiological spectrum 
(i.e. pH between 6 and 8). As for the case of ionic strength discussed in the previous paragraph, 
increasing the electrostatic repulsion among phage K did not result in any significant difference 
(figure 4.7). The width of the main peak plus the shoulder above 200 nm indicates that aggregates 
are present within the studied range when the concentration of phage K is 5 x 1010 PFU ml-1.  
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Figure 4.7│Phage K size distribution profile measured by NTA: pH effect. Phage K in Tris buffer pH 6 (solid 
line), phage K in Tris buffer pH 7 (dashed line), phage K in Tris buffer pH 8 (dotted line). 
 
4.3.2 Phage T3 aggregation  
 
Purified phage T3 in SM buffer was diluted in series to a final concentration of 1010 PFU ml-1, 109 
PFU ml-1, 108 PFU ml-1, 107 PFU ml-1, and its state of aggregation analysed by NTA (figure 4.8). 
Results for NTA show that T3 is highly prone to form aggregates and could be found in its 
monodisperse state only at a titre of 107 PFU ml-1. At this concentration, a sharp peak at 100 nm 
was recorded, compatible with monodispersion, being T3 diameter of 66 nm. From 108 PFU ml-1 
upwards, the size of the aggregates ranged between 200 nm and 800 nm (i.e. cluster with 3 to up 
to 10-15 virions), reaching 1000 nm for the highest tested concentration, 1010 PFU ml-1. In 
particular, the average size increased and spanned as follows among the samples at varying 
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concentration: 126.2 +/- 26.5 nm, 206.5 +/- 14.5 nm,  268.6 +/- 41.0 nm and 288.4 +/- 47.0 nm 
respectively for 107 PFU ml-1, 108 PFU ml-1, 109 PFU ml-1 and 1010 PFU ml-1. Finally, a broadening 
of the size distribution profiles was observed at increasing concentrations, indicating a more 
heterogeneous population.  
 
 
Figure 4.8│Phage T3 size distribution profile measured by NTA: effect of phage titre. Phage concentration 
1010 PFU ml-1 (solid line), phage concentration 109 PFU ml-1 (dots), phage concentration 108 PFU ml-1 (dash), 
phage concentration 107 PFU ml-1 (short dots). 
 
The lysate of phage T3 at a concentration of 1010 PFU ml-1 was further characterized. Size 
distribution measurements by QNano supported the findings from the NTA analysis; T3 displayed a 
high tendency to form aggregates that range between 100 nm and 400 nm, with an average size of 
159 nm. Curiously, no particles were detected below 100 nm, indicating no presence of single 
virions in the phage lysate. Despite some discrepancies in size values obtained with both 
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techniques, NTA and the QNano, a high tendency and degree of aggregation was observed for 
phage T3. Such behaviour could not be predicted by the value of zeta potential that, being -34.8 
mV, hence negative,  (with the 80% of the particles falling in the range between -20 and -50 mV), 
suggests a moderate stability of phage T3 (figure 4.9). Overall, we have no evidence that T3 phage 
lysate contains any virions in a monodisperse state above the limit of detection for any of the 
techniques employed. 
 
 
 
 
Figure 4.9│Phage T3 size distribution profile measured TRPS. Phage T3 size and zeta measurements taken 
with QNano (phage concentration 1010 PFU ml-1).  
 
 
Phage T3 was purified using 100 kDa amicon tube, washed with SM buffer until complete 
exchange of the initial lysate media, concentrated to 5 x 1011 PFU ml-1 and imaged using 
CryoTEM. The structure of a T3 phage was characterized, consisting of an icosahedral head 
(figure 4.10) and a size of approximately 60 nm, in agreement with what found by QNano. Phage 
T3 forms clusters of up to tens of particles, with size ranging from 200 nm to 700 nm (figure 4.10a, 
4.10b, 4.10c and 4.10d) and some examples of  aggregates bigger than 1 µm. Interestingly, a 
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piece of information that was not acquired previously by the other analyses is the presence of 
several empty capsids, suggesting that DNA had been ejected with consequent phage inactivation. 
Further studies to understand and address such issue will be performed.  After extensive 
purification, washes and filtration using a 100 kDa filter, the sample looks contaminated with cell 
membranes, proteins and other cell debris. Only few phages were found as single virions, while the 
majority were engaged in the formation of aggregates of varying sizes, mostly > 200 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10│Cryo electron microscopy of T3 phage. T3 phage at 1011 PFU ml-1 in SM buffer was imaged using 
CryoTEM; (a) T3 aggregate with full-capsid, (b,c,d) T3 aggregates contaminated with debris showing many 
empty capsids.  
a b 
c d
c 
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To try to break the aggregates that T3 forms and improve monodispersity we studied the effect of 
surfactant and ionic strength on phage aggregation. As for phage K we tested: (1) Poloxamer 188 
at a final concentration of 50 mg ml-1 and Tween 80 1% w/v and (2) NaCl to a final concentration of 
1M. All these factors were tested at a concentration of T3 of 1010 PFU ml-1, at which aggregation of 
phages is most extensive and clusters are bigger (> 200 nm).  
 
 
Figure 4.11│T3 phage size distribution profile measured by NTA: surfactant effect. T3 phage lysate with 
addition of poloxamer (final concentration 50 mg ml-1, dashed line), phage T3 lysate with addition of Tween-
80 (final concentration 1% w/v, solid line). 
 
The effect of Poloxamer 188 and Tween 80 on phage T3 aggregation has been evaluated by 
measuring the particle size via NTA (figure 4.11). While Tween 80 has neither a positive nor a 
negative effect on the size of the aggregates, retaining an average size of 173.5 +/- 60 nm, 
Poloxamer 188 worsened the aggregation state. With an average size of 587.5 +/- 249 nm and 
aggregates up to 1.5 µm in size, Poloxamer seemed to have an effect on inducing further phage 
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aggregation. The main peak at around 200 nm that we have consistently found for T3 lysate at a 
concentration of 1010 PFU ml-1 disappeared and particle size distribution broadened. A similar 
outcome  had been observed for phage K, suggesting that surfactants might interact with phages 
in solution, mostly regardless phage identity and that interaction is detrimental to the phage 
monodispersion, exacerbating their aggregation in clusters. 
 
 
Figure 4.12│T3 phage size distribution profile measured by NTA: salt effect. T3 phage lysate (solid line), T3 
phage in Tris buffer NaCl 0.5 M (dashed line). 
 
To evaluate whether salt has an effect in the aggregation of phage T3, we added sodium chloride 
to the phage lysate at a final concentration of 0.5 M. From the comparison between the size 
distribution profile of T3 lysate and lysate added with NaCl (figure 4.12) we can see no significant 
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difference on the aggregation state. As for phage K, modulating ionic strength via NaCl 
concentration did not impact clustering formation for T3 phage. 
Overall, disrupting potential phage interactions did not discourage the aggregation of T3 phages, 
similarly to what found for phage K. Based on CryoTEM imaging results, we advance the 
hypothesis that other factors are at the basis of such persistent phage aggregation. Although not 
previously observed and discussed in the literature, to the best of our knowledge, we wondered 
whether the interaction of phages with other macromolecules present in the bacterial lysates could 
account for the broader particle size distribution recorded by NTA, QNano and CryoTEM. In 
particular, seen the higher propensity of phage T3 to form aggregates, we concentrated our effort 
in macromolecules that are most abundant in gram-negative bacteria such as E. coli. Endotoxins 
or LPS is a class of macromolecule found in the outer membrane of gram-negative bacteria. LPS is 
made up of two parts: a lipid component and a polysaccharide component, respectively a lipophilic 
and hydrophilic portion. Due to their chemical structure and amphiphilic potential, LPS above a 
certain concentration (i.e. critical micellar concentration, CMC, (Aurell and Wistrom 1998)) is able 
to self-assemble in micelles. To evaluate whether endotoxins present in the bacterial lysates might 
favour or even participate in T3 phage aggregation, we measured size distribution of T3 phage 
samples after removal of endotoxins. To ensure the highest removal of endotoxins, we combined 
three traditional approaches, namely liquid-liquid extraction with 1-octanol, ultrafiltration through 
membranes with a 1000 kDa cut-off and hydrophobic interaction with octyl resin. Firstly, we 
propagated T3 phage as usual in LB broth and divided it into two batches, one was centrifuged and 
filtered to remove bacteria (serving as a control) and the second one was centrifuged, filtered, 
washed several times to exchange buffer and remove LPS using a 1000 kDa membrane and finally 
sterile filtered. Our results (figure 4.13) show that despite the washing steps, there is no change in 
average size, distribution profile or even zeta potential. Results from both NTA and QNano (figures 
4.13 and 4.14 respectively) show no difference between the lysate (control) and the ultrafiltrated 
sample. Moreover, no change in the zeta value (-35.9 mV for the control and -34.8 mV for the 
washed sample) indicates that all the charged molecules that contribute to average zeta potential 
are retained during the washing through the 1000 kDa filter.  
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Figure 4.13│T3 phage size distribution profile measured by NTA: effect of ultrafiltration. T3 phage lysate 
(solid line), T3 phage after ultrafiltration through 1000 kDa cut-off membrane, using endotoxin-free PBS 
(dashed line). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14│T3 phage size distribution profile measured by QNano: effect of ultrafiltration. T3 phage lysate 
(green dots), T3 phage after ultrafiltration through 1000 kDa cut-off membrane, using endotoxin-free PBS 
(yellow dots). 
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To estimate the endotoxin removal efficacy during the washing and filtration steps, we used the 
Pierce™ LAL Chromogenic Endotoxin Quantitation. Measurements of the endotoxin indicate the 
endotoxin concentration was still in the range between 105 – 104 EU ml-1. If the endotoxins were 
dispersed in solution as molecules or aggregates smaller than 1000 kDa and considering the 
amount of buffer exchanged during the washing steps, we were expecting to have a final LPS 
concentration below 5 EU ml-1, unfortunately this did not happen. A potential explanation is that if 
LPS itself is in an aggregated state, with aggregates bigger than 1000 kDa, ultrafiltration through 
this cut off membrane alone would not result in efficient LPS removal. Therefore, we attempted to 
remove endotoxins with a different approach, namely liquid-liquid extraction using 1-octanol and at 
the same time, we looked at any effect on the phage aggregation state. In order to increase the 
kinetic of endotoxin transfer from the aqueous phase to the organic phase, we increased the 
surface area mixing 1:1 phage lysate and 1-octanol under constant stirring, using a homogenizer. 
Result of the liquid-liquid extraction (LLE) are shown in picture 4.15:  neither increasing the time of 
extraction, nor the number of washing steps reduced further the LPS concentration that fluctuates 
steadily around 103 EU ml-1. These data support at least two points: (1) the liquid extraction is 
effective at reducing the endotoxins levels when aggregates are present; (2) once the 
concentration of LPS is below its CMC, 1-octanol extraction is not further able to remove 
endotoxins from the aqueous phase. We then studied the aggregation state and the zeta potential 
of T3 lysate that was extracted with 1-octanol overnight. The figure below (figure 4.15) shows the 
comparison between the sample before and after treatment with 1-octanol.  
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Figure 4.15│T3 phage size distribution profile measured before and after 1-octanol extraction. a, size 
distribution was measured by NTA. T3 phage lysate (dash line), T3 phage after LLE (solid line). b, size 
distribution was measured by TRPS. T3 phage lysate (black dots), T3 phage after LLE (empty circles). 
 
 
Both measurements indicate a shift in average size when phages were extracted in 1-octanol, 
resulting in a narrower distribution. The average size changes from 295.4 +/- 32.5 nm to 131.7 +/- 
6.5 nm when control and octanol-extracted phages were respectively measured by NTA, and from 
a 
b 
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159.2 +/- 40.0 nm to 76.0 +/- 10.0 nm when respectively measured by QNano. Measurements by 
QNano are in agreement with the sizes measured from cryoTEM images of phage T3, with only 
minor and negligible variations due to the difference in the measurement principle. Moreover, if we 
consider the slight shift in size values obtained between the QNano and the NTA, we can also 
assume that the narrow peak at 130 nm obtained with the latter corresponds to phage T3 in its 
monodisperse state. The zeta potential shows a variation too, decreasing from -34.9 mV to -12.9 
mV. Since LPS are negatively charged molecules (Dullah and Ongkudon 2017) we hypothesized 
that this variation is due to LPS removal from solution. Moreover, we found out that samples of T3 
phage deprived of endotoxins were not forming aggregates even at the highest phage titre tested 
of 1010 PFU ml-1 (figure 4.15). These results are extremely important and finally provide an 
effective way to disrupt T3 aggregation, paving the way to an efficient encapsulation in nano 
vesicles. To evaluate whether the endotoxins left in solution can be removed and since additional 
1-octanol extraction steps did not result in any measurable reduction of LPS, we coupled LLE with 
either ultrafiltration or hydrophobic interaction separation. To filter out the endotoxins, we took the 
phage suspension that was extracted with octanol and we swapped the sample buffer using a 
1000 kDa-ultrafiltration membrane.  
 
Figure 4.16│Endotixin removal from phage lysate. Concentration of endotoxins in T3 sample lysate, after 
LLE and ultrafiltration using a 1000 kDa membrane (square). Phage titre for each step is also reported 
(circles).   
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Samples were washed thoroughly and paying attention that the LPS would not be concentrated 
above their CMC (Aurell and Wistrom 1998). By measuring the concentration of endotoxin, we 
found out that the use of ultrafiltration via a 1000 kDa membrane is not effective at removing 
endotoxin, suggesting that endotoxins are either too big for this membrane cut off or that 
endotoxins are phage bound. The results obtained by 1-octanol extraction and  ultrafiltration 
washes are reported on figure 4.16, where the phage titre is indicated for each step (dots) as well 
as the variation of endotoxin concentration (EU ml-1, squares). After an initial steep drop of the 
endotoxin due to the 1-octanol extraction, the endotoxin concentration reduction does not follow 
the volume of buffer exchanged with fresh endotoxin-free water. When 94.75% of the buffer has 
been exchanged, the concentration of endotoxins is still in the same order of the endotoxins after 
LLE. This demonstrates that a 1000 kDa membrane is not effective in removing aggregated or 
phage bound endotoxins but more importantly are in disagreement with what previously found 
(Szermer-Olearnik and Boratyński 2015). On the other hand, if the phage sample after LLE was 
further purified by hydrophobic interaction (LLEH) we observed a statistical reduction of 
endotoxins. Indeed, after mixing 1 ml of phage suspension containing 4x103 EU ml-1 with 1 ml of 
octyl resin for 6h at 4°C in a rotary mixer, we measured in the permeate 760 EU ml-1. While the 
phage titre was not affected (table 4.0), the endotoxins in solution vary by almost 3600 EU ml-1 that 
accounts for the 80% of the initial concentration.  
 
 Endotoxin 
concentration 
Phage titre Zeta potential 
Concentration after LLE 4352 +/- 254 EU ml-1 4.3x108 PFU ml-1 19.8 mV 
After octyl resin (LLEH) 762 +/- 25 EU ml-1 2.8x108 PFU ml-1 21.5 mV  
 
Table 4.0│ Endotoxin removal from phage lysate. Concentration of endotoxins in T3 sample after LLE (initial 
concentration) and after further purification by hydrophobic interaction (octyl resin). 
 
As the monodispersity of T3 phage is efficiently achieved after the 1-octanol extraction step, we 
then take advantage exclusively of the zeta potential measurements to evaluate whether the phage 
surface charge has changed following the further reduction of endotoxins in solution. The values of 
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zeta potential are shown on table 4.0 and indicate that the endotoxin reduction from 4x103 EU ml-1 
to 760 EU ml-1 does not affect greatly the surface charge of T3.  
 
 
4.4 Novel interaction of phage K with phosphatidylcholine vesicles and phosphate ions 
(Section 2) 
 
During the characterization of the encapsulation in nano liposomes of staphylococcal phage K via 
alcohol injection method (as reported in chapter 3), we observed the unprecedented binding of 
some of phages K to the liposome surface 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 4.17│CryoTEM image  of phage K. Phage K bound to a fragment of a lipid bilayer (left) and of  several 
phages K interacting with a lipid bilayer (right).   
 
The majority of the phages in the sample displayed contracted tails and/or empty heads, 
suggesting the prior release of their genetic material. In addition, considerable amounts of bound 
phages with contracted tails have heads detached from the tail. We speculate that separation of 
tail and head could be either a consequence of weakening of the head-tail bonds after contraction 
or a consequence of the encapsulation method. Based on these findings, we wanted to evaluate 
the degree of phage adsorption onto liposomes surface as this, not only is a fascinating process, 
but above all could hinder the efficient encapsulation of phages in liposomes and even further 
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affect phage therapy. Phage K was mixed at a concentration of ~ 1010 PFU ml-1 with pre-made 
empty PC : cholesterol liposomes (molar ratio 5 : 1) for 15 min at three different temperatures, 
namely 4° C, 25° C and 37° C. After incubation, liposomes were separated by centrifugation and 
the phage titre in the supernatant was measured. Titre of phages in solution decreased by 50% at 
4° C, 40% at 25° C and 30% at 37° C (figure 4.18) when compared to the control value, consisting 
in 2.8x1010 PFU ml-1. Results from this test confirm what previously observed via CryoTEM: the 
interaction between phage and lipid membrane is observed at any of the temperatures tested, 
although we found no statistical difference among them. To assess if the interaction between pre-
made liposomes and phage K is reversible, we used a 0.22 µm hollow fibre to remove free phages 
while liposomes were retained in the retentate.  
 
 
 
 
 
 
 
 
 
Figure 4.18│Free phage K interacting with pre-made empty PC-liposome. The titre of free phages before 
and after incubation with empty liposomes at 4°C, 25°C and 37°C for 15 min. After incubation liposomes were 
separated by centrifugation at 13,000 x g for 3 min and the phage titre in the supernatant was measured. 
The difference in the titre was due to phage adsorption onto the bilayer membrane. Statistical significance 
was calculated by performing one-way ANOVA with Tukey post-hoc test (** p<0.01, *** p<0.001, **** 
p<0.0001). 
 
This study is discussed in details in section 4 (figure 4.23) where we show that the interaction 
between preformed liposomes and phages is reversible. However, some liposomes were lost 
during washes, probably due to interactions with the filtering fibres, making this system not ideal for 
the removal of free phages (this part will be discussed in more details in chapter 4, section 4). 
Based on this observation and the published literature (Xia et al. 2011), we investigated further the 
interaction between phage K and the phosphate ion. Indeed, in a work by Xia et al. it is suggested 
that the negative charge on the cell wall of the gram-negative bacteria Staphylococcus aureus 
induces phage K binding to the bacterial cell wall, in a reversible fashion. In particular, it was 
115 
 
shown how the phosphate group of the teichoic acid on S. aureus is responsible of such 
interaction. Notably, the surface of PC liposomes is rich in phosphate groups. To test the effect of 
the phosphate group on phage K, we imaged phage K at 1012 PFU ml-1 in SM buffer and compared 
it with phage K in PBS, using CryoTEM. Phage K in SM buffer served as control for the usual 
phage K morphology and behaviour, displaying very few empty capsids and a long thin tail. 
Remarkably, as previously observed for the encapsulation of phage K using alcohol injection 
method (figure 3.11 and 4.17), almost the totality of phages in PBS had contracted tail, regardless 
of their aggregation state (figure 4.19). From a visual examination it appeared that phage K in PBS 
presents a higher number of empty heads when compared with phage K in SM buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19│CryoTEM images of phage K in PBS. Concentrated phage K purified by CsCl was diluted in fresh 
PBS, snap-frozen and imaged by CryoTEM. PBS induced tail contraction and few empty head were also 
observed. 
 
 
Finally, as the release of genetic material is lethal for phages, we wanted to compare phage K 
viability over time when stored in SM buffer vs. PBS, in which tail contraction (which usually 
precedes the release of the genetic material) was easily observed, as well as a few empty phage 
heads. Phage K was diluted in SM buffer (control) and PBS at a final concentration of 1010 PFU ml-
1. Phage titre was measured at day 0, day 7 and day 14. We found out that the titre  
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 PBS SM buffer 
Day 0 9.2x1010  +/- 3.6x1010  8.4x1010  +/- 3.5x1010 
Day 7 7.7x1010  +/- 3.1x1010 8.8x1010  +/- 3.3x1010 
Day 14 3.0x1010  +/- 1.0x1010 4.7x1010  +/- 2.5x1010 
 
Table 4.1│Phage K stability over 2-week time. Phage K titre stored in PBS or SM buffer after 0, 7 and 14 days. 
Statistical significance was calculated by t-test. 
 
variation is not statistically significant over the 14 days for the sample stored in SM buffer. On the 
other hand, the sample in PBS shows a statistical decrease when phage K at day 0 is compared 
with phage K after 14 days of storage. This finding reflects the CryoTEM data that indicate a 
moderate number of empty heads when phage K is in PBS. However, all our data support the 
hypothesis that the tail contraction induced by phosphate ions is not sufficient to produce a marked 
DNA ejection from the phage head, yet this process may have a time dependence.  
 
4.5 The effect of low-carbon chain alcohols on phage viability (Section 3) 
 
To establish the best conditions for our microfluidic experiments and avoid phage loss due to the 
toxicity of the alcohol, which is employed for the encapsulation, we assessed the effect of low-
carbon chain alcohols on phage K and T3 viability (Olofsson et al., 1998). We tested in particular a 
range of alcohol between 10% and 50%, which are typically employed in a microfluidic experiment. 
We tested the effect of ethanol (EtOH) and isopropanol (IPA) that are commonly used for the 
alcohol injection technique. Experiments were conducted at 37° C and at two time points, 10 min 
and 30 min. Additionally, the effect of trehalose on preventing phage denaturation was assessed. 
Results from viability measurements indicated that both phage K and T3 are sensitive to EtOH and 
IPA in a concentration dependent manner. When alcohol was kept between 10 and 20 %, the 
phage titre was not affected at any time point, while it decreased slightly when exposed to 30%, for 
which condition we registered some  variations among replicates, never higher than 1 log. In 
particular, time exposure played a crucial role, when the “threshold” value of 30% ethanol was 
tested, as ~ 1 log difference was recorded between the sample exposed for 10 min and for 30 min 
(figure 4.20a).  At alcohol concentration above 30%, the titre drop was always > 2 log, regardless 
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the time of exposure.  EtOH and IPA showed a comparable effect on denaturing phage proteins 
and resulting viability loss. Finally, as hypothesized, trehalose served as protective agent: samples 
exposed to 40% or 50% alcohol had a higher value of viability when also 5% w/v trehalose was 
present in solution, reducing the damaging effect of high % al alcohol. We also tested the effect of 
glycerol (5% w/v) as chemical chaperone (data not shown) to reduce the toxic effect of EtOH and 
IPA. Surprisingly, at concentrations of alcohol equal or above 30%, the combination of alcohol and 
glycerol resulted completely lethal regardless the length of exposure as no plaques were present 
anymore. To the best of our knowledge, the effect of glycerol in enhancing alcohol lethality was not 
previously observed. The study of this phenomenon exceeds the scope of this thesis, but it is a 
fascinating one that is worth further investigation. 
Overall, results were robust and highly reproducible, with minor variations due to intrinsic chemical 
difference between the two phages. Our results, in agreement with other previous works, 
characterize further and in detail, the toxic effect of alcohol to phages and advance the defining of 
optimal working conditions for the efficient encapsulation of phages via microfluidic techniques.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20│Effect of alcohol on phage K and T3 viability. a, Phage K viability at increasing concentration of 
ethanol taken at two time points 10 (black bars) and 30 min (grey bars) ; b, Effect of 5% trehalose after 10min; 
c, Effect of 5% trehalose after 30min; d, T3 viability at increasing concentration of IPA (black bars) compared 
with 5% trehalose (grey bars). Statistical significance was calculated by performing one-way ANOVA with 
Tukey post-hoc test. 
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4.6 Isolation of phage-carrying liposomes (Section 4) 
 
Once phages have been encapsulated into liposomes, the isolation of vesicles that carry phages 
and the removal of free phages is a crucial requirement in view of the long-term goal of phage 
therapy in patients. For therapeutic purposes, it is essential to define precisely the administered 
titre of encapsulated phages, which can only be measured once the free phages are removed or 
deactivated. Furthermore, it has been suggested that free phages may trigger innate immune 
response in humans in vivo, (Krut, et al., 2019) resulting in rapid phage clearance and, therefore, 
reduced efficacy of the therapy.  
To nullify the contribution of free phages in a sample of encapsulated phages in liposomes, we 
envisioned strategies either based on the different physical properties of phages and liposomes, 
such as size, or based on the deactivation of free phages. Due to its peculiar behaviour, phage K 
was chosen as model during these studies.  
As we have seen in the previous section, encapsulation of phage K using the alcohol injection 
method yielded a complex mix of encapsulated phages, free phages and liposome-bound phages. 
Since phage K is sensitive to low pH (< pH 5), we evaluated the inactivation of free and bound 
phage by exposing the mix to low pH 2.75. Firstly, we checked (1) phage K viability at low pH; (2) 
viability of liposome-bound phage at low pH. In the latter case, empty liposomes were left in 
contact with phage K for 15min at 37°C to allow the phages to adsorb to the liposomes (as 
described in section 2). The solution was then dialyzed against glycine-HCl buffer (pH 2.75) for 
60min, neutralized with NaOH (0.1 M) and the phage titre was measured by double overlay plaque 
assay. Likewise, free phages were dialyzed against glycine-HCl buffer (pH 2.75) for 60min, 
neutralized with NaOH (0.1 M) and the phage titre measured. After such treatment, no countable 
plaques were found, implying that none of the phages, neither free nor liposome-bound, were able 
to withstand the low pH (figure 4.21b).  
To test whether encapsulated phages could instead survive at low pH we encapsulated a 
suspension of phage K in SM buffer pH 7.5 in DSPC : cholesterol liposomes. The product of the 
encapsulation was exposed to pH 2.75 (glycine-HCl buffer) for 60 min, neutralized with NaOH (0.1 
M), disrupted by Triton X-100 (Patra et al., 1998) and phage counted by double overlay plaque 
assay. Surprisingly, we did not count any viable phage particle. We hypothesized that phage 
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viability could be affected by the proton concentration gradient and the proton flux across the 
membrane caused during the process and potentially resulting in pH change within the liposome 
compartment (Deamer, 1987). Therefore, we encapsulated a suspension of phage K at a lower pH 
than so far described, i.e. in acetate buffer pH 5.5 in DSPC : cholesterol liposomes. The product of 
the encapsulation was exposed to pH 2.75 (glycine-HCl buffer) for 60 min, neutralized with NaOH 
(0.1 M), disrupted by Triton X-100 (Patra et al., 1998) and phage counted by double overlay plaque 
assay. While encapsulation at pH 7.5 resulted in complete inactivation of phage K in the liposomes 
after exposure to pH 2.75, lowering of the internal pH to pH 5.5 resulted in viable phage recovery 
(figure 4.21a). Overall, the results of this set of experiments are threefold:(1) Bound phage are 
inactivated as well as free phages, supporting the hypothesis that phage-liposome interaction is 
reversible (2) Interaction with liposomes membrane is not effective in preserve phage infectivity 
(viability) (3) Encapsulating phage in liposomes can preserve phage viability from low pH giving 
that the ΔpH across the membrane is kept below 3log units 
 
 
Figure 4.21│Effect of low pH on phage viability. a, Stability at low pH for phage K (control) and encapsulated 
phage K in liposomes before and after treatment with Triton X-100.; b, stability at low pH for phage K mixed 
with pre-made empty liposomes after 15 min incubation at 37°C. Statistical significance was calculated by 
performing one-way ANOVA with Tukey post-hoc test (* p<0.05, **** p<0.0001). 
 
To remove free phages by exploiting the size difference between free and encapsulated phages, 
as an alternative to the presented inactivation of free phage, we employed a size-exclusion method 
consisting of hollow fibres with a cut-off of 220 nm. Free phages with an average head of 90 nm 
are expected to pass through such hollow fibre, since phage lysate are routinely filtered through 
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0.22 µm filtering membranes. On the other hand, phages encapsulated in liposomes (if we 
consider that liposomes bearing phages can only have a minimum diameter that equals the length 
of phage K ~ 300nm) will be retained. With this purification approach, we aimed to clean up the 
samples in at least three way: (1) by removing free phages; (2) by removing the portion of empty 
liposomes that are smaller than the cut-off (3) by removing bound phages (assuming that the 
interaction phage-liposome is a dynamic equilibrium and that moving free phages from solution 
should encourage phage detachment from the liposome surface towards the bulk). In order to 
reduce the impact of concentration polarization effect during filtration runs, the sample was never 
concentrated for more than 90% of its initial volume before adding fresh buffer. We firstly assessed 
whether free phage K was able to pass through the membrane. Figure 4.22 shows that starting 
from an initial titre of 3 x 1010 PFU ml-1 (black solid bar) within six washes (6x50% of the initial 
volume) the titre in the retentate was brought down to less than 108 PFU ml-1 (white bar with black 
dots) while the recovery in the permeate was almost complete (grey solid bar). Secondly, we 
evaluated if the hollow-fibre is effective in removing liposome-bound phages. In order to do so, we 
mixed pre-made empty liposomes (DSPC : cholesterol liposomes, concentration 1011 particles / ml) 
with phage K at a concentration of 2 x 109 PFU ml-1 and as image 4.23 shows we manage to 
reduce the titre in the retentate to 104 PFU ml-1 that is equal to remove 99.999% of the initial 
phages. Eleven washes are needed to reach a plateau at 104 PFU ml-1, each wash corresponding 
to 50% of the initial volume, while further washes were ineffective (figure 4.23) 
 
 
 
 
 
 
 
Figure 4.22│Filtration of phage K through a 0.22 µm loop hollow fibre. Black bar indicates the phage titre in 
the feed. White bars with black dots represents phage K titre in the retentate after the volume was reduce 
by 50% and fresh buffer was added. These washing steps were repeated 6 times. Grey bar indicate phage K 
titre in the permeate.  
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Figure 4.23│Filtration of liposome-bound phage K through a 0.22 µm loop hollow fibre. Black bar indicates 
the phage titre in the feed. White bars with black dots represents phage K titre in the retentate after the 
volume was reduce by 50% and fresh buffer was added. These washing steps were repeated 21 times.   
 
Then, we studied how the hollow-fibre changes the size distribution profile of pre-made empty 
liposomes. In this case, the hollow-fibre was used in diafiltration mode in order to minimize the 
impact of concentration polarization effect on the surface of the membrane.  
 
 
 
 
 
 
 
 
 
Figure 4.24│Size distribution profile of DSPC : cholesterol liposomes filtered through a 0.22 µm loop hollow 
fibre. Pre-made empty liposomes were circulated in a 0.22 µm loop hollow fibre. Size distribution of 
liposomes in the permeate (dots), retentate (dashes) and initial feed (solid line) were taken by NTA. 
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While the initial sample  consisted of one single distributed liposome population (control; black 
solid line, figure 4,24), the sample resulting from this experiment consisted of two new liposome 
populations, one being the retentate (dashed line, figure 4.24) and one in the permeate (dotted 
line, figure 4.24). The control sample has a main peak at 155 nm with the population having a 
mean size of 317.3 +/- 82.5 nm, while the permeate has a main peak at 105 nm with the population 
having a mean size of 142.0 +/- 32.5 nm and the retentate has a main peak at 215 nm with the 
population having a mean size of 319.2 +/- 55.5 nm.  
 
 
 
 
 
 
 
 
Figure 4.25│Separation of free and liposome-bound phage K from encapsulated phage K using a 0.22 µm 
loop hollow fibre. Dark grey bar indicates phage titre before purification. Light grey bar and white bar with 
black dots indicate phage K titre after purification respectively before and after disruption of the bilayer with 
Triton X-100. Statistical significance was calculated by performing one-way ANOVA with Tukey post-hoc test 
(* p<0.05, **** p<0.0001). 
 
Finally, phage K was encapsulated in DSPC : cholesterol liposome using the alcohol injection 
method. The sample was dialysed to remove the excess of alcohol and the phage particles were 
counted by plaque assay (dark grey bar). Afterwards, the sample was purified from free and non-
encapsulated phages using a hollow fibre with a cut off of 0.22 µm in diafiltration mode and phage 
particles were counted before and after disruption of the bilayer with Triton X-100 (figure 4.25). Our 
results indicate the hollow fibre as an effective purification method  to remove free from bound 
phages and effectively isolating liposomes within a selected size range, as well as showing that 
disruption of the liposomes with Triton X-100 resulted in a significant (P value <0.05) increase of 
countable phage particles.  
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4.7 Discussion 
In this chapter, we discuss some major challenges associated with phage encapsulation in nano 
vesicles and strategies to overcome them. With this work, we advance dramatically the 
understanding of phage encapsulation and we define conditions to encapsulate efficiently viable 
phages and produce a purified samples of encapsulated phages. We show that phage particles 
aggregate to form clusters that cannot be encapsulated in nano liposomes. We propose some 
rationale for such phenomenon, laying the basis to further efforts aimed to address such limitation. 
In particular, we found out that phage T3 pronounced tendency to aggregate is mainly due to the 
presence of LPS in solution, to which it binds, therefore encouraging its aggregation. We show for 
the first time that phage K responds to the presence of the phosphate ion in solution or on the 
surface of liposomes, either by binding to it or by contracting its tail, potentially releasing its genetic 
material. We characterized the limitations of the alcohol injection method for the encapsulation of 
biological entities by affecting viability and we identify trehalose as chemical chaperone to 
counteract the damaging effect of alcohol, while strongly excluding glycerol that instead exacerbate 
it. Finally, we identify two approaches to separate or deactivate free and non-encapsulated 
phages, to yield a sample of encapsulated phages that is more suitable to patience administration, 
i.e. free from immuno-sensitising agents and at a well-defined titre. 
 
4.7.1 Aggregation 
In the first paragraph, we describe our efforts to characterize and disrupt the aggregation of both K 
and T3 phages that is undesired and detrimental as it hinders the success of phage encapsulation. 
Encapsulation methods that relies on statistical entrapping of dispersed particles requires high 
concentration of solutes to increase encapsulation efficiency. Previous works on bacteriophage 
encapsulation in liposomes have used high titres of phages (1010-1013 PFU ml−1)  to increase the 
encapsulation efficiency (Colom et al. 2015; Chadha et al. 2017; Leung et al. 2018). However, in 
other publications, it has been shown that phage particles are prone to form aggregates (Bourdin 
et al. 2014; Dika et al. 2013; Olearnik et al. 2017; Serwer et al. 2007) with an average size up to a 
micron. Reasonably, at higher concentrations the process of aggregation of phages is expected to 
be further favoured, hindering, on the other hand, the encapsulation of phages. Indeed, the 
encapsulation of nano objects in nanoparticles becomes further challenging when particle 
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aggregation occurs, and the yield of encapsulation will be dramatically reduced if some or most of 
the sample consists of particles with an average size in the order of micron. In the first section of 
this chapter, we reported that by increasing the titre of phage T3 from 109 to 1010 PFU ml−1 we 
could increase the encapsulated phage yield. However, increasing further the titre to 1011 PFU ml−1 
resulted in a reduction of phage T3 encapsulation yield (chapter 3 figure 3.8). We hypothesised 
and collected evidence to support that the reduction of encapsulation efficiency above a certain 
titre of phage is a direct consequence of phage aggregation, which becomes more pronounced as 
the phage titre increases. Indeed, tail phages have been imaged while forming clusters and 
rosettes structures with each other, both by us and in previous works. (Serwer et al., 2007; Bourdin 
et al., 2014)   We observed aggregation for both phage T3 and K via CryoTEM imaging. We found 
out that the degree of aggregation is concentration-dependent, implying that increasing the 
concentration of phage particles in solution to favour encapsulation efficiency in nanovesicles, as 
previously suggested (Colom et al. 2015; Chadha et al. 2017; Leung et al. 2018), without 
characterizing the aggregation state of phages could be counterproductive. We found out that, at 
high titre, phages bind to each other to form clusters that are up to one micron in size, reducing the 
amount of phage in a monodisperse state and available for encapsulation. We speculate that also 
the diffusion rate of phages may be negatively affected by phage aggregation. The diffusion rate of 
particles in solution is inversely proportional to the radius of the particle, as described by the 
Stokes-Einstein equation. Consequently, phage aggregates travel slower than their monodisperse 
counterparts do. For some applications (e.g. microbiome regulation in phage therapy) phage are 
required to diffuse inside the mucus barrier of the intestine to reach the bacterial target. However, 
only particles that are smaller than 500 nm can effectively travel through the mucin structure (Lai, 
et al., 2009) and reach the deep layers of the mucus where some bacteria may reside. On the 
other hand, during bacteriophage encapsulation, the large phage aggregates that are not in the 
vicinity of closing bilayers may diffuse too slowly and therefore are not trapped in the liposomes. 
Being aggregation of phages undesired in most cases or even detrimental for their applications in 
medical technologies, achieving monodispersion of phages in solution results to be crucial for 
further use of the phages and relative technology development. 
To disrupt such phage aggregation, we referred to the literature and effort previously attempted to 
induce dispersion of the phage aggregates. (Brakke 1959; Floyd and Sharp 1977; Gerba and 
Betancourt 2017; Jensen, et al., 1980; Konz et al. 2005; Olearnik et al. 2017; Pinto et al. 2010; 
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Riaz et al. 2016; Samandoulgou, et al., 2015; Wallis and Melnick 1967) None of the approaches 
tested for T4 phage in another work (Olearnik et al. 2017) (i.e. surfactant, vary ionic strength, 
change pH) resulted in a satisfactory disruption of the big aggregates of phage K, regardless the 
prior purification approach (Dika et al. 2013). Nevertheless, phage K can be obtained in a fairly 
monodisperse state up to the concentration of demonstrates to 109 PFU ml-1.This is not possible 
with phage T3 that shows a much higher tendency to form aggregates even at low titre (107 – 1010 
PFU ml-1). After testing several standard approaches to disrupt T3 aggregation with no success, 
we explored the hypothesis that such persistent and easily-occurring aggregation could be 
attributed to the secondary effect of contaminants in solution. We speculated that amphipathic 
molecules in solution could induce phage aggregation by self-assembling a complex structure 
where phages either are entrapped or take part. In particular, we evaluated whether endotoxins, 
namely LPS, could induce T3 aggregation, since endotoxins are naturally occurring in samples of 
gram-negative bacteria that are the target of T3 and since LPS/protein interactions have been 
previously reported (Magalhães, et al., 2007). Additionally, at a concentration that exceeds their 
CMC, LPSs self-assemble to form supramolecular structures (Aurell and Wistrom 1998; Mueller et 
al. 2004, 2005; Santos et al. 2003; Yu et al. 2006) that are in the range of few tens of nanometers.  
Our hypothesis, then supported by our results, was that T3 aggregation and LPS concentration are 
intrinsically correlated. The usual concentration of LPS in a phage lysate is around 106 EU ml-1, 
which is 2-3 order of magnitude above their CMC. Therefore, in a sample of phages, the phage 
particles in solution coexist most certainly with LPS micelles. In either the case that the phage 
binds to LPS micelles or that take part with LPS in supramolecular aggregations, any approach of 
isolation of phages based on size would be ineffective at removing endotoxins from the solution 
and so at achieving monodispersion of phages. Indeed, our work shows that ultrafiltration is 
ineffective at lowering endotoxin levels and phage aggregation. On the other hand, liquid-liquid 
extraction with 1-octanol is an efficient approach to lower endotoxin concentration below their 
CMC, as also previously demonstrated (Szermer-olearnik and Boraty 2015). As a result of this, we 
show that phages that were previously entrapped in a complex structure are free to move as single 
particles. However, although monodispersion of phage particles was achieved, the concentration of 
endotoxins after 1-octanol extraction was still above the accepted limit of 5 EU ml-1 (Dawson and 
White 2017), not even by increasing the number of 1-octanol washes. In contrast to what 
previously reported (Szermer-olearnik and Boraty 2015), we could not achieve further reduction of 
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LPS concentration by using ultrafiltration through 1000kDa membrane. Giving that our 
observations are based on numerous measurements, we hypothesize that our different outcome 
compared with previous works is due to the different phage tested. Nevertheless, we managed to 
further reduce the level of LPS by a different strategy. By combining in series liquid-liquid 
extraction with 1-octanol and hydrophobic interaction purification using octyl resin we manage to 
reduce the LPS down to 760 EU ml-1, without affecting phage monodispersity and titre. Our 
strategy not only addresses the issue of aggregation for phage T3 without affecting its titre and, 
thus, allowing its efficient encapsulation in liposomes, but also spans a wider area of interest as it 
represents an effective way to remove endotoxins associated to bacteriophages from a solution.  
 
4.7.2 Phage K binding  
In the second section, we present a surprising and unique finding on the behaviour of phage K in 
the presence of phosphate ions. Our results show that the phosphate ions present on the surface 
of the liposomes as part of the lipids head is sufficient to cause binding of phage K and to trigger 
tail contraction. Phage K binds to the lipid bilayers due to electrostatic interactions between 
negatively charged phosphate groups on the phospholipid head (figure 3.11) and positively 
charged residues on the tail fibres of the phages, leading to tail contraction and in some cases 
DNA ejection. This interaction resembles a reversible interaction between phages and their hosts 
via wall teichoic acids, e.g., glycopolymers present in Gram-positive bacterial cell membranes. In 
particular, for phage K has been demonstrated that the anionic backbone of the wall teichoic acid 
(WTA) is responsible for adsorption on the bacterial surface (Xia et al. 2011). Although liposomes 
are structurally similar to the bacterial cellular membrane, our observation was unexpected and 
fascinating, which, to the best of our knowledge, was not previously reported. Our finding is 
important not only because the phosphate ion is ubiquitous and plays a variety of roles in biological 
systems due to its peculiar chemical characteristics (Kamerlin et al. 2013), but also, and most 
relevantly to the scope of this work, it suggests that phages might bind externally to liposomes and 
give false positives or overestimation of the encapsulation efficiency. Furthermore, it poses some 
serious limitations in regards to the molecules and buffer that can be used to encapsulate phages 
or simply to store them. In support of this, we found that the actual phosphate ion present in buffers 
like PBS is sufficient to trigger contraction of phage K tail with consequent loss of viability probably 
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due to release of the phage DNA, although we found out it occurs at a very low rate. Importantly, 
we speculate that a way to address such peculiar and detrimental behaviour of phage K would be 
masking the negative charge of the phosphate group in the lipid head via alkylation, so as to nullify 
the interaction between the phage and the lipid bilayer. Our work underpins a deeper 
understanding of the encapsulation process, even in its unexplored and yet crucial aspects, 
therefore supporting a better design for the encapsulation and for a potential phage therapy.  
 
4.7.3 Alcohol effect  
What makes bacteriophages the most abundant organism on Earth is their ability to adapt to 
adverse conditions, as a result of the natural selection that has worked for many years to shape 
phages in their diversity. Despite being adaptable creatures, bacteriophage survival is the result of 
a tight and controlled equilibrium, and even a punctual genetic mutation may affect dramatically the 
response of phages to an external factor. Literature on bacteriophages is heavily lacking in a 
systematic characterization of phage sensitivity to external chemical and physical factors (Jo et al. 
2011) or phage viability in the presence of organic media (Olofsson et al. 1998). Therefore, it is 
ideal to test preliminarily phage viability and phage response to the experimental conditions to 
which phages will be exposed to during the experiment. Among the factors that affect phage 
viability, shear stress  was found to have a significant impact since phages are delicate structures 
made of assembled proteins (Malik et al. 2017; Vandenheuvel et al. 2013).  Therefore, we decided 
to investigate phage encapsulation in nano vesicles via the alcohol injection method (Jahn et al. 
2004, 2008, 2010; Tien Sing Young and Tabrizian 2015; Vladisavljevic et al. 2014) that exerts low 
shear stress on the sample. On the other hand, however, the use of organic solvents for the 
alcohol injection method may affect phage viability as well. For this reason, we tested phage K and 
T3 phage viability within the alcohol concentration range that is routinely used during liposomes 
formation in microchannel. Our results show that both phages are sensitive to concentrations of 
alcohol greater that 20%, with viability highly affected with the increase of concentration, in 
agreement with what previously published (Olofsson, et al.,1998). It is important to define the 
highest possible sub-lethal concentration of alcohol to which phages can be exposed to because it 
is known that the liposome size, formed by alcohol injection, increases with the percentage of the 
alcohol phase that carries the lipid molecules. Consequently, when a phage is highly sensitive to 
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alcohol, and only a low percentage of alcohol can be mixed with the aqueous phase, therefore 
forming few liposomes, the chance that the phage may be trapped in the liposome inner core 
decreases dramatically, and even more in the case of long tailed phages. To be able to use higher 
percentages of alcohol, we investigated whether chemical chaperones could be employed to 
minimize the damaging effect of alcohol. Our results show that trehalose that is routinely used to 
reduce damages caused by shear stress (Vandenheuvel et al., 2013) is likewise effective in 
preventing alcohol damages. Surprisingly, glycerol displayed the opposite effect, and when used in 
combination with either ethanol or isopropanol at concentration above 20% has devastating 
consequences on phage viability. 
 
4.7.4 Deactivation/isolation 
Phage encapsulation in liposomes has only been studied since recently (Colom et al., 2015; 
Chadha et al., 2017; Leung et al., 2018). In most of the works, an encapsulation efficiency between 
40 and 80 % has been reported, and usually no attempts to remove non-encapsulated phages 
(ranging between 20 and 60% of the total) is thoroughly described. In spite of some differences, all 
encapsulation methods roughly rely on the same principle, also used in this study: the statistical 
capturing of suspended particles. After encapsulation, we found that the majority of the phage 
particles end up outside the liposomes. Therefore, we wonder whether, in the light of this finding, 
some of the previously reported encapsulation efficiencies are in fact overestimated. The major 
ground for our concern is indeed the discovery that some phages bind to the liposome surface and, 
therefore, might be counted as encapsulated. Additionally, three further considerations would 
suggest that some of the reported measurements of encapsulated phages might have been biased 
by the reason above. First, assuming that phages are monodispersed in solution and that 
liposomes are unilamellar, the volume that can be encapsulated is limited by the amount of lipids 
and influenced by the average liposome size. Second, phages can only be encapsulated in the 
proximity of closing bilayers, which is a principle of wide application among all the encapsulation 
methods that rely on statistical encapsulation. Third, if the phages aggregate, the number of virions 
available for encapsulation in nanovesicles diminishes with the increase of the average size of the 
phage aggregates. All these considerations suggest that diverse factors connected with the 
encapsulation of phage in liposome lead to a certain amount of non-encapsulated phages that 
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need either to be removed to avoid side effects (Krut et al. 2019), or deactivation for a better 
estimation of encapsulation efficiency. In this work, we first studied phage deactivation by mean of 
high proton concentration and subsequently, we evaluated the use of hollow fibres to separate free 
and bound phages from encapsulated ones. In an effort to minimize acid-induced phage 
inactivation within the internal liposome compartment, we reduced the transmembrane pH gradient 
between the liposome core and the external solution to minimize proton permeability across the 
DSPC-cholesterol lipid membrane (Bilotiet al., 2003). Phage encapsulated liposomes exposed to 
pH 2.75 showed a significant fall in phage titre, down to 104 PFU ml−1, with a statistically significant 
increase of ∼1 log in phage K titre upon liposome disruption with Triton X-100, indicating that some 
or perhaps all encapsulated phages survived the acid treatment. The encapsulated phage K titre 
was, however, quite low ∼105 PFU ml−1. Following liposome formation, external phages may 
subsequently bind to the outer liposome membrane. CryoTEM images suggested that only one or 
two phages were encapsulated in each liposome. The 1 log increase in phage titre upon liposome 
disruption suggests that removal of free phages and inactivation of bound phages followed by 
disruption of the liposomes provide a mean by which evaluating the titre of encapsulated phages. 
In a previous study, a 60min exposure of liposome-encapsulated Salmonella phages (prepared 
using thin film hydration technique) to simulated gastric fluid (pH 2.8) resulted in a significant 
reduction in phage titre (by 4–5 orders of magnitude). (Colom et al., 2015) Our findings on phage 
sensitivity to pH support and give a rationale for the work on Salmonella phages (Colom et al., 
2015).  
To remove physically free and bound phages, as a second strategy to isolate encapsulated phages 
only, we found the hollow fibres are efficient at removing physically free and bound phages. 
However, we also found that the running mode is crucial to avoid liposome loss during purification. 
Indeed, when the purification was carried out in diafiltration mode, the liposomes recovery was 
much higher than it is without controlling the amount of exchanged volume. We hypothesised that 
the concentration of liposomal suspension may lead to surface polarization phenomena, with 
consequent disruption of the lipid shell. This result further supports the above finding on phage K 
binding in a reversible fashion to the outer leaflet of liposomes. 
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4.8 Conclusions 
We have demonstrated that phage encapsulation in liposomes is a complex process governed by 
several factors and can be therefore easily hindered by unsuitable encapsulation conditions, phage 
toxicity, or undesired phage behaviours and interactions. Phages have evolved in an environment 
rich of lipids, and have developed defence mechanisms to survive and overcome the harshest 
conditions. The resulting high resilience and natural affinity to lipids of phages make their 
encapsulation challenging, for which a deep understanding and the fine-tuning of technical 
parameters are required. In this work, we show an unpreceded correlation between phage 
aggregation and concentration of contaminants, we characterize and suggest a strategy to harness 
the denaturing effect of alcohol, and we describe for the first time that phages can interact with lipid 
membranes. To address the detrimental consequences of this latter observation, we developed a 
method to inactivate free phages and liposome-bound K phages, whilst retaining the activity of 
phages encapsulated within the liposomes. By excluding the contribution of both free and 
liposome-bound phages, we could achieve a more accurate estimation of the encapsulation 
efficiency that is often otherwise overestimated. Finally, we evaluated the efficacy of hollow fibres 
to remove free and liposome-bound phages; such strategy could be used downstream to a phage 
production line in continuous to refine the products and improve the yield of liposome-encapsulated 
phages. 
Overall, this doctoral work advances the understanding of the multifactorial process of phage 
encapsulation, uncovering some unprecedented observations of phage behaviours, and uses the 
gained expertise to improve significantly its technology and encapsulation yield. The observations 
of this study are thoroughly characterized and well-supported by cutting-edge techniques, laying 
solid bases for the further development of strategies for an improved phage encapsulation and its 
clinical application. 
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Chapter 5: Macrophage trafficking of liposome-encapsulated phages and co-encapsulation 
with a lysin protein for cargo release into the cytoplasm 
 
In Section 5.2 of this chapter, we show that the uptake of free phages in macrophages is extremely 
low, underlining the need for a delivery system for phages to enter the bacterial cell. When we 
tested the uptake of liposomes where phages can be encapsulated using our developed strategy, 
we were able to image a high number of liposomes inside the macrophage cell. We encapsulated 
phages via two different formulations of liposomes to test the hypothesis that liposome formulation 
could affect the cellular uptake, and we characterized the trafficking of encapsulated phages inside 
macrophages. We found out that phages could not kill bacteria, regardless ofwwwedrt the 
liposome formulation. Phages could not reach the cytosol and were instead trapped in macrophage 
vesicles, resulting eventually in lysosomal degradation. A strategy for overcoming such issue is 
presented in section 5.3. 
In Section 5.3, we discuss the co-encapsulation of CHAPK endolysin protein, which is known to be 
toxic to Staphylococcus aureus (S. aureus), and of LLO hemolysin protein, which is used to escape 
endosomal degradation by Listeria monocytogenes (L. monocytogenes). We performed 
encapsulation in three different formulations of lipids, which resulted in the uptake into 
macrophages via two alternative pathways, as also characterized in the previous chapter. 
Additionally, we performed microtoming of macrophages infected with S. aureus and incubated 
with liposomes, to assess whether CHAPK was able to disrupt S. aureus membrane and induce its 
death. We found out that S. aureus was killed by CHAPK, indicating not only an efficient delivery to 
the cytosol, but also that the lytic activity of CHAPK was correctly retained in our delivery system. 
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5.1 Abstract 
Encapsulation of phages in liposomes is a promising strategy for the delivery to and treatment of 
intestinal infections. However, for the treatment of any intracellular infection, uptake of phages and 
delivery to the cytosol is additionally required. Even after encapsulation and uptake, the delivery of 
phages to the cytosol, where they can explicate their deadly action and kill the bacteria, could be 
hindered by cellular mechanisms of foreign body sequestering (i.e. phagocytosis). The efficacy of 
phage therapy is dependent on their correct delivery, which represents a major challenge of the 
field. 
In Section 5.2 of this work, we characterize the uptake and trafficking of phages and liposomes 
inside macrophages, acquiring essential information for the development of delivery systems that 
can be effectively utilized for phage therapy. By fluorescent imaging, we first assessed the 
importance of encapsulation of phages for the treatment of intracellular conditions, as we find that 
free phages are poorly internalized in cells. Instead, we observe that the uptake of liposomes is 
highly efficient. We find that viability of the bacterial cell was not affected by the uptake of 
encapsulated phages. This suggests that the liposomes might have been sequestered by 
macrophage cellular mechanisms of clearance such as phagocytosis, before being able to deliver 
their cargo of phages in the proximity of staphylococcus cells. To test this hypothesis, we studied 
the macrophage trafficking of encapsulated phages. We encapsulated phage K in both 
phosphatidylserine (PS) and dioleylphosphatidylethanolamine-cholesteryl hemisuccinate (DOPE-
CHEMS) liposomes to test whether the chemical composition of the delivery system has an impact 
on the uptake and trafficking itself. To evaluate the co-localization of our delivery components 
inside the macrophage, we fluorescently labelled phages and liposomes, and stained for the 
different compartments of the macrophage with specific fluorescent antibodies. We incubated the 
encapsulated phages with macrophages and observed by confocal imaging how they localized in 
the different macrophage compartments. Regardless of the chemical formulation of liposomes, we 
could detect phages in all tested compartments, suggesting that liposomes are able to enter the 
macrophages via multiple pathways. The identification and characterization of these processes lay 
the basis for overcoming liposome degradation in the cell, and ensuring effective phage delivery to 
the cytoplasm. To escape lysosomal degradation or other processes of segregation of foreign 
bodies in cellular vesicles, we envisioned a strategy consisting of phage co-encapsulation with an 
agent able to disrupt the endosomal membrane, such as a hemolysin proteins.  
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We discuss preliminary results concerning the aforementioned strategy in Section 5.3, where we 
test the co-encapsulation of a hemolysin protein with a second toxic protein that serves as a 
simplified model for phages. CHAPK is an endolysin protein known to be toxic to S. aureus. 
However, its delivery and activity on intracellular S. aureus is hindered by the natural cellular 
defences to foreign bodies consisting in phagosomal degradation. Even when encapsulated into 
liposomes for targeted and enhanced delivery, liposomes will be incorporated into either 
endosomes or phagosomes, to be degraded then via lysosomes, as it was shown also in Section 
5.2. Lysteriolysin O (LLO) protein is a hemolysin produced by L. monocytogenes able to make 
pores into the endosomal membrane. Co-encapsulation of LLO and a drug or a macromolecule is 
a common strategy to escape cellular degradation and ensure delivery into the cytosol. The focus 
of Section 5.2 is: (1) assess whether the known LLO-induced disruption of endosome results in the 
actual release of CHAPK into the cytosol with consequent killing of intracellular S. aureus; (2) test 
whether the combination CHAPK - LLO encapsulated in PS liposomes is equally effective in 
clearing intracellular S. aureus; (3) determine if a transfection formulation Dioleoyl-3-
trimethylammonium propane (DOPE-DOTAP) can be used to deliver CHAPK into the cytosol 
without the help of LLO. By confocal imaging and microtoming, we found that CHAPK co-
encapsulated with LLO in DOPE-CHEMS liposomes was efficiently delivered to the cytosol and 
could eradicate S. aureus infection. On the contrary, PS liposome-based delivery gave no 
measurable recovery of macrophages from infection and no significant difference from control 
sample consisting of empty liposomes, suggesting that delivery is formulation-dependent. 
In conclusion, the knowledge gained on phage encapsulation and on liposome formulation 
(Chapters 3 and 4) is combined and expanded herein to address a commonly encountered pitfall in 
the intracellular delivery of drugs that are trapped in cellular compartment for either recycling or 
degradation, nullifying in effect the intracellular delivery itself. Following all the efforts of 
optimization and characterization of encapsulation and delivery, addressing this challenge 
represents a pivotal step for a real-life use of liposome-encapsulated phages for the treatment of 
intracellular bacterial infections. In the last chapter of this thesis, we identify the major challenges 
in the actual delivery of phages to the cytosol and we test strategies to overcome this issue. The 
findings and advances of this work represent a massive step forward to achieve the most 
optimized and characterized delivery system of phages to extracellular (e.g. intestinal) and 
intracellular infections. 
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5.2 Trafficking inside macrophages of liposome-encapsulated phages  
 
5.2.1 The cellular uptake of free phages is low and insufficient 
To test whether bacteriophages are effective at treating intracellular infections, we exposed human 
RAW macrophages to S. aureus and allow them to be phagocytized. To assess the activity of 
bacteriophages, we looked at how macrophages recovered upon incubation with phages. As 
positive and negative controls for recovery, we imaged respectively healthy macrophages (figure 
5.0 top row, showing the intact nucleus (blue) and the actin filaments (white)) and macrophages 
after exposure to a high dose of bacteria (figure 5.0 bottom row). In this latter case, the cell 
structure that is marked by the actin filaments has disappeared, the nucleus looks irregular and 
hence unhealthy and the macrophage is surrounded by many bacteria cells (blue dots), and the 
number of viable cells was very low.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.0│Top, Confocal imaging of healthy macrophage. After growth macrophages were permealised 
and stained. Actin filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (white, left) 
DNA is stained with DAPI (blue, centre). Image on the right is the merged image. Bottom, Confocal imaging 
of macrophage infected with Staphylococcus aureus.  After growth macrophages were infected with 109 
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CFU ml-1 S. aureus, cells were then permealised and stained as before. The actin that delineates the 
structure of the cell is reduced to a minimum amount just around the edges of the nucleus and the blue 
spots indicate a high concentration of extracellular S. aureus. Scale bar 10 µm.  
Having established control images for healthy and infected macrophages alone, we then exposed 
macrophages to phage K at a concentration of 1010 PFU ml-1 and let them in contact under 
constant shaking to facilitate the uptake process. Our data show that although the ratio 
phage/macrophage used is quite high (109 phages / 4x105 cells), the majority of the macrophages 
have not internalized any phage, while a small percentage presents only one or two spots (bright 
spot in figure 5.1, top row, centre right). As expected, we found that phages are poorly or slowly 
engulfed by macrophages. Nevertheless, we were interested in assessing whether intracellularized 
phages, although in limited amount, were able to infect intracellular S. aureus. Therefore, we first 
exposed the macrophage culture to a deadly concentration of S. aureus and then we added phage 
K (> 1010 PFU ml-1). We found that, even when few phages are located inside the macrophage, 
macrophages do not survive the exposure to S. aureus (figure 5.1, bottom row). This observation 
might suggest that free phages may be degraded during the uptake process, making them 
unviable and so unable to treat intracellular infections.  
 
 
 
 
Figure 5.1│Top, Confocal imaging of healthy macrophage exposed to free phage K. After growth 
macrophages were exposed to purified phage K at 1010 PFU ml-1, then permealised and stained. Actin 
filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (white, left) DNA is stained with 
DAPI (blue, left centre). Phage K was pre-stained with SYBR gold (magenta, right centre). Image on the right 
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is the merged image. Bottom, Confocal imaging of macrophage exposed to S. aureus and then treated 
with phage K. After growth macrophages were exposed to S. aureus at 109 CFU ml-1 and after 1 hour were 
treated with phage K at 109 PFU ml-1. Staining as above. Scale bar 10 µm. 
 
Following the results of the previous experiments, we were interested in determining if liposomes 
are internalized by macrophages in a greater number compared to phages. Therefore, we 
produced nano PS liposomes using the alcohol injection methods reported in Chapter 3. This 
formulation is known to facilitate (Borisenko et al. 2003; Fadok et al. 1998; Geelen et al. 2012; 
Hosseini et al. 2015; Rodriguez-Fernandez et al. 2018; Rothkopf et al. 2005; Wu, et al., 2006) the 
uptake process due to the presence of a small percentage of phosphatidylserine on the 
membrane, which induces phagocytic activity in macrophage. Liposomes were stained with a 
fluorescent lipid in a molar proportion of 0.01% and macrophages were exposed to a comparable 
concentration to the one used during the phage experiment (1010 liposome ml-1). The results shown 
in Figure 5.2 (top row) demonstrate that the liposomes produced with our method, having PS in the 
formulation are effectively and consistently intracellularized by the macrophages. Encouraged by 
these results, we encapsulated phage K, as previously described in this thesis (Chapter 3), and we 
looked at the effect on infected macrophages. As Figure 5.2 (bottom row) shows, although 
macrophages have internalized liposomes-containing phages to a significantly higher level than 
free phages, the number of macrophages left is very low and with an unhealthy morphology. 
Therefore, we could not observe a statistical recovery of the infected macrophages when 
compared to the control. These data indicate that although liposomes can be used to increase the 
number of phages that are delivered inside the macrophage, some other processes may take 
place nullifying the beneficial effects of the phage treatment.  
We speculated on a few possible reasons for not having observed recovery of macrophages even 
upon the efficient uptake of phages. First, the non-encapsulated phages might have been 
degraded in the phagocytic process and the concentration of encapsulated phage K is still too low 
to be effective against S. aureus, as also observed in Chapters 3 and 4 (titre of encapsulated 
phages ≈ 105 – 106 PFU ml-1). Second, encapsulated phage K might have not been able to reach 
the compartments were S. aureus resides or could have been degraded via the phagocytic 
process. Finally, even if phage K reached the same compartments were S. aureus resides, the 
Brownian motion in a gel-like environment is not efficient and the chance that phage K encounters 
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a bacteria cell is very low. In the following sections we study the trafficking of encapsulate phages 
in macrophages to address some of our hypothesis above. 
  
 
 
Figure 5.2│Top line, Confocal imaging of macrophage exposed to empty PS-liposomes After growth 
macrophages were exposed to PS liposomes at 1010 liposome ml-1, then permealised and stained. Actin 
filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (white, left) DNA is stained with 
DAPI (blue, left centre). Liposome formulation contained 0.01% molar ratio of NBD PC (magenta, right 
centre). Image on the right is the merged image. Bottom line, Confocal image of a macrophage exposed to 
S. aureus and then treated with phage K encapsulated in PS liposomes After growth macrophages were 
exposed to S. aureus at 109 CFU ml-1 and after 1 hour were treated with phage K encapsulated in liposomes. 
Staining as above. Scale bar 10 µm. 
 
 
5.2.2 Liposomes accumulate in the cell and enter the macrophages via phagocytic and endocytic 
pathway 
 
Following our previous results, we wanted to determine whether the lipid formulation of liposomes 
could have an effect on the trafficking inside the macrophages. Therefore, we studied the cell 
trafficking for encapsulated phages in PS liposomes (as in section 5.1.1 where encapsulated 
phages resulted ineffective in treating intracellular S. aureus) and in DOPE-CHEMS liposome, 
which is a well-characterized and common lipid formulation. DOPE-CHEMS formulation has been 
used efficiently in the past years to deliver a great variety of chemicals and macromolecules and 
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favour cell uptake  and cytosol delivery (Bossche et al. 2011; Chen et al. 2012; Chul, et al., 1994; 
Drummond, et al.,x 2000; Fattal, et al., 2004; Ganta et al. 2008; Gerasimov et al. 1999; Lorenzi 
and Lee 2005; Simões et al. 2001, 2004; Walker 2010; York 1984).   
In this experiment, we stained for phage K, and not for liposomes like in Section 5.1.1, using a 
commonly employed dye for DNA, SYBR gold (Colom et al. 2015; Egley and Breitbart 2003; Patel 
et al. 2007; Pollard 2012; To et al. 2017; Tolba et al. 2010). We incubate phages with SYBR gold 
from before encapsulation, to be able to track phage K through its journey inside the mammalian 
cell. By imaging after the uptake in macrophages, we found that encapsulated phages are at a 
much higher concentration inside the cells (Figure 5.3, green spots indicated by white arrows) 
when compared to free phages (Figure 5.1, top row). We also found that phage uptake activated 
the macrophages as indicated by the actin fibrils and overall change in morphology. Although the 
macrophages are activated, the phage is not cytotoxic to the cells. 
 
 
 
Figure 5.3│Confocal imaging of macrophages exposed to phage K encapsulated in PS liposomes. After 
growth, macrophages were exposed to phage K encapsulated in PS liposomes, then permealised and stained. 
Phage K was pre-stained with SYBR gold (green, left). DNA is stained with DAPI (blue, left centre). Actin 
filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (red, right centre). Image on the 
right is the merged image. Scale bar 10 µm. 
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Figure 5.4│Confocal imaging of a macrophages exposed to phage K encapsulated in PS liposomes. After 
growth, macrophages were exposed to phage K encapsulated in PS liposomes, then permealised and stained. 
Phage K was pre-stained with SYBR gold (green, left). DNA is stained with DAPI (blue, left centre). Phagosomes 
are stained for Rab7 (red, right centre). Image on the right is the merged image. Scale bar 10 µm. 
 
Hence, in order to determine the pathway that phage K encapsulated in PS liposome undertook to 
enter the macrophage and to try to explain the lack of cytotoxicity, we stained the endosome and 
the phagosome of macrophages. Our results show that phages do not co-localize almost at all with 
the endosome, but with the phagosome as it is shown in Figure 5.4, where a significant amount of 
phages co-localize with the phagosome marker Rab7. This finding suggests us that the PS 
liposome-encapsulated phage K is introduced intracellular by phagocytosis, as already described, 
(Fadok et al. 1998; Rodriguez-Fernandez et al. 2018), explaining also why we observed activated 
macrophages (Figure 5.3).  
Given that S. aureus can escape the phagocytic process before it is completed, and translocate to 
the cytosol (Flannagan, et al., 2016) where it further spreads, we were interested to assess 
whether phage K could be able to also escape phagocytosis and the following degradation in the 
lysosome. Therefore, we stained the lysosomal compartment and we looked at co-localization with 
encapsulated phages. Figure 5.5 shows indeed that phage K encapsulated in PS liposome co-
localizes with the lysosome (white arrows). This is not in agreement with what found previously 
145 
 
(Nieth et al. 2015), where a similar formulation gave co-localization with the endosome, but yet an 
increase in the uptake was recorded. 
Moreover, although phage K encapsulated in PS liposomes is not effective in fighting intracellular 
S. aureus during our experiments we observed two interesting aspects: 1) at a visual examination, 
compared to the control there is less extracellular S. aureus, indicating that the non-encapsulated 
phages are still viable; 2) Some phages co-localize with S. aureus (figure 5.6 white arrows). 
 
 
 
Figure 5.5│Confocal imaging of macrophages exposed to phage K encapsulated in PS liposomes. After 
growth, macrophages were exposed to phage K encapsulated in PS liposomes, then permealised and stained. 
Phage K was pre-stained with SYBR gold (green, left). DNA is stained with DAPI (blue, left centre). Lysosome 
is stained for cathepsin-L (red, right centre). Image on the right is the merged image. Scale bar 10 µm. 
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Figure 5.6│Confocal imaging of macrophages exposed to S. aureus and then treated with phage K 
encapsulated in PS liposomes. After growth, macrophages were exposed to S. aureus and then treated with 
phage K encapsulated in PS liposomes, then permealised and stained. Phage K was pre-stained with SYBR 
gold (green, left). DNA is stained with DAPI (blue, left centre). Actin filaments are stained with 
phalloidin/CFR680 Cy5 fluorophore conjugate (red, right centre). Image on the right is the merged image. 
Scale bar 10 µm. 
 
To test whether another liposome formulation could be more successful at delivering phages, due 
to a different chemical interaction with the cellular membrane and different mechanism of uptake, 
we encapsulated phage K in DOPE-CHEMS liposomes and studied their trafficking in 
macrophages. DOPE-CHEMS liposomes are known to enter the cell via endocytic pathway (Chul, 
et al., 1994; Simões et al. 2001). We were interested to test whether the uptake of encapsulated 
phages by another cellular route could result in defeating effectively the intracellular infection of S. 
aureus. To evaluate whether the uptake of phage K encapsulated in DOPE-CHEMS liposomes is 
effective at killing S. aureus and restore healthy macrophages, we infected macrophages with S. 
aureus and incubated with DOPE-CHEMS liposomes containing phage K. To assess the effect on 
S. aureus and on the macrophage, we compared samples that have been (bottom images of 
relevant figures) and not been (upper images) infected. Furthermore, to be able to localize the 
phage in the cell and gain information on its uptake, we stained for the different cellular 
compartments of macrophages. 
Thus, we encapsulated phage K in DOPE-CHEMS liposomes and imaged phage and macrophage 
compartments by fluorescent staining and confocal microscopy. Similarly, to PS liposomes, DOPE-
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CHEMS liposomes were internalized to a high level as we imaged a high intracellular concentration 
of fluorescent phage inside the macrophages. Upon uptake of phage K in DOPE-CHEMS 
liposomes, macrophage cells became activated (Figure 5.7) but still viable, indicating that 
encapsulated phage K was not cytotoxic to the macrophages.  
 
 
 
Figure 5.7│Confocal images of macrophages exposed to phage K encapsulated in DOPE-CHEMS liposomes. 
After growth, macrophages were exposed to phage K encapsulated in DOPE-CHEMS liposomes, then 
permealised and stained. Phage K was pre-stained with SYBR gold (green, left). DNA is stained with DAPI 
(blue, left centre). Actin filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (red, right 
centre). Image on the right is the merged image. Scale bar 10 µm. 
 
By staining for the markers of endosomes, EEA1, (figure 5.8 bottom) or phagosomes, Rab7, (figure 
5.8 top we found out that phages encapsulated in DOPE-CHEMS liposomes entered the 
macrophage cell mostly via endosomal pathway as already described (Chul, et al., 1994; 
Drummond, et al., 2000; Fattal, et al., 2004; Gerasimov et al. 1999; Simões et al. 2001, 2004) We 
observed that uptake of encapsulated phages was the same regardless the presence of S. aureus. 
While trapping in endosomes does not necessarily mean degradation of foreign bodies to prevent 
their release into the cytosol, infected macrophages did not show a significant sign of recovery, 
suggesting that, despite the successful uptake of the encapsulated phage K, delivery to the cytosol 
was not achieved. Given the trapping of phages in endosomes, we hypothesized that this could 
have been resulted in phage and liposome degradation via lysosomal pathway. Interested in 
testing our hypothesis and in characterizing the cellular trafficking of encapsulated phages after 
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their uptake in macrophages via endosomal pathway, we stained for lysosomes. Indeed, we 
observed that encapsulated phages co-localize with lysosomes (Figure 5.9). This finding could be 
explained by the fusion of late endosomes containing DOPE-CHEMS liposomes with the 
lysosomes to initiate degradation of the foreign body.  
 
 
 
Figure 5.8│Confocal images of macrophages exposed to phage K encapsulated in DOPE-CHEMS liposomes. 
After growth, macrophages were exposed to phage K encapsulated in DOPE-CHEMS liposomes, then 
permealised and stained. Phage K was pre-stained with SYBR gold (green, left). DNA is stained with DAPI 
(blue, left centre). Endosomes are stained for Rab7 (top) and EEA1 (bottom), (red, right centre). Image on the 
right is the merged image. Arrow indicate colocalization. Scale bar 10 µm.  
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Figure 5.9│Confocal imaging of macrophages exposed to phage K encapsulated in DOPE-CHEMS liposomes. 
After growth, macrophages were exposed to phage K encapsulated in DOPE-CHEMS liposomes, then 
permealised and stained. Phage K was pre-stained with SYBR gold (green, left). DNA is stained with DAPI 
(blue, left centre). Lysosomes are stained for chatepsin-L (red, right centre). Image on the right is the merged 
image. Scale bar 10 µm. 
 
Finally, we did not observe any restoration of macrophage uninfected morphology upon incubation 
with DOPE-CHEMS-encapsulated phages (Figure 5.10) and instead we are able to image 
intracellular nuclear material of S. aureus, confirming our findings and hypothesis on their 
intracellular fate.  
 
 
Figure 5.10│Confocal images of macrophages exposed to phage K encapsulated in DOPE-CHEMS liposomes. 
After growth, macrophages were exposed to phage K encapsulated in PS liposomes, then permealised and 
stained. Phage K was pre-stained with SYBR gold (green, left). DNA is stained with DAPI (blue, left centre). 
Actin filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (red, right centre). Image on 
the right is the merged image. Scale bar 10 µm. 
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Given the successful uptake of encapsulated phages and yet unsuccessful treatment of 
intracellular S. aureus, we finally focused on envisioning strategies for evading lysosomal 
degradation and achieving the release of phages into the cytosol, consisting of the co-
encapsulation of phages with an agent, such as hemolysin proteins, able to disrupt the endosomal 
and phagosomal membrane before fusion with the lysosome. We discuss this strategy and 
preliminary results using a simplified model in section 5.2. 
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5.3 Co-encapsulation of lysin proteins LLO and CHAPK in liposomes for the treatment of 
intracellular S. aureus infection  
 
To engineer liposomes that are able escape lysosomal degradation or other processes of 
segregation of foreign bodies in cellular vesicles, we co-encapsulated two relevant proteins in 
liposomes with different formulation (1) CHAPK protein, an endolysin toxic to S. aureus (M Fenton 
et al. 2011; Mark Fenton et al. 2010, 2012; Gutiérrez and Fernández 2018; Hathaway et al. 2016; 
Kashani et al. 2017; Marta Sanz-Gaitero, et al., 2014; Strategies 2018), and (2) LLO protein, a 
hemolysin protein able to disrupt the endosome (Alberti-segui, et al., 2007; Antonini et al. 2012; 
Birmingham et al. 2008; Carrero et al. 2004; Cells 2005; Churchill, et al., 2005; Dramsi and Cossart 
2002; Dubail et al. 2018; Fattal, et al., 2004; Gekara et al. 2005; Gilert et al. 2016; Glomski et al. 
2002; Goldfine et al. 1997; Jacobs, et al., 1998; Kayal and Charbit 2018; Kullberg, et al., 2010; 
Listeriolysin and Reversibly 2017; Lorenzi and Lee 2005; Mathew et al. 2003; Meyer-morse et al. 
2010; Osborne, et al., 2016; Podobnik et al. 2015; Ruan et al. 2016; Schnupf et al. 2007; Schnupf 
and Portnoy 2007; Schuerch, et al., 2005; Vadia and Seveau 2014; Walls et al. 2013). Our strategy 
is based on the principle that LLO, in the presence of cholesterol and in a low-pH environment, 
self-assembles to make nanopores on the endosomal membrane, releasing the content in the 
cytosol. Some liposome formulations such as DOPE-CHEMS are pH-responsive, meaning that 
when the pH inside the endosome drops below pH 6, it will cause a destabilization of the liposome 
structure (Chul, et al., 1994; Simões et al. 2004; York 1984) with a consequent release of the 
liposome cargo. Furthermore, LLO protein is mostly active at low pHs, making our system tightly 
controlled and selectively activated only upon endosomal trapping. To make sure that the liposome 
content can leave the pored endosome and be effectively released into the cytosol, we first tested 
the co-encapsulation of LLO protein with CHAPK protein, which is toxic to S. aureus but 10-fold 
smaller than phage K. CHAPK protein will, therefore, serve as a model for phages that is easier to 
handle, and as a control for our co-encapsulation strategy. The smaller size of CHAPK allows us to 
evaluate our strategy, while controlling other relevant processes such as the passage through the 
pored endosome and cytosol mobility that would be less easy to control with phages. 
Additionally, we tested different formulations of liposomes. By encapsulating CHAPK and LLO in 
PS or DOPE-CHEMS liposomes, we could evaluate (1) the importance of pH-responsiveness (as 
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PS liposomes are not pH-responsive) and/or (2) the capacity of LLO protein to induce degradation 
of phagosomes (as PS liposomes are mostly internalized by phagosomes) (Fadok et al. 1998; 
Rodriguez-Fernandez et al. 2018). Additionally, we also encapsulated CHAPK in DOPE-DOTAP 
liposomes, which are supposed to fuse with the membrane of the endosome, causing the release 
of the liposome content to the outside of the endosome, i.e. the cytosol, without any need of 
generating holes in the endosome membrane by means of LLO (Ambrose et al.; Balazs and 
Godbey 2011; Bergese, et al., 2005; Kim et al. 2015; Koltover 2012; Li et al. 2013; Mok and Cullis 
1997; Pires 1999; Serbina and Huang 1995; Stegmann 1997; Wrobel and Collins 1995). 
In our first attempt, we encapsulated LLO and CHAPK in pH-responsive DOPE-CHEMS liposomes. 
Macrophages were infected with a deadly concentration of S. aureus and then treated with either 
empty liposomes as a control (Figure 5.11, top row) or LLO/CHAPK liposomes (Figure 5.11, bottom 
row). In the former sample, we found that only few living cells (Figure 5.11, top row) and those that 
are alive are heavily infected with S. aureus (as shown by cell morphology and presence of 
intracellular S. aureus). In the endolysin-treated sample, instead, we found a high number of cells 
with normal morphology, implying recovery from the infection, and decreased occurrence of 
intracellular S. aureus. 
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Figure 5.11│Confocal imaging of macrophages exposed to S. aureus and then treated with CHAPK and LLO 
encapsulated in DOPE-CHEMS liposomes. After growth, macrophages were exposed to to S. aureus and then 
treated with DOPE-CHEMS liposomes loaded with CHAPK and LLO, then permealised and stained. DNA is 
stained with DAPI (blue, left). Actin filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate 
(red, centre). Image on the right is the merged image. Top row = control, bottom row = treated sample. Scale 
bar 10 µm. 
 
This observation is in accordance with what was previously published for the cytosol delivery of 
small molecules and macromolecules (Kullberg, et al., 2010; Lorenzi and Lee 2005; Mathew et al. 
2003; Walls et al. 2013). To further support that this delivery system combining LLO and CHAPK is 
able to kill intracellular S. aureus, we looked at the control and the treated sample under CryoTEM. 
After pelleting, the samples were fixed and sliced in a nanometre thick portion and visualized in 
Cryo-mode. The result of this experiment are shown in figure 5.12a, where it can be seen 
intracellular S. aureus cells, some of which have the outer membrane degraded with consequent 
death (white arrow heads). These data support our confocal experiments and give a visual prove of 
the endolytic function against S. aureus of CHAPK even in the cytosol of mammalian cells. Finally, 
DOPE-CHEMS liposomes encapsulating CHAPK but not LLO were used to determine the actual 
importance of the latter to kill intracellular S. aureus. As expected, the macrophage recovery was 
very poor (figure 5.12b) even at lower concentrations of extracellular S. aureus than what tested so 
far, supporting that the observed cytotoxicity of CHAPk is dependent on the use of LLO for an 
effective delivery into the cytosol.  
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Figure 5.12│a, Microtoming of macrophages exposed to S. aureus and then treated with CHAPK and LLO 
encapsulated in DOPE-CHEMS liposomes, white arrows point at dead bacteria. Scale bar 10 µm (left) 5 µm 
(right). b, Confocal imaging of macrophages exposed to S. aureus and then treated with DOPE-CHEMS 
liposomes containing  CHAPK. Left = control with empty liposomes, right = treated sample. Arrows point at S. 
aureus cells.  
 
Successively, we tested whether the PS formulation that is known to enter via phagocytosis 
(Borisenko et al. 2003; Fadok et al. 1998; Geelen et al. 2012; Hosseini et al. 2015; Rodriguez-
Fernandez et al. 2018; Rothkopf et al. 2005; Wu, et al., 2006) gives similar result to the successful 
DOPE-CHEMS previously tested. We found a marked cell rescue between the control and the 
treated sample when PS liposomes are used to deliver CHAPK in the presence of LLO (Figure 
5.13). Moreover, even cells that were found alive were heavily infected with a high number of 
extracellular S. aureus as well. Thus, the presence of LLO did not alleviate the issue experienced 
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in Section 5.2.1 where phage K encapsulated in PS liposomes resulted to be ineffective in treating 
infected macrophages.  
Finally, we tested the ability of CHAPK to treat intracellular infection of S. aureus when 
encapsulated in DOPE-DOTAP liposomes. The mechanism by which these liposomes deliver their 
content in the cytosol it is still not completely clear (Ambrose et al.; Balazs and Godbey 2011; 
Bergese, et al., 2005; Kim et al. 2015; Koltover 2012; Li et al. 2013; Mok and Cullis 1997; Pires 
1999; Serbina and Huang 1995; Stegmann 1997; Wrobel and Collins 1995). From what is known, 
however, it seemed that cellular delivery in DOPE-DOTAP liposome did not require the use of LLO 
to escape the endosomal degradation. Figure 5.14 shows that there is a noticeable increase in cell 
density and fewer S. aureus both extra and intracellularly, similarly to DOPE-CHEMS formulation 
although to a lower extent. This suggests that the DOPE-DOTAP liposomes can be used as 
delivery system for proteins and that it has considerable potential to rescue cells from infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 │ Confocal imaging of macrophages exposed to S. aureus and then treated with CHAPK and LLO 
encapsulated in PS liposomes. After growth, macrophages were exposed to to S. aureus and then treated 
with PS liposomes loaded with CHAPK and LLO, then permealised and stained. Nuclei are stained with DAPI 
(blue, left). Actin filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (red, centre). 
Image on the right is the merged image. Top row = control, bottom row = treated sample. Scale bar 10 µm. 
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Figure 5.14│Confocal imaging of macrophages exposed to S. aureus and then treated with CHAPK 
encapsulated in DOPE-DOTAP liposomes. After growth, macrophages were exposed to to S. aureus and then 
treated with DOPE-DOTAP liposomes loaded with CHAPK, then permealised and stained. Nuclei are stained 
with DAPI (blue, left). Actin filaments are stained with phalloidin/CFR680 Cy5 fluorophore conjugate (red, 
centre). Image on the right is the merged image. Top row = control, bottom row = treated sample. Scale bar 
10 µm. 
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5.4 Discussion 
 
In this chapter, we discuss the applicability of encapsulated phages to tackle intracellular infections 
in RAW macrophages. We chose S. aureus as intracellular pathogen, for which phage K that has 
been extensively characterized and employed for encapsulation (Chapter 3-4) is specific. We 
showed that free phages are poorly taken up by the macrophages and fail to fight intracellular S. 
aureus. We encapsulated phage K in different lipid formulations, which were known to deliver their 
cargo via different cellular routes. However, we did not observe any improvement in the number of 
rescued macrophage cells, suggesting that phage K was not effectively delivered. Therefore, we 
tested a simplified system consisting of a small protein instead of phages, called CHAPK, which 
has endolytic activity against S. aureus. Given its smaller size and the higher achievable 
concentration of encapsulation, we expected CHAPK to be an easier working model to test the 
delivery strategy. In particular, we tested different lipid formulations, in the presence or absence of 
a hemolytic protein, i.e. LLO, and found that delivery into the cytosol and consequent clearance of 
intracellular S. aureus was liposome formulation-dependent. 
 
5.4.1 Uptake of free and encapsulated phages 
The employment of phages to treat bacterial infections is a popular strategy holding the promise to 
overcome bacterial resistance by co-evolution of bacteria and phages in a so-called “arms-race”. 
Several works have been showing the efficacy of phages in killing AMR bacteria in vitro (Bhetwal 
et al. 2017; Lehman et al. 2019; Nagel 2018; Publication 2016; Rohde, et al., 2020; Saha et al.). 
However, the translation from bench-side to bedside and the use of phages as a routine medical 
procedure is still far away from reality. First, phage therapy is hurdled by regulations (Furfaro, et 
al., 2018) associated with the clinical use of these antimicrobial agents. Second and foremost, the 
efficacy of phage therapy is hindered by the scarce bioavailability of phages when administered in 
vivo, due to the fast clearance of phages (Anna, et al., 2017; Kortright et al. 2019; Krut, et al., 
2019; Krystyna 2019; Ly-chatain 2014). Indeed, the current use of phages is restrained to topical 
infections, such as wounds, burns and ulcers (Morozova, et al., 2018), and rare cases of 
intracellular infections, where repeated high doses are required (Lavergne et al.). Such massive 
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use of phages for the treatment of infections, not only is not practically sustainable, but also could 
easily incur into undesired and uncontrolled side effects, such as the development of resistance, 
making phage therapy approval even more challenging. 
The targeted delivery of phages to the site of infection is a promising strategy to alleviate both 
aforementioned limitations in the current state of art of phage therapy. If on one side the targeted 
delivery of antimicrobial agents would be highly controlled and controllable, and therefore 
subjected to an easier regulation path, on the other side, it would undoubtedly result in high 
efficacy and fast treatment of intracellular infections. In this work and other studies (Nieth et al. 
2015), it was indeed shown how the uptake of free phages occurs poorly in cells, even in vitro. 
Attempts of delivery systems consisting of either liposomes (Chadha, et al., 2017; Colom et al. 
2015b; Leung et al. 2018; Nieth et al. 2015; S. Singla et al. 2016) or microparticles (Agarwal et al. 
2019; Colom et al. 2017; Ma et al. 2008; Vinner et al. 2017; Vinner and Malik 2018) have been 
previously reported. In particular, Colom et al. 2015 encapsulated phages for the treatment of 
intestinal infections, while Nieth et al. characterized the in vitro uptake of phages. However, these 
studies were either not performed on intracellular infections or only focused on the uptake of 
phages without showing the effective clearance of bacteria. There is currently a lack of knowledge 
and technology to allow the intracellular delivery of phages and treatment of bacterial infections.  
In this work, we show that we are able to significantly increase the uptake of phages by 
encapsulating them in liposomes, prepared with suitable formulations. In the next paragraphs, we 
discuss how uptake into cells is a necessary but not sufficient condition to treat intracellular 
bacteria, explaining why this was not previously achieved. We discuss how we tackled this issue 
and effectively succeeded in fighting intracellular infections by combining strategies of co-
encapsulation and a suitable chemistry of liposomes. 
 
5.4.2 Trafficking in macrophages of liposome-encapsulated phage K 
To verify and characterize the uptake of encapsulated phages to the cytosol, where they can 
effectively kill bacteria that reside intracellularly, we studied the trafficking of liposome-
encapsulated phages inside macrophages that have been infected with S. aureus. The trafficking 
of liposomes carrying diverse cargos inside mammalian cells has been extensively investigated 
previously (Ahsan et al. 2002; Drulis-kawa and Dorotkiewicz-jach 2010; Huth, et al., 2006; 
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Kawakami et al. 2000; Lima et al. 2003; Torchilin 2005; Torchilin et al. 2001; Ulrich 2002; Un et al. 
2012). It was found that the lipid formulation of liposomes is pivotal in determining the fate of 
liposomes themselves into the cells. It was observed that liposomes enter the cell either by 
endocytosis (Huth, et al., 2006; Pollock et al. 2010; Simões et al. 2001) or phagocytosis (Nieth et 
al. 2015; Rodriguez-Fernandez et al. 2018), resulting in the recycling and degradation of 
liposomes, unless strategies for the direct uptake are devised (one remarkable example consisting 
of membrane fusion between the cellular membrane and the liposomes, using lipopeptides 
attached on the surface of liposomes) (Yang et al. 2016). In this work, we came to similar 
conclusions and found that PS liposomes are internalized via phagocytosis, while DOPE-CHEMS 
liposomes are mainly taken up via endocytosis. Given that we did not observe any sign of 
macrophage recovery and, thus, bacterial eradication, we speculate that, regardless the mode of 
uptake of liposomes, encapsulated phages have no capacity to evade cellular vesicles and escape 
fusion with lysosomes, which resulting in liposome and phage degradation. In such systems, we 
could never observe localization of phages in the cytosol, and we could only detect phages 
compartmentalized into either endosomes, phagosomes or, in a later step, lysosomes. Thus, we 
consider unlikely the possibility to kill intracellular bacteria without undertaking further strategies, 
and wonder if other artefacts might have contributed to the assessment of successful infection 
treatment with encapsulated phages reported by only one previous work (Saloni Singla et al. 
2016). Instead, we suggest that strategies to overcome the trapping of liposomes into cellular 
vesicles need to be devised to avoid liposome and phage degradation and promote the successful 
delivery into the cytosol. Thus, we envisioned and tested such strategies, which are discussed in 
the following final paragraph. 
 
5.4.3 Strategies to escape lysosomal degradation 
LLO is a hemolysin protein produced by L. monocytogenes to evade cellular degradation when 
trapped inside an endosome (Birmingham et al. 2008; Dubail et al. 2018; Jacobs, et al., 1998; 
Kayal and Charbit 2018; Lety et al. 2002; Meyer-morse et al. 2010; Osborne, Brumell, and Brumell 
2016; Ruan et al. 2016; Schnupf et al. 2007; Schnupf and Portnoy 2007). LLO is released from L. 
monocytogenes during the acidification of the endosome and, although is activated only when the 
pH drops below a value of 6, it is only in the presence of cholesterol that LLO exerts its function 
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(Glomski et al. 2002; Podobnik et al. 2015). Upon interaction with cholesterol-containing 
membranes, LLO undergoes structural changes that lead to the oligomerization of the LLO 
monomer to form a pre-pore arch structure. It is not clear whether the pore structure is first formed 
and then inserted into the membrane or if transition from pre-pore to pore happens within the 
membrane. Eventually, between 35 to 47 monomers of LLO are arranged in a ring shape of 
variable size (diameter between 320 Å to 430 Å) (Osborne, et al., 2016). For its natural capacity to 
disrupt the endosomal membrane, LLO protein has been employed with success for enhancing 
cytosol delivery of RNA and other macromolecules, by being co-encapsulated in pH-responsive 
liposomes (Kullberg, et al., 2010; Lorenzi and Lee 2005; Mathew et al. 2003). In this work, we 
employed LLO to overcome the previously experienced challenge of delivering liposome-
encapsulated phages into the cytosol for the treatment of intracellular infections. However, 
considering the size of the LLO-generated pores vs. the size of phages, as well as the question on 
whether and how phages are able to diffuse within the cytosol once delivered there, we first tested 
the co-encapsulation of LLO with a protein that is cytotoxic to S. aureus but smaller than phages, 
namely CHAPK.  
CHAPK is a small protein (18kDa, i.e. < 5nm) as it is a truncated derivative of a phage lysin from 
the Myoviridae staphylococcal phage K. CHAPK has been previously employed for the treatment of 
S. aureus biofilms and in mice (Mark Fenton et al. 2010, 2012; Kashani et al. 2017). Therefore, it 
can serve as a tool to characterize the effective delivery of liposomes to the cytosol by mean of 
assessing whether macrophages infected with S. aureus recover upon incubation with CHAPK-
containing liposomes. Furthermore, proteins that are smaller than 5 nm are known to diffuse in the 
cytosol, regardless the cytoskeleton state (Franosch et al. 2019; M. Delarue, et al., 2017).  
In this work, we combine the capacity of LLO protein to promote endosomal escaping with the 
cytotoxic properties of CHAPK protein towards S. aureus, to test whether a different lipid 
formulation can have an impact on the cytosol delivery. By co-encapsulating LLO and CHAPK in 
PS and DOPE-CHEMS liposomes, we could assess that, by generating pores into the endosomal 
membrane, LLO protein effectively caused the released of the liposomal content into the cytosol, 
eventually killing S. aureus. We observed that infected macrophages could recover only when 
incubated with DOPE-CHEMS liposomes containing CHAPK, and not PS liposomes. We also 
tested the cytotoxic potential towards intracellular S. aureus of CHAPK protein encapsulated in 
DOPE-DOTAP liposomes. DOPE-DOTAP liposomes are known to fuse with the membrane of the 
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endosome (Ambrose et al.; Balazs and Godbey 2011; Bergese, et al.,; 2005; Kim et al. 2015; 
Koltover 2012; Li et al. 2013; Mok and Cullis 1997; Pires 1999; Serbina and Huang 1995; 
Stegmann 1997; Wrobel and Collins 1995), causing the release of the liposome content to the 
outside of the endosome, i.e. the cytosol. For this reason, in the case of DOPE-DOTAP we did not 
include LLO. We found that indeed CHAPK encapsulated in DOPE-DOTAP is delivered to the 
cytosol and could kill S. aureus without any need of co-encapsulation with LLO. 
Future perspectives include the extension of our delivery strategy from the small protein CHAPK to 
phages. We will encapsulate phage K in DOPE-DOTAP liposomes or co-encapsulate it with LLO 
protein in DOPE-CHEMS liposomes, and test for its cytosol delivery and for the clearance of 
intracellular S. aureus. In these cases, the cytosolic diffusion of phages will need to be 
characterized, as well as the passage of phages through LLO-generated pores, which could be 
enlarged if needed by the encapsulation with a third protein, e.g. phospholipase C (Alberti, et al., 
2007; Goldfine et al. 1997; Poussin, et al., 2009).  
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5.5 Conclusions 
In this work, we made significant advances in the understanding and development of strategies for 
the intracellular delivery of antimicrobial agents. We showed that phage K requires encapsulation 
to be successfully delivered inside RAW macrophages, while liposome are highly internalized. 
Therefore, we encapsulated phage K in liposomes, taking advantage of the encapsulation 
procedures previously developed and described in Chapter 3 and 4. However, when macrophages 
were infected with S. aureus, we did not observe any recovery of macrophages from the bacteria 
upon incubation with liposomes containing phage K, suggesting that the uptake is not sufficient for 
the intracellular delivery of phages to the sites of S. aureus, in the cytosol. Thus, we applied to our 
system known approaches for the cytosolic delivery of liposomes, such as the co-encapsulation of 
a hemolysin protein, we included an agent that is specifically cytotoxic to S. aureus, and we 
successfully achieved bacterial clearance from the macrophages. With the acquired knowledge 
and technical expertise, we anticipate to be able to extend and adapt easily the herein developed 
strategy to the delivery of phages. In this chapter, we identified common pitfalls that hinder the use 
of encapsulated phages for phage therapy of intracellular infections, and we suggested and tested 
a strategy to overcome it. The extensive and rigorous characterization of this thesis work lays solid 
bases for the development of liposome-phage systems that can effectively be employed for the 
treatment of intracellular infections. 
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Chapter 6: Conclusions and future work 
Antibiotic resistance is a highly serious problem that is threatening our modern world and for which 
there is currently no real solution available, opening the scene to a post-antibiotic era where a 
simple infection could lead to death. Antimicrobial alternatives are available and await to be studied 
and used; however, research and combined efforts are required to make their utilization possible, 
not harmful, and effective. Bacteriophages are viruses that exploit bacteria to replicate, killing their 
host eventually, once the process has been accomplished. Phage outnumber bacteria by a factor 
of 10 and naturally co-evolve with them providing always a working alternative even in the case of 
new resistant species. However, phage are not able to resist as well as bacteria do to any 
environment and condition and in order to fight successfully some pathogens, particularly 
intracellular ones, phages need a system for targeted delivery, such as encapsulation.  
In this thesis, we have studied the feasibility of phage encapsulation in nanoliposomes using 
microfluidics in combination with the alcohol injection methods to generate liposomes that hide 
phages in their aqueous core. During our studies, we found that the encapsulation efficiency is 
very low, in disagreement with previous reports, mostly due to phage aggregation. We also found 
that some phages may interact with the membrane, worsening further the success of the 
encapsulation process and triggering the contraction of the phage tail with possible DNA release. 
Once correctly characterized and overcome such challenges, we studied the trafficking of 
encapsulated phages using two different formulations that are known to access human 
macrophages via different routes of uptake. We found that, regardless the formulation, phage in 
liposomes are not able to escape the degradation process that starts with phagocytosis and ends 
in the lysosome where any biological entity is digested. While this prevents phages from reaching 
the site of infection and fighting the bacteria in the cytosol, such limitation is not intrinsic of the use 
of phages but is rather experimental and can be overcome by escaping lysosomal degradation. 
We, therefore, envisioned a strategy consisting in the co-encapsulation with a hemolysin that is 
known to facilitate phagosomal escaping by creating pores in the phagosome. To test our strategy, 
we employed an alternative, smaller antimicrobial agent, a phage lysin. We used three different 
lipid formulations to encapsulate the two proteins in nanometre-scale liposomes. We were 
successfully able to achieve cytosol delivery and we found that the efficiency of bacteria clearing is 
formulation-dependent.  
175 
 
The results and data accumulated in this thesis are of high impact and relevance for the 
employment of phage therapy to fight bacteria resistant to conventional antibiotics. Findings and 
observations suggest that with an accurate encapsulation strategy phage can be successfully 
encapsulated in nanoliposomes. However, to use them in intracellular infections further effort is 
needed. We assessed that phages are unable to escape the phagosomal degradation when 
encapsulated, while free phages are poorly taken-up. We showed that co-encapsulation with a 
hemolysin allowed escape of a small lysin from phagosomal degradation. We expect that the 
combined use of phages and functional proteins will result in a promising delivery to the cytosol. As 
future perspective, we suggest to co-encapsulate phages with hemolysin and test whether, in 
these conditions, phages are able to escape the phagosome and reach the niches were 
intracellular pathogens hide. In case even in the presence of a hemolysin phages are not able to 
reach the cytosol, probably due to their bigger size when compared to the tested lysin, a second 
protein proficient at disrupting completely the phagosome membrane could be included to increase 
the chance of delivery phages in the cytosol. Finally, given that phages are nanoparticles and the 
cytosol is a crowd gel-like environment were nanoparticles need motor proteins to move, further 
future studies should focus on the evaluation of phage particles movement inside the cytosol as 
such or as genetically modified phages that express oligopeptide naturally recognized by motor 
proteins. We believe that our strategy made significant advances in the use of phages for phage 
therapy and set strong bases for the further development of delivery systems for phages that are 
not only effective at fighting intracellular infections but also meet the therapeutic requirements and 
could be used in real-life cases. 
 
